{
  "file_name": "CUAD_v1/full_contract_pdf/Part_I/Promotion/ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement.pdf",
  "annotations": [
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Document Name_0",
      "question": "Highlight the parts (if any) of this contract related to \"Document Name\" that should be reviewed by a lawyer. Details: The name of the contract",
      "answer_text": "COLOGUARDÂ® PROMOTION AGREEMENT",
      "page_number": 0,
      "words": [
        {
          "text": "PROMOTION AGREEMENT",
          "bbox": [
            1379.0,
            398.0,
            1930.0,
            435.0
          ],
          "confidence": 0.9990187287330627
        }
      ],
      "nearby_headers": [
        {
          "text": "COLOGUARD?",
          "page": 0,
          "bbox": [
            1497.0,
            342.0,
            1812.0,
            378.0
          ]
        },
        {
          "text": "PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1379.0,
            398.0,
            1930.0,
            435.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1464.0,
            455.0,
            1845.0,
            492.0
          ]
        },
        {
          "text": "EXACT SCIENCES CORPORATION",
          "page": 0,
          "bbox": [
            1303.0,
            513.0,
            2008.0,
            545.0
          ]
        },
        {
          "text": "PFIZER INC.",
          "page": 0,
          "bbox": [
            1530.0,
            621.0,
            1778.0,
            658.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Parties_4",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Pfizer and Exact may each be referred to herein individually as a \"Party\" and collectively as the \"Parties\".",
      "page_number": 4,
      "words": [
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        }
      ],
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Pfizer Inc.",
      "page_number": 0,
      "words": [
        {
          "text": "PFIZER INC.",
          "bbox": [
            1530.0,
            621.0,
            1778.0,
            658.0
          ],
          "confidence": 0.9955017566680908
        }
      ],
      "nearby_headers": [
        {
          "text": "COLOGUARD?",
          "page": 0,
          "bbox": [
            1497.0,
            342.0,
            1812.0,
            378.0
          ]
        },
        {
          "text": "PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1379.0,
            398.0,
            1930.0,
            435.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1464.0,
            455.0,
            1845.0,
            492.0
          ]
        },
        {
          "text": "EXACT SCIENCES CORPORATION",
          "page": 0,
          "bbox": [
            1303.0,
            513.0,
            2008.0,
            545.0
          ]
        },
        {
          "text": "PFIZER INC.",
          "page": 0,
          "bbox": [
            1530.0,
            621.0,
            1778.0,
            658.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Exact",
      "page_number": 0,
      "words": [
        {
          "text": "EXACT SCIENCES CORPORATION",
          "bbox": [
            1303.0,
            513.0,
            2008.0,
            545.0
          ],
          "confidence": 0.9992802739143372
        }
      ],
      "nearby_headers": [
        {
          "text": "COLOGUARD?",
          "page": 0,
          "bbox": [
            1497.0,
            342.0,
            1812.0,
            378.0
          ]
        },
        {
          "text": "PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1379.0,
            398.0,
            1930.0,
            435.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1464.0,
            455.0,
            1845.0,
            492.0
          ]
        },
        {
          "text": "EXACT SCIENCES CORPORATION",
          "page": 0,
          "bbox": [
            1303.0,
            513.0,
            2008.0,
            545.0
          ]
        },
        {
          "text": "PFIZER INC.",
          "page": 0,
          "bbox": [
            1530.0,
            621.0,
            1778.0,
            658.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Exact Sciences Corporation",
      "page_number": 0,
      "words": [
        {
          "text": "EXACT SCIENCES CORPORATION",
          "bbox": [
            1303.0,
            513.0,
            2008.0,
            545.0
          ],
          "confidence": 0.9992802739143372
        }
      ],
      "nearby_headers": [
        {
          "text": "COLOGUARD?",
          "page": 0,
          "bbox": [
            1497.0,
            342.0,
            1812.0,
            378.0
          ]
        },
        {
          "text": "PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1379.0,
            398.0,
            1930.0,
            435.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1464.0,
            455.0,
            1845.0,
            492.0
          ]
        },
        {
          "text": "EXACT SCIENCES CORPORATION",
          "page": 0,
          "bbox": [
            1303.0,
            513.0,
            2008.0,
            545.0
          ]
        },
        {
          "text": "PFIZER INC.",
          "page": 0,
          "bbox": [
            1530.0,
            621.0,
            1778.0,
            658.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Pfizer",
      "page_number": 0,
      "words": [
        {
          "text": "PFIZER INC.",
          "bbox": [
            1530.0,
            621.0,
            1778.0,
            658.0
          ],
          "confidence": 0.9955017566680908
        }
      ],
      "nearby_headers": [
        {
          "text": "COLOGUARD?",
          "page": 0,
          "bbox": [
            1497.0,
            342.0,
            1812.0,
            378.0
          ]
        },
        {
          "text": "PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1379.0,
            398.0,
            1930.0,
            435.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1464.0,
            455.0,
            1845.0,
            492.0
          ]
        },
        {
          "text": "EXACT SCIENCES CORPORATION",
          "page": 0,
          "bbox": [
            1303.0,
            513.0,
            2008.0,
            545.0
          ]
        },
        {
          "text": "PFIZER INC.",
          "page": 0,
          "bbox": [
            1530.0,
            621.0,
            1778.0,
            658.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Agreement Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Agreement Date\" that should be reviewed by a lawyer. Details: The date of the contract",
      "answer_text": "August 21, 2018",
      "page_number": 0,
      "words": [
        {
          "text": "August 21, 2018",
          "bbox": [
            1493.0,
            676.0,
            1818.0,
            722.0
          ],
          "confidence": 0.9991703033447266
        }
      ],
      "nearby_headers": [
        {
          "text": "COLOGUARD?",
          "page": 0,
          "bbox": [
            1497.0,
            342.0,
            1812.0,
            378.0
          ]
        },
        {
          "text": "PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1379.0,
            398.0,
            1930.0,
            435.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1464.0,
            455.0,
            1845.0,
            492.0
          ]
        },
        {
          "text": "EXACT SCIENCES CORPORATION",
          "page": 0,
          "bbox": [
            1303.0,
            513.0,
            2008.0,
            545.0
          ]
        },
        {
          "text": "PFIZER INC.",
          "page": 0,
          "bbox": [
            1530.0,
            621.0,
            1778.0,
            658.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Effective Date_0",
      "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effectiveÂ ",
      "answer_text": "August 21, 2018",
      "page_number": 0,
      "words": [
        {
          "text": "August 21, 2018",
          "bbox": [
            1493.0,
            676.0,
            1818.0,
            722.0
          ],
          "confidence": 0.9991703033447266
        }
      ],
      "nearby_headers": [
        {
          "text": "COLOGUARD?",
          "page": 0,
          "bbox": [
            1497.0,
            342.0,
            1812.0,
            378.0
          ]
        },
        {
          "text": "PROMOTION AGREEMENT",
          "page": 0,
          "bbox": [
            1379.0,
            398.0,
            1930.0,
            435.0
          ]
        },
        {
          "text": "BY AND BETWEEN",
          "page": 0,
          "bbox": [
            1464.0,
            455.0,
            1845.0,
            492.0
          ]
        },
        {
          "text": "EXACT SCIENCES CORPORATION",
          "page": 0,
          "bbox": [
            1303.0,
            513.0,
            2008.0,
            545.0
          ]
        },
        {
          "text": "PFIZER INC.",
          "page": 0,
          "bbox": [
            1530.0,
            621.0,
            1778.0,
            658.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Expiration Date_4",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "This Agreement shall be effective as of the Effective Date and shall continue in effect through December 31, 2021 and any Renewal Term (the \"Term\"), unless terminated earlier as set forth herein.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Governing Law_4",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "This Agreement shall be governed by and interpreted in accordance with the substantive laws of the State of New York, without regard to conflict of law principles thereof.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Commencing on the Launch Date, Exact and its Affiliates hereby grant to Pfizer and its Affiliates, on an exclusive basis for the Co-Promote Field (except as to Exact and its Affiliates), and Pfizer accepts, the right and obligation to Promote and Detail the Product in the Territory during the Term jointly with Exact, in accordance with the terms and conditions of this Agreement, all Applicable Laws and the applicable Annual Marketing Plan.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1425.0,
            256.0,
            1880.0,
            292.0
          ],
          "confidence": 0.972561240196228
        },
        {
          "text": "Page",
          "bbox": [
            2886.0,
            309.0,
            2985.0,
            359.0
          ],
          "confidence": 0.9998502731323242
        },
        {
          "text": "1.",
          "bbox": [
            270.0,
            358.0,
            321.0,
            407.0
          ],
          "confidence": 0.8988077640533447
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            468.0,
            364.0,
            745.0,
            400.0
          ],
          "confidence": 0.9987927079200745
        },
        {
          "text": "1",
          "bbox": [
            2998.0,
            362.0,
            3030.0,
            402.0
          ],
          "confidence": 0.9999563694000244
        },
        {
          "text": "2.",
          "bbox": [
            263.0,
            408.0,
            326.0,
            469.0
          ],
          "confidence": 0.9996874332427979
        },
        {
          "text": "GOVERNANCE",
          "bbox": [
            468.0,
            420.0,
            774.0,
            457.0
          ],
          "confidence": 0.9996355772018433
        },
        {
          "text": "10",
          "bbox": [
            2974.0,
            417.0,
            3034.0,
            460.0
          ],
          "confidence": 0.9995191097259521
        },
        {
          "text": "2.1",
          "bbox": [
            462.0,
            471.0,
            522.0,
            517.0
          ],
          "confidence": 0.9998382925987244
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            651.0,
            475.0,
            1115.0,
            517.0
          ],
          "confidence": 0.9998593926429749
        },
        {
          "text": "10",
          "bbox": [
            2982.0,
            471.0,
            3034.0,
            517.0
          ],
          "confidence": 0.9996199607849121
        },
        {
          "text": "2.2",
          "bbox": [
            462.0,
            528.0,
            524.0,
            572.0
          ],
          "confidence": 0.999803364276886
        },
        {
          "text": "Joint Operations Committee",
          "bbox": [
            652.0,
            534.0,
            1167.0,
            570.0
          ],
          "confidence": 0.9999331831932068
        },
        {
          "text": "13",
          "bbox": [
            2983.0,
            530.0,
            3030.0,
            572.0
          ],
          "confidence": 0.9999063611030579
        },
        {
          "text": "2.3",
          "bbox": [
            462.0,
            583.0,
            522.0,
            629.0
          ],
          "confidence": 0.9998774528503418
        },
        {
          "text": "Joint Review Committee",
          "bbox": [
            651.0,
            587.0,
            1097.0,
            627.0
          ],
          "confidence": 0.976010262966156
        },
        {
          "text": "14",
          "bbox": [
            2977.0,
            580.0,
            3036.0,
            632.0
          ],
          "confidence": 0.9999385476112366
        },
        {
          "text": "2.4",
          "bbox": [
            462.0,
            640.0,
            524.0,
            683.0
          ],
          "confidence": 0.9998382925987244
        },
        {
          "text": "Finance Representative",
          "bbox": [
            652.0,
            643.0,
            1089.0,
            683.0
          ],
          "confidence": 0.9999425411224365
        },
        {
          "text": "15",
          "bbox": [
            2982.0,
            638.0,
            3032.0,
            685.0
          ],
          "confidence": 0.9998509287834167
        },
        {
          "text": "2.5",
          "bbox": [
            462.0,
            696.0,
            524.0,
            740.0
          ],
          "confidence": 0.9998595118522644
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            652.0,
            696.0,
            1010.0,
            744.0
          ],
          "confidence": 0.9999042749404907
        },
        {
          "text": "15",
          "bbox": [
            2982.0,
            694.0,
            3032.0,
            742.0
          ],
          "confidence": 0.9997546076774597
        },
        {
          "text": "2.6",
          "bbox": [
            462.0,
            751.0,
            526.0,
            797.0
          ],
          "confidence": 0.9999013543128967
        },
        {
          "text": "Compliance Managers",
          "bbox": [
            651.0,
            753.0,
            1073.0,
            801.0
          ],
          "confidence": 0.9998858571052551
        },
        {
          "text": "16",
          "bbox": [
            2979.0,
            748.0,
            3035.0,
            800.0
          ],
          "confidence": 0.9997362494468689
        },
        {
          "text": "3.",
          "bbox": [
            272.0,
            810.0,
            319.0,
            852.0
          ],
          "confidence": 0.9999758005142212
        },
        {
          "text": "APPOINTMENT; PRODUCT OWNERSHIP; MARKETING AND SALES",
          "bbox": [
            468.0,
            813.0,
            1843.0,
            850.0
          ],
          "confidence": 0.9891181588172913
        },
        {
          "text": "17",
          "bbox": [
            2972.0,
            810.0,
            3032.0,
            853.0
          ],
          "confidence": 0.9998164176940918
        },
        {
          "text": "3.1",
          "bbox": [
            462.0,
            864.0,
            522.0,
            908.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "Appointment",
          "bbox": [
            650.0,
            866.0,
            906.0,
            912.0
          ],
          "confidence": 0.9999716281890869
        },
        {
          "text": "17",
          "bbox": [
            2980.0,
            864.0,
            3032.0,
            910.0
          ],
          "confidence": 0.9999139308929443
        },
        {
          "text": "3.2",
          "bbox": [
            462.0,
            921.0,
            524.0,
            965.0
          ],
          "confidence": 0.9997804760932922
        },
        {
          "text": "Responsibility for Product",
          "bbox": [
            652.0,
            925.0,
            1146.0,
            967.0
          ],
          "confidence": 0.9999520182609558
        },
        {
          "text": "19",
          "bbox": [
            2983.0,
            923.0,
            3030.0,
            965.0
          ],
          "confidence": 0.9998000860214233
        },
        {
          "text": "3.3",
          "bbox": [
            462.0,
            978.0,
            524.0,
            1021.0
          ],
          "confidence": 0.9999095797538757
        },
        {
          "text": "Annual Marketing Plan",
          "bbox": [
            654.0,
            981.0,
            1086.0,
            1018.0
          ],
          "confidence": 0.9967995882034302
        },
        {
          "text": "26",
          "bbox": [
            2980.0,
            976.0,
            3032.0,
            1021.0
          ],
          "confidence": 0.9998294115066528
        },
        {
          "text": "3.4",
          "bbox": [
            462.0,
            1032.0,
            524.0,
            1076.0
          ],
          "confidence": 0.999795138835907
        },
        {
          "text": "Sales Promotion, Detailing Efforts and IDN Promotion",
          "bbox": [
            654.0,
            1038.0,
            1651.0,
            1074.0
          ],
          "confidence": 0.9988903403282166
        },
        {
          "text": "27",
          "bbox": [
            2980.0,
            1032.0,
            3032.0,
            1080.0
          ],
          "confidence": 0.999879777431488
        },
        {
          "text": "3.5",
          "bbox": [
            462.0,
            1089.0,
            524.0,
            1133.0
          ],
          "confidence": 0.999901533126831
        },
        {
          "text": "Pfizer Investment and Support.",
          "bbox": [
            652.0,
            1091.0,
            1218.0,
            1133.0
          ],
          "confidence": 0.9910087585449219
        },
        {
          "text": "28",
          "bbox": [
            2980.0,
            1089.0,
            3032.0,
            1137.0
          ],
          "confidence": 0.9999079704284668
        },
        {
          "text": "3.6",
          "bbox": [
            462.0,
            1146.0,
            526.0,
            1190.0
          ],
          "confidence": 0.999901533126831
        },
        {
          "text": "Exact Investment and Support.",
          "bbox": [
            651.0,
            1146.0,
            1218.0,
            1191.0
          ],
          "confidence": 0.9756210446357727
        },
        {
          "text": "29",
          "bbox": [
            2980.0,
            1144.0,
            3032.0,
            1191.0
          ],
          "confidence": 0.9997735023498535
        },
        {
          "text": "3.7",
          "bbox": [
            462.0,
            1201.0,
            524.0,
            1246.0
          ],
          "confidence": 0.9998155236244202
        },
        {
          "text": "Changes in Shared M&P Expenses.",
          "bbox": [
            651.0,
            1202.0,
            1300.0,
            1248.0
          ],
          "confidence": 0.9710713624954224
        },
        {
          "text": "30",
          "bbox": [
            2980.0,
            1199.0,
            3032.0,
            1246.0
          ],
          "confidence": 0.9996087551116943
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1259.0,
            317.0,
            1301.0
          ],
          "confidence": 0.9998270273208618
        },
        {
          "text": "ACCOUNTING",
          "bbox": [
            466.0,
            1261.0,
            761.0,
            1299.0
          ],
          "confidence": 0.9994717836380005
        },
        {
          "text": "30",
          "bbox": [
            2972.0,
            1257.0,
            3032.0,
            1301.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "4.1",
          "bbox": [
            462.0,
            1312.0,
            522.0,
            1358.0
          ],
          "confidence": 0.9998102784156799
        },
        {
          "text": "Responsibility for Shared M&P Expenses.",
          "bbox": [
            652.0,
            1318.0,
            1423.0,
            1360.0
          ],
          "confidence": 0.9861323237419128
        },
        {
          "text": "30",
          "bbox": [
            2976.0,
            1309.0,
            3034.0,
            1361.0
          ],
          "confidence": 0.9994354844093323
        },
        {
          "text": "4.2",
          "bbox": [
            462.0,
            1369.0,
            524.0,
            1414.0
          ],
          "confidence": 0.99981290102005
        },
        {
          "text": "Promotion Fee",
          "bbox": [
            654.0,
            1374.0,
            924.0,
            1411.0
          ],
          "confidence": 0.9999128580093384
        },
        {
          "text": "31",
          "bbox": [
            2980.0,
            1367.0,
            3030.0,
            1414.0
          ],
          "confidence": 0.9999569058418274
        },
        {
          "text": "4.3",
          "bbox": [
            462.0,
            1425.0,
            524.0,
            1469.0
          ],
          "confidence": 0.9997981190681458
        },
        {
          "text": "Fee Statements and Payments",
          "bbox": [
            651.0,
            1427.0,
            1211.0,
            1469.0
          ],
          "confidence": 0.9828200936317444
        },
        {
          "text": "33",
          "bbox": [
            2982.0,
            1427.0,
            3029.0,
            1469.0
          ],
          "confidence": 0.9999467730522156
        },
        {
          "text": "4.4",
          "bbox": [
            462.0,
            1482.0,
            524.0,
            1526.0
          ],
          "confidence": 0.9997560381889343
        },
        {
          "text": "Taxes and Withholding.",
          "bbox": [
            649.0,
            1478.0,
            1086.0,
            1530.0
          ],
          "confidence": 0.977773904800415
        },
        {
          "text": "34",
          "bbox": [
            2980.0,
            1482.0,
            3032.0,
            1528.0
          ],
          "confidence": 0.9999403357505798
        },
        {
          "text": "4.5",
          "bbox": [
            462.0,
            1537.0,
            524.0,
            1582.0
          ],
          "confidence": 0.9998634457588196
        },
        {
          "text": "No Partnership Provision",
          "bbox": [
            651.0,
            1540.0,
            1122.0,
            1583.0
          ],
          "confidence": 0.9925678372383118
        },
        {
          "text": "35",
          "bbox": [
            2980.0,
            1537.0,
            3032.0,
            1582.0
          ],
          "confidence": 0.9999524354934692
        },
        {
          "text": "4.6",
          "bbox": [
            462.0,
            1595.0,
            526.0,
            1639.0
          ],
          "confidence": 0.9998771548271179
        },
        {
          "text": "Payments; Currency.",
          "bbox": [
            650.0,
            1593.0,
            1033.0,
            1643.0
          ],
          "confidence": 0.9698137044906616
        },
        {
          "text": "35",
          "bbox": [
            2980.0,
            1593.0,
            3032.0,
            1639.0
          ],
          "confidence": 0.9999392032623291
        },
        {
          "text": "4.7",
          "bbox": [
            462.0,
            1650.0,
            524.0,
            1694.0
          ],
          "confidence": 0.999767005443573
        },
        {
          "text": "Maintenance of Records; Audits.",
          "bbox": [
            652.0,
            1656.0,
            1265.0,
            1692.0
          ],
          "confidence": 0.9820064306259155
        },
        {
          "text": "35",
          "bbox": [
            2980.0,
            1650.0,
            3032.0,
            1696.0
          ],
          "confidence": 0.9999517202377319
        },
        {
          "text": "5.",
          "bbox": [
            274.0,
            1705.0,
            317.0,
            1751.0
          ],
          "confidence": 0.9999572038650513
        },
        {
          "text": "REPRESENTATIONS, WARRANTIES AND COVENANTS",
          "bbox": [
            468.0,
            1710.0,
            1580.0,
            1747.0
          ],
          "confidence": 0.9886522889137268
        },
        {
          "text": "37",
          "bbox": [
            2972.0,
            1707.0,
            3032.0,
            1751.0
          ],
          "confidence": 0.9999163746833801
        },
        {
          "text": "5.1",
          "bbox": [
            464.0,
            1762.0,
            522.0,
            1807.0
          ],
          "confidence": 0.9998762607574463
        },
        {
          "text": "Mutual Representations and Warranties.",
          "bbox": [
            652.0,
            1765.0,
            1401.0,
            1807.0
          ],
          "confidence": 0.9904761910438538
        },
        {
          "text": "37",
          "bbox": [
            2980.0,
            1763.0,
            3032.0,
            1809.0
          ],
          "confidence": 0.9999504089355469
        },
        {
          "text": "5.2",
          "bbox": [
            464.0,
            1818.0,
            524.0,
            1864.0
          ],
          "confidence": 0.9026532173156738
        },
        {
          "text": "Representations and Warranties of Exact",
          "bbox": [
            652.0,
            1822.0,
            1410.0,
            1862.0
          ],
          "confidence": 0.9908421039581299
        },
        {
          "text": "38",
          "bbox": [
            2980.0,
            1818.0,
            3032.0,
            1866.0
          ],
          "confidence": 0.9998841285705566
        },
        {
          "text": "5.3",
          "bbox": [
            464.0,
            1873.0,
            524.0,
            1919.0
          ],
          "confidence": 0.8968498110771179
        },
        {
          "text": "Covenants",
          "bbox": [
            652.0,
            1876.0,
            859.0,
            1919.0
          ],
          "confidence": 0.9998775124549866
        },
        {
          "text": "39",
          "bbox": [
            2980.0,
            1873.0,
            3032.0,
            1919.0
          ],
          "confidence": 0.9998854994773865
        },
        {
          "text": "5.4",
          "bbox": [
            461.0,
            1927.0,
            527.0,
            1978.0
          ],
          "confidence": 0.9997851848602295
        },
        {
          "text": "Compliance with Law and Ethical Business Practices",
          "bbox": [
            656.0,
            1935.0,
            1626.0,
            1972.0
          ],
          "confidence": 0.9921623468399048
        },
        {
          "text": "40",
          "bbox": [
            2980.0,
            1930.0,
            3032.0,
            1975.0
          ],
          "confidence": 0.9993378520011902
        },
        {
          "text": "5.5",
          "bbox": [
            464.0,
            1986.0,
            524.0,
            2032.0
          ],
          "confidence": 0.8501482009887695
        },
        {
          "text": "Notice of Investigations",
          "bbox": [
            651.0,
            1988.0,
            1106.0,
            2030.0
          ],
          "confidence": 0.9999415278434753
        },
        {
          "text": "43",
          "bbox": [
            2982.0,
            1988.0,
            3029.0,
            2030.0
          ],
          "confidence": 0.9999153017997742
        },
        {
          "text": "5.6",
          "bbox": [
            464.0,
            2041.0,
            524.0,
            2087.0
          ],
          "confidence": 0.9998176693916321
        },
        {
          "text": "Representation by Legal Counsel",
          "bbox": [
            654.0,
            2047.0,
            1276.0,
            2089.0
          ],
          "confidence": 0.9850961565971375
        },
        {
          "text": "43",
          "bbox": [
            2976.0,
            2038.0,
            3032.0,
            2088.0
          ],
          "confidence": 0.9999315142631531
        },
        {
          "text": "5.7",
          "bbox": [
            462.0,
            2098.0,
            524.0,
            2143.0
          ],
          "confidence": 0.9998096823692322
        },
        {
          "text": "No Inconsistent Agreements.",
          "bbox": [
            652.0,
            2100.0,
            1193.0,
            2145.0
          ],
          "confidence": 0.9836775660514832
        },
        {
          "text": "43",
          "bbox": [
            2977.0,
            2093.0,
            3034.0,
            2147.0
          ],
          "confidence": 0.9998714327812195
        },
        {
          "text": "5.8",
          "bbox": [
            464.0,
            2154.0,
            524.0,
            2200.0
          ],
          "confidence": 0.999863862991333
        },
        {
          "text": "Disclaimer",
          "bbox": [
            652.0,
            2158.0,
            848.0,
            2196.0
          ],
          "confidence": 0.9999488592147827
        },
        {
          "text": "44",
          "bbox": [
            2980.0,
            2154.0,
            3032.0,
            2200.0
          ],
          "confidence": 0.999557614326477
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            2213.0,
            319.0,
            2255.0
          ],
          "confidence": 0.7983464002609253
        },
        {
          "text": "INDEMNIFICATION; LIMITATION OF LIABILITY AND INSURANCE",
          "bbox": [
            466.0,
            2217.0,
            1798.0,
            2253.0
          ],
          "confidence": 0.9960425496101379
        },
        {
          "text": "44",
          "bbox": [
            2976.0,
            2215.0,
            3032.0,
            2253.0
          ],
          "confidence": 0.9999170899391174
        },
        {
          "text": "6.1",
          "bbox": [
            462.0,
            2268.0,
            522.0,
            2312.0
          ],
          "confidence": 0.9997587203979492
        },
        {
          "text": "Indemnification",
          "bbox": [
            652.0,
            2269.0,
            944.0,
            2310.0
          ],
          "confidence": 0.9998759031295776
        },
        {
          "text": "44",
          "bbox": [
            2980.0,
            2268.0,
            3032.0,
            2313.0
          ],
          "confidence": 0.99964839220047
        },
        {
          "text": "6.2",
          "bbox": [
            464.0,
            2323.0,
            524.0,
            2368.0
          ],
          "confidence": 0.9997497200965881
        },
        {
          "text": "Insurance Requirements",
          "bbox": [
            651.0,
            2324.0,
            1108.0,
            2370.0
          ],
          "confidence": 0.9962896704673767
        },
        {
          "text": "45",
          "bbox": [
            2983.0,
            2324.0,
            3030.0,
            2366.0
          ],
          "confidence": 0.9999210834503174
        },
        {
          "text": "6.3",
          "bbox": [
            464.0,
            2379.0,
            524.0,
            2423.0
          ],
          "confidence": 0.9997426867485046
        },
        {
          "text": "Limitation of Liability.",
          "bbox": [
            649.0,
            2377.0,
            1048.0,
            2427.0
          ],
          "confidence": 0.9703847765922546
        },
        {
          "text": "46",
          "bbox": [
            2983.0,
            2381.0,
            3030.0,
            2423.0
          ],
          "confidence": 0.9999144077301025
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4437.0,
            1287.0,
            4479.0
          ],
          "confidence": 0.9897373914718628
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1425.0,
            256.0,
            1880.0,
            292.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 1,
          "bbox": [
            468.0,
            364.0,
            745.0,
            400.0
          ]
        },
        {
          "text": "GOVERNANCE",
          "page": 1,
          "bbox": [
            468.0,
            420.0,
            774.0,
            457.0
          ]
        },
        {
          "text": "APPOINTMENT; PRODUCT OWNERSHIP; MARKETING AND SALES",
          "page": 1,
          "bbox": [
            468.0,
            813.0,
            1843.0,
            850.0
          ]
        },
        {
          "text": "ACCOUNTING",
          "page": 1,
          "bbox": [
            466.0,
            1261.0,
            761.0,
            1299.0
          ]
        },
        {
          "text": "REPRESENTATIONS, WARRANTIES AND COVENANTS",
          "page": 1,
          "bbox": [
            468.0,
            1710.0,
            1580.0,
            1747.0
          ]
        },
        {
          "text": "INDEMNIFICATION; LIMITATION OF LIABILITY AND INSURANCE",
          "page": 1,
          "bbox": [
            466.0,
            2217.0,
            1798.0,
            2253.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Exclusivity_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Commencing on the Launch Date, Exact and its Affiliates hereby grant to Pfizer and its Affiliates, on an exclusive basis for the Co-Promote Field (except as to Exact and its Affiliates), and Pfizer accepts, the right and obligation to Promote and Detail the Product in the Territory during the Term jointly with Exact, in accordance with the terms and conditions of this Agreement, all Applicable Laws and the applicable Annual Marketing Plan.",
      "page_number": 2,
      "words": [
        {
          "text": "7.",
          "bbox": [
            274.0,
            254.0,
            317.0,
            300.0
          ],
          "confidence": 0.9998791813850403
        },
        {
          "text": "CONFIDENTIALITY; PUBLICITY",
          "bbox": [
            469.0,
            258.0,
            1115.0,
            294.0
          ],
          "confidence": 0.9989007711410522
        },
        {
          "text": "46",
          "bbox": [
            2974.0,
            254.0,
            3032.0,
            300.0
          ],
          "confidence": 0.9997206926345825
        },
        {
          "text": "7.1",
          "bbox": [
            462.0,
            311.0,
            522.0,
            355.0
          ],
          "confidence": 0.9999106526374817
        },
        {
          "text": "Confidentiality",
          "bbox": [
            650.0,
            309.0,
            930.0,
            358.0
          ],
          "confidence": 0.9999611973762512
        },
        {
          "text": "46",
          "bbox": [
            2980.0,
            311.0,
            3032.0,
            356.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "7.2",
          "bbox": [
            462.0,
            367.0,
            524.0,
            411.0
          ],
          "confidence": 0.9996507167816162
        },
        {
          "text": "Authorized Disclosure and Use",
          "bbox": [
            654.0,
            371.0,
            1236.0,
            407.0
          ],
          "confidence": 0.993081271648407
        },
        {
          "text": "47",
          "bbox": [
            2976.0,
            362.0,
            3034.0,
            414.0
          ],
          "confidence": 0.9998974204063416
        },
        {
          "text": "7.3",
          "bbox": [
            462.0,
            422.0,
            522.0,
            468.0
          ],
          "confidence": 0.9999073147773743
        },
        {
          "text": "Certain Regulatory Filings",
          "bbox": [
            651.0,
            422.0,
            1140.0,
            472.0
          ],
          "confidence": 0.9997837543487549
        },
        {
          "text": "47",
          "bbox": [
            2980.0,
            422.0,
            3032.0,
            468.0
          ],
          "confidence": 0.9999006986618042
        },
        {
          "text": "7.4",
          "bbox": [
            462.0,
            479.0,
            524.0,
            523.0
          ],
          "confidence": 0.9998576641082764
        },
        {
          "text": "Public Announcements",
          "bbox": [
            652.0,
            480.0,
            1093.0,
            523.0
          ],
          "confidence": 0.9984183311462402
        },
        {
          "text": "47",
          "bbox": [
            2980.0,
            479.0,
            3032.0,
            524.0
          ],
          "confidence": 0.999897301197052
        },
        {
          "text": "7.5",
          "bbox": [
            462.0,
            534.0,
            524.0,
            579.0
          ],
          "confidence": 0.9998933672904968
        },
        {
          "text": "Use of Names",
          "bbox": [
            650.0,
            535.0,
            914.0,
            578.0
          ],
          "confidence": 0.97193843126297
        },
        {
          "text": "48",
          "bbox": [
            2983.0,
            537.0,
            3030.0,
            579.0
          ],
          "confidence": 0.9995381236076355
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            592.0,
            317.0,
            636.0
          ],
          "confidence": 0.9999796152114868
        },
        {
          "text": "TERM AND TERMINATION",
          "bbox": [
            468.0,
            598.0,
            1008.0,
            629.0
          ],
          "confidence": 0.9702898263931274
        },
        {
          "text": "48",
          "bbox": [
            2974.0,
            590.0,
            3032.0,
            636.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "8.1",
          "bbox": [
            462.0,
            647.0,
            522.0,
            693.0
          ],
          "confidence": 0.9998836517333984
        },
        {
          "text": "Term",
          "bbox": [
            647.0,
            647.0,
            749.0,
            693.0
          ],
          "confidence": 0.9997935891151428
        },
        {
          "text": "48",
          "bbox": [
            2980.0,
            647.0,
            3032.0,
            694.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "8.2",
          "bbox": [
            464.0,
            704.0,
            524.0,
            747.0
          ],
          "confidence": 0.9999227523803711
        },
        {
          "text": "Renewal",
          "bbox": [
            652.0,
            705.0,
            814.0,
            744.0
          ],
          "confidence": 0.9998234510421753
        },
        {
          "text": "48",
          "bbox": [
            2982.0,
            702.0,
            3032.0,
            749.0
          ],
          "confidence": 0.9999050498008728
        },
        {
          "text": "8.3",
          "bbox": [
            461.0,
            756.0,
            525.0,
            806.0
          ],
          "confidence": 0.9998739361763
        },
        {
          "text": "Termination for Cause",
          "bbox": [
            652.0,
            764.0,
            1062.0,
            800.0
          ],
          "confidence": 0.9999273419380188
        },
        {
          "text": "48",
          "bbox": [
            2983.0,
            760.0,
            3030.0,
            802.0
          ],
          "confidence": 0.9998279809951782
        },
        {
          "text": "8.4",
          "bbox": [
            466.0,
            819.0,
            526.0,
            859.0
          ],
          "confidence": 0.9999211430549622
        },
        {
          "text": "Termination Without Cause",
          "bbox": [
            651.0,
            817.0,
            1164.0,
            857.0
          ],
          "confidence": 0.9992270469665527
        },
        {
          "text": "49",
          "bbox": [
            2980.0,
            813.0,
            3032.0,
            861.0
          ],
          "confidence": 0.9997913241386414
        },
        {
          "text": "8.5",
          "bbox": [
            462.0,
            870.0,
            524.0,
            915.0
          ],
          "confidence": 0.9999166131019592
        },
        {
          "text": "Mutual Termination",
          "bbox": [
            652.0,
            873.0,
            1021.0,
            914.0
          ],
          "confidence": 0.9999244213104248
        },
        {
          "text": "49",
          "bbox": [
            2982.0,
            870.0,
            3032.0,
            917.0
          ],
          "confidence": 0.9998093843460083
        },
        {
          "text": "8.6",
          "bbox": [
            462.0,
            928.0,
            526.0,
            972.0
          ],
          "confidence": 0.9998876452445984
        },
        {
          "text": "Termination for Change of Control",
          "bbox": [
            651.0,
            930.0,
            1291.0,
            970.0
          ],
          "confidence": 0.9878026843070984
        },
        {
          "text": "49",
          "bbox": [
            2982.0,
            926.0,
            3032.0,
            974.0
          ],
          "confidence": 0.9998805522918701
        },
        {
          "text": "8.7",
          "bbox": [
            462.0,
            985.0,
            524.0,
            1029.0
          ],
          "confidence": 0.9998836517333984
        },
        {
          "text": "Royalty Upon Expiration",
          "bbox": [
            651.0,
            985.0,
            1113.0,
            1031.0
          ],
          "confidence": 0.9998092651367188
        },
        {
          "text": "49",
          "bbox": [
            2980.0,
            983.0,
            3032.0,
            1029.0
          ],
          "confidence": 0.9997520446777344
        },
        {
          "text": "8.8",
          "bbox": [
            462.0,
            1040.0,
            524.0,
            1085.0
          ],
          "confidence": 0.9999175071716309
        },
        {
          "text": "Consequences of Termination",
          "bbox": [
            654.0,
            1043.0,
            1209.0,
            1084.0
          ],
          "confidence": 0.9935645461082458
        },
        {
          "text": "50",
          "bbox": [
            2983.0,
            1042.0,
            3030.0,
            1084.0
          ],
          "confidence": 0.9998683929443359
        },
        {
          "text": "8.9",
          "bbox": [
            464.0,
            1095.0,
            524.0,
            1140.0
          ],
          "confidence": 0.9999069571495056
        },
        {
          "text": "Survival of Certain Obligations",
          "bbox": [
            651.0,
            1096.0,
            1229.0,
            1142.0
          ],
          "confidence": 0.9996927380561829
        },
        {
          "text": "50",
          "bbox": [
            2980.0,
            1095.0,
            3032.0,
            1140.0
          ],
          "confidence": 0.999791145324707
        },
        {
          "text": "9.",
          "bbox": [
            274.0,
            1151.0,
            317.0,
            1197.0
          ],
          "confidence": 0.9999210834503174
        },
        {
          "text": "MISCELLANEOUS",
          "bbox": [
            464.0,
            1153.0,
            837.0,
            1191.0
          ],
          "confidence": 0.9989362955093384
        },
        {
          "text": "51",
          "bbox": [
            2974.0,
            1151.0,
            3030.0,
            1197.0
          ],
          "confidence": 0.9999614357948303
        },
        {
          "text": "9.1",
          "bbox": [
            462.0,
            1208.0,
            522.0,
            1254.0
          ],
          "confidence": 0.9999165534973145
        },
        {
          "text": "Interpretation",
          "bbox": [
            654.0,
            1213.0,
            910.0,
            1252.0
          ],
          "confidence": 0.9999763369560242
        },
        {
          "text": "51",
          "bbox": [
            2982.0,
            1210.0,
            3029.0,
            1252.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "9.2",
          "bbox": [
            462.0,
            1265.0,
            524.0,
            1308.0
          ],
          "confidence": 0.9998903274536133
        },
        {
          "text": "Assignment",
          "bbox": [
            652.0,
            1268.0,
            884.0,
            1312.0
          ],
          "confidence": 0.999955952167511
        },
        {
          "text": "51",
          "bbox": [
            2980.0,
            1263.0,
            3030.0,
            1310.0
          ],
          "confidence": 0.9998958706855774
        },
        {
          "text": "9.3",
          "bbox": [
            462.0,
            1319.0,
            524.0,
            1365.0
          ],
          "confidence": 0.9999290108680725
        },
        {
          "text": "Further Actions",
          "bbox": [
            652.0,
            1325.0,
            952.0,
            1363.0
          ],
          "confidence": 0.9999575018882751
        },
        {
          "text": "51",
          "bbox": [
            2980.0,
            1319.0,
            3030.0,
            1367.0
          ],
          "confidence": 0.9998900890350342
        },
        {
          "text": "9.4",
          "bbox": [
            462.0,
            1376.0,
            526.0,
            1420.0
          ],
          "confidence": 0.9998784065246582
        },
        {
          "text": "Force Majeure.",
          "bbox": [
            652.0,
            1381.0,
            923.0,
            1420.0
          ],
          "confidence": 0.9674030542373657
        },
        {
          "text": "51",
          "bbox": [
            2980.0,
            1374.0,
            3030.0,
            1422.0
          ],
          "confidence": 0.9997887015342712
        },
        {
          "text": "9.5",
          "bbox": [
            462.0,
            1433.0,
            524.0,
            1476.0
          ],
          "confidence": 0.9998992085456848
        },
        {
          "text": "Notices",
          "bbox": [
            649.0,
            1432.0,
            800.0,
            1477.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "52",
          "bbox": [
            2980.0,
            1433.0,
            3032.0,
            1478.0
          ],
          "confidence": 0.9999459385871887
        },
        {
          "text": "9.6",
          "bbox": [
            462.0,
            1487.0,
            526.0,
            1533.0
          ],
          "confidence": 0.999930202960968
        },
        {
          "text": "Amendment",
          "bbox": [
            650.0,
            1487.0,
            885.0,
            1535.0
          ],
          "confidence": 0.9999175667762756
        },
        {
          "text": "53",
          "bbox": [
            2982.0,
            1486.0,
            3030.0,
            1535.0
          ],
          "confidence": 0.9999337792396545
        },
        {
          "text": "9.7",
          "bbox": [
            462.0,
            1544.0,
            524.0,
            1590.0
          ],
          "confidence": 0.9998974800109863
        },
        {
          "text": "Waiver",
          "bbox": [
            650.0,
            1546.0,
            791.0,
            1590.0
          ],
          "confidence": 0.9999167919158936
        },
        {
          "text": "53",
          "bbox": [
            2982.0,
            1542.0,
            3030.0,
            1592.0
          ],
          "confidence": 0.9999328851699829
        },
        {
          "text": "9.8",
          "bbox": [
            462.0,
            1601.0,
            524.0,
            1645.0
          ],
          "confidence": 0.9999217987060547
        },
        {
          "text": "Severability",
          "bbox": [
            649.0,
            1600.0,
            872.0,
            1649.0
          ],
          "confidence": 0.9999056458473206
        },
        {
          "text": "53",
          "bbox": [
            2983.0,
            1603.0,
            3029.0,
            1645.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "9.9",
          "bbox": [
            462.0,
            1657.0,
            524.0,
            1701.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Descriptive Headings",
          "bbox": [
            649.0,
            1659.0,
            1055.0,
            1705.0
          ],
          "confidence": 0.999782383441925
        },
        {
          "text": "53",
          "bbox": [
            2983.0,
            1659.0,
            3029.0,
            1701.0
          ],
          "confidence": 0.9999603629112244
        },
        {
          "text": "9.10",
          "bbox": [
            462.0,
            1714.0,
            544.0,
            1756.0
          ],
          "confidence": 0.9999563694000244
        },
        {
          "text": "Governing Law",
          "bbox": [
            650.0,
            1714.0,
            941.0,
            1764.0
          ],
          "confidence": 0.999907374382019
        },
        {
          "text": "53",
          "bbox": [
            2983.0,
            1714.0,
            3029.0,
            1756.0
          ],
          "confidence": 0.9999500513076782
        },
        {
          "text": "9.11",
          "bbox": [
            464.0,
            1771.0,
            540.0,
            1813.0
          ],
          "confidence": 0.9998437166213989
        },
        {
          "text": "Dispute Resolution",
          "bbox": [
            654.0,
            1774.0,
            1013.0,
            1813.0
          ],
          "confidence": 0.9999619722366333
        },
        {
          "text": "53",
          "bbox": [
            2983.0,
            1771.0,
            3029.0,
            1813.0
          ],
          "confidence": 0.9999603629112244
        },
        {
          "text": "9.12",
          "bbox": [
            462.0,
            1824.0,
            546.0,
            1871.0
          ],
          "confidence": 0.9999512434005737
        },
        {
          "text": "Entire Agreement of the Parties",
          "bbox": [
            652.0,
            1829.0,
            1236.0,
            1871.0
          ],
          "confidence": 0.987617015838623
        },
        {
          "text": "54",
          "bbox": [
            2983.0,
            1826.0,
            3030.0,
            1868.0
          ],
          "confidence": 0.9999532103538513
        },
        {
          "text": "9.13",
          "bbox": [
            460.0,
            1880.0,
            546.0,
            1928.0
          ],
          "confidence": 0.9999438524246216
        },
        {
          "text": "Independent Contractors",
          "bbox": [
            654.0,
            1888.0,
            1122.0,
            1924.0
          ],
          "confidence": 0.9999504089355469
        },
        {
          "text": "54",
          "bbox": [
            2983.0,
            1882.0,
            3030.0,
            1924.0
          ],
          "confidence": 0.9999532103538513
        },
        {
          "text": "9.14",
          "bbox": [
            464.0,
            1939.0,
            546.0,
            1981.0
          ],
          "confidence": 0.9999440908432007
        },
        {
          "text": "No Legal Advice",
          "bbox": [
            651.0,
            1941.0,
            970.0,
            1984.0
          ],
          "confidence": 0.9905310869216919
        },
        {
          "text": "54",
          "bbox": [
            2980.0,
            1937.0,
            3032.0,
            1983.0
          ],
          "confidence": 0.9999135732650757
        },
        {
          "text": "9.15",
          "bbox": [
            460.0,
            1992.0,
            546.0,
            2039.0
          ],
          "confidence": 0.9999337196350098
        },
        {
          "text": "Counterparts",
          "bbox": [
            650.0,
            1995.0,
            899.0,
            2043.0
          ],
          "confidence": 0.9999749064445496
        },
        {
          "text": "54",
          "bbox": [
            2983.0,
            1995.0,
            3030.0,
            2037.0
          ],
          "confidence": 0.9999554753303528
        },
        {
          "text": "EXHIBITS",
          "bbox": [
            277.0,
            2054.0,
            482.0,
            2092.0
          ],
          "confidence": 0.9985084533691406
        },
        {
          "text": "Exhibit 1.24",
          "bbox": [
            275.0,
            2105.0,
            490.0,
            2147.0
          ],
          "confidence": 0.9998055100440979
        },
        {
          "text": "Cost of Sales",
          "bbox": [
            808.0,
            2109.0,
            1053.0,
            2147.0
          ],
          "confidence": 0.9995453953742981
        },
        {
          "text": "Exhibit 1.39",
          "bbox": [
            277.0,
            2165.0,
            488.0,
            2202.0
          ],
          "confidence": 0.9993863105773926
        },
        {
          "text": "Exact Trademarks",
          "bbox": [
            810.0,
            2167.0,
            1129.0,
            2204.0
          ],
          "confidence": 0.9999196529388428
        },
        {
          "text": "Exhibit 2.2(c)(iv)",
          "bbox": [
            273.0,
            2214.0,
            580.0,
            2264.0
          ],
          "confidence": 0.9976734519004822
        },
        {
          "text": "Calendar Quarter Performance Metrics.",
          "bbox": [
            808.0,
            2220.0,
            1517.0,
            2260.0
          ],
          "confidence": 0.9893094897270203
        },
        {
          "text": "Exhibit 3.2(c)(i)",
          "bbox": [
            277.0,
            2273.0,
            555.0,
            2321.0
          ],
          "confidence": 0.9983024597167969
        },
        {
          "text": "Sales Deployment Plan",
          "bbox": [
            806.0,
            2275.0,
            1236.0,
            2321.0
          ],
          "confidence": 0.9996693134307861
        },
        {
          "text": "Exhibit 3.3(b)",
          "bbox": [
            273.0,
            2328.0,
            521.0,
            2378.0
          ],
          "confidence": 0.9708530306816101
        },
        {
          "text": "Annua1 Marketing Plan Outline",
          "bbox": [
            810.0,
            2337.0,
            1387.0,
            2374.0
          ],
          "confidence": 0.9817324876785278
        },
        {
          "text": "Exhibit 3.4(a)",
          "bbox": [
            273.0,
            2384.0,
            517.0,
            2434.0
          ],
          "confidence": 0.9990342855453491
        },
        {
          "text": "Promotion Fee Reduction",
          "bbox": [
            807.0,
            2392.0,
            1280.0,
            2429.0
          ],
          "confidence": 0.9958807826042175
        },
        {
          "text": "Exhibit 7.4",
          "bbox": [
            277.0,
            2447.0,
            469.0,
            2485.0
          ],
          "confidence": 0.9636997580528259
        },
        {
          "text": "Press Release",
          "bbox": [
            807.0,
            2447.0,
            1064.0,
            2483.0
          ],
          "confidence": 0.9969821572303772
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIALITY; PUBLICITY",
          "page": 2,
          "bbox": [
            469.0,
            258.0,
            1115.0,
            294.0
          ]
        },
        {
          "text": "TERM AND TERMINATION",
          "page": 2,
          "bbox": [
            468.0,
            598.0,
            1008.0,
            629.0
          ]
        },
        {
          "text": "MISCELLANEOUS",
          "page": 2,
          "bbox": [
            464.0,
            1153.0,
            837.0,
            1191.0
          ]
        },
        {
          "text": "EXHIBITS",
          "page": 2,
          "bbox": [
            277.0,
            2054.0,
            482.0,
            2092.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Exclusivity_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Subject to compliance by Pfizer with the terms of this Section 3.2(d), during the Term, Exact agrees (A) not to enter into any new binding arrangement with any media vendor for Advertising of the Product without the written consent of Pfizer, which consent shall not be unreasonably withheld, (B) not to meet with any advertising agency or media vendor to discuss any Advertising proposals for content development and creative direction of the Product, without providing Pfizer with a reasonable opportunity for a representative of Pfizer present and participate and (C) to promptly inform Pfizer if it enters into any arrangement with any advertising agency with respect to the Product.",
      "page_number": 3,
      "words": [
        {
          "text": "Exhibit 8.8(b)",
          "bbox": [
            277.0,
            254.0,
            519.0,
            302.0
          ],
          "confidence": 0.9773956537246704
        },
        {
          "text": "Tail Period Advertising Services",
          "bbox": [
            808.0,
            258.0,
            1403.0,
            298.0
          ],
          "confidence": 0.9866174459457397
        },
        {
          "text": "i1",
          "bbox": [
            1638.0,
            312.0,
            1668.0,
            355.0
          ],
          "confidence": 0.6335347294807434
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4437.0,
            1287.0,
            4479.0
          ],
          "confidence": 0.9964374303817749
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Exclusivity_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealingÂ  commitment with the counterparty? This includes a commitment to procure all ârequirementsâ from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition onÂ  collaborating or working with other parties), whether during the contract orÂ  after the contract ends (or both).",
      "answer_text": "Subject to compliance by Pfizer with the terms of this Section 3.2(d), during the Term, Exact agrees (A) not to enter into any new binding arrangement with any media vendor for Advertising of the Product without the written consent of Pfizer, which consent shall not be unreasonably withheld, (B) not to meet with any advertising agency or media vendor to discuss any Advertising proposals for content development and creative direction of the Product, without providing Pfizer with a reasonable opportunity for a representative of Pfizer present and participate and (C) to promptly inform Pfizer if it enters into any arrangement with any advertising agency with respect to the Product.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Termination For Convenience_5",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate thisÂ  contract without cause (solely by giving a notice and allowing a waitingÂ  period to expire)?",
      "answer_text": "After the date that is eighteen (18) months after the Effective Date, either Party may terminate this Agreement upon six (6) months prior written notice to the other Party.",
      "page_number": 5,
      "words": [
        {
          "text": "1.5\"Alliance Manager\" shall have the meaning set forth in Section 2.5.",
          "bbox": [
            475.0,
            254.0,
            1796.0,
            298.0
          ],
          "confidence": 0.9890038371086121
        },
        {
          "text": "1.6\"Annual Marketing Plan\"' shall mean the plan for the Marketing and Promotion of the Product in the Territory for each full or partial",
          "bbox": [
            477.0,
            316.0,
            2992.0,
            353.0
          ],
          "confidence": 0.9888446927070618
        },
        {
          "text": "Calendar Year as described in Section 3.3, as prepared and updated from time to time pursuant to Section 3.3..",
          "bbox": [
            642.0,
            369.0,
            2659.0,
            413.0
          ],
          "confidence": 0.9882045984268188
        },
        {
          "text": "1.7\"Annual Supplemental Promotion Fee\"' shall have the meaning set forth in Section 4.2(c)(i)..",
          "bbox": [
            477.0,
            426.0,
            2238.0,
            468.0
          ],
          "confidence": 0.9870630502700806
        },
        {
          "text": "1.8\"Applicable Compliance/Review Policies\"' shall mean, with respect to Pfizer, its written Code of Ethics and Professional Conduct and,.",
          "bbox": [
            477.0,
            482.0,
            3014.0,
            524.0
          ],
          "confidence": 0.9912572503089905
        },
        {
          "text": "with respect to Exact, its written Code of Business Conduct and Ethics, and such policies and standard operating procedures",
          "bbox": [
            642.0,
            539.0,
            2969.0,
            581.0
          ],
          "confidence": 0.9917171001434326
        },
        {
          "text": "that are adhered to by such Party in connection with the Product and any payments or services contemplated by this",
          "bbox": [
            640.0,
            592.0,
            2820.0,
            638.0
          ],
          "confidence": 0.9860061407089233
        },
        {
          "text": "Agreement, as the same may be amended from time to time.",
          "bbox": [
            643.0,
            651.0,
            1736.0,
            691.0
          ],
          "confidence": 0.9950719475746155
        },
        {
          "text": "1.9\"Applicable Law\"' shall mean any law, statute, rule, regulation, order, judgment, ordinance, administrative code, decree, directive,",
          "bbox": [
            475.0,
            704.0,
            2916.0,
            751.0
          ],
          "confidence": 0.9942479729652405
        },
        {
          "text": "injunction or permit (including Regulatory Approvals) of any court, arbitral body, agency, department, authority or other.",
          "bbox": [
            643.0,
            764.0,
            2882.0,
            806.0
          ],
          "confidence": 0.9893744587898254
        },
        {
          "text": "instrumentality of any national, state, county, city or other political subdivision applicable to a Party's activities to be performed",
          "bbox": [
            642.0,
            820.0,
            3021.0,
            863.0
          ],
          "confidence": 0.9948800206184387
        },
        {
          "text": "under this Agreement. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall",
          "bbox": [
            643.0,
            875.0,
            2989.0,
            917.0
          ],
          "confidence": 0.9867214560508728
        },
        {
          "text": "be deemed to include all amendments, replacements or successors thereto.",
          "bbox": [
            642.0,
            932.0,
            2028.0,
            974.0
          ],
          "confidence": 0.9949407577514648
        },
        {
          "text": "1.10\"Audited Party\" shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            985.0,
            1831.0,
            1029.0
          ],
          "confidence": 0.9958505630493164
        },
        {
          "text": "1.11\"Auditing Party\"' shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            1043.0,
            1849.0,
            1085.0
          ],
          "confidence": 0.9746250510215759
        },
        {
          "text": "1.12\"Baseline Laboratory Service Revenue\" shall mean, with respect to a particular Calendar Year during the Term, the amounts set.",
          "bbox": [
            473.0,
            1096.0,
            2934.0,
            1140.0
          ],
          "confidence": 0.9947289228439331
        },
        {
          "text": "forth in Section 4.2(b).",
          "bbox": [
            642.0,
            1155.0,
            1051.0,
            1195.0
          ],
          "confidence": 0.9629735946655273
        },
        {
          "text": "1.13\"Baseline M&P Expense\" shall have the meaning set forth in Section 3.6..",
          "bbox": [
            475.0,
            1212.0,
            1923.0,
            1254.0
          ],
          "confidence": 0.9764768481254578
        },
        {
          "text": "1.14\"Business Day\"' shall mean any day other than a Saturday, Sunday, or a bank or other public holiday in New York, New York, United.",
          "bbox": [
            475.0,
            1266.0,
            3016.0,
            1310.0
          ],
          "confidence": 0.9815430045127869
        },
        {
          "text": "States.",
          "bbox": [
            639.0,
            1323.0,
            769.0,
            1365.0
          ],
          "confidence": 0.9991849660873413
        },
        {
          "text": "1.15\"Calendar Quarter' shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30,",
          "bbox": [
            473.0,
            1376.0,
            2905.0,
            1422.0
          ],
          "confidence": 0.988274335861206
        },
        {
          "text": "September 30 or December 31.",
          "bbox": [
            643.0,
            1436.0,
            1202.0,
            1478.0
          ],
          "confidence": 0.9999055862426758
        },
        {
          "text": "1.16\"Calendar Year' shall mean the respective periods of twelve (12) calendar months, each such period ending on December 31 of the.",
          "bbox": [
            473.0,
            1491.0,
            2996.0,
            1535.0
          ],
          "confidence": 0.9880089163780212
        },
        {
          "text": "applicable year for as long as this Agreement is in effect.",
          "bbox": [
            642.0,
            1544.0,
            1697.0,
            1594.0
          ],
          "confidence": 0.9885498285293579
        },
        {
          "text": "1.17\"Calendar Year Baseline Laboratory Service Revenue\" shall have the meaning set forth in Section 4.2(b).",
          "bbox": [
            475.0,
            1604.0,
            2525.0,
            1646.0
          ],
          "confidence": 0.9913415908813477
        },
        {
          "text": "1.18\"Change of Control' shall mean, with respect to a Party: (a) the sale of all or substantially all of such Party's assets or business.",
          "bbox": [
            475.0,
            1661.0,
            2929.0,
            1703.0
          ],
          "confidence": 0.9942373037338257
        },
        {
          "text": "relating to the subject matter of this Agreement; (b) a merger, reorganization, or consolidation involving such Party in which the.",
          "bbox": [
            638.0,
            1712.0,
            3018.0,
            1763.0
          ],
          "confidence": 0.9887958765029907
        },
        {
          "text": "holders of voting securities of such Party outstanding immediately",
          "bbox": [
            640.0,
            1771.0,
            1883.0,
            1816.0
          ],
          "confidence": 0.9987452030181885
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1831.0,
            1669.0,
            1866.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9922685027122498
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Rofr/Rofo/Rofn_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "During the Term, if Exact desires to grant an exclusive commercial license to a Third Party solely to Promote or sell the Product in the OB/Gyn Field in the Territory (the \"OB/Gyn Commercial Rights\"), Exact shall first notify Pfizer of such intent (a \"OB/Gyn Commercial Rights Transfer Notice\") and Pfizer shall have thirty (30) days thereafter to notify Exact of its desire to obtain the OB/Gyn Commercial Rights that are the subject of the OB/Gyn Commercial Rights Transfer Notice.",
      "page_number": 3,
      "words": [
        {
          "text": "Exhibit 8.8(b)",
          "bbox": [
            277.0,
            254.0,
            519.0,
            302.0
          ],
          "confidence": 0.9773956537246704
        },
        {
          "text": "Tail Period Advertising Services",
          "bbox": [
            808.0,
            258.0,
            1403.0,
            298.0
          ],
          "confidence": 0.9866174459457397
        },
        {
          "text": "i1",
          "bbox": [
            1638.0,
            312.0,
            1668.0,
            355.0
          ],
          "confidence": 0.6335347294807434
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4437.0,
            1287.0,
            4479.0
          ],
          "confidence": 0.9964374303817749
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Rofr/Rofo/Rofn_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "During the Term, if Exact desires to grant an exclusive commercial license to a Third Party solely to Promote or sell the Product in the OB/Gyn Field in the Territory (the \"OB/Gyn Commercial Rights\"), Exact shall first notify Pfizer of such intent (a \"OB/Gyn Commercial Rights Transfer Notice\") and Pfizer shall have thirty (30) days thereafter to notify Exact of its desire to obtain the OB/Gyn Commercial Rights that are the subject of the OB/Gyn Commercial Rights Transfer Notice.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Rofr/Rofo/Rofn_4",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the OB/Gyn Commercial Rights.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Rofr/Rofo/Rofn_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "If Pfizer and Exact are unable to reach agreement on the terms of such Product rights within forty-five (45) days of the commencement of negotiations, Exact shall be free to enter into negotiations and consummate an agreement with any Third Party regarding such Ex-US Commercial Rights; provided that the economic terms of such agreement shall be no more favorable to such Third Party than those last offered to Pfizer.",
      "page_number": 3,
      "words": [
        {
          "text": "Exhibit 8.8(b)",
          "bbox": [
            277.0,
            254.0,
            519.0,
            302.0
          ],
          "confidence": 0.9773956537246704
        },
        {
          "text": "Tail Period Advertising Services",
          "bbox": [
            808.0,
            258.0,
            1403.0,
            298.0
          ],
          "confidence": 0.9866174459457397
        },
        {
          "text": "i1",
          "bbox": [
            1638.0,
            312.0,
            1668.0,
            355.0
          ],
          "confidence": 0.6335347294807434
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4437.0,
            1287.0,
            4479.0
          ],
          "confidence": 0.9964374303817749
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Rofr/Rofo/Rofn_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "If Pfizer and Exact are unable to reach agreement on the terms of such Product rights within forty-five (45) days of the commencement of negotiations, Exact shall be free to enter into negotiations and consummate an agreement with any Third Party regarding such Ex-US Commercial Rights; provided that the economic terms of such agreement shall be no more favorable to such Third Party than those last offered to Pfizer.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Rofr/Rofo/Rofn_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "If Pfizer and Exact are unable to reach agreement on the terms of such Product rights within forty-five (45) days of the commencement of negotiations, then Exact shall be free to enter into negotiations and consummate an agreement with any Third Party regarding such OB/Gyn Commercial Rights; provided that the economic terms of such agreement shall be no more favorable to such Third Party than those last offered to Pfizer.",
      "page_number": 3,
      "words": [
        {
          "text": "Exhibit 8.8(b)",
          "bbox": [
            277.0,
            254.0,
            519.0,
            302.0
          ],
          "confidence": 0.9773956537246704
        },
        {
          "text": "Tail Period Advertising Services",
          "bbox": [
            808.0,
            258.0,
            1403.0,
            298.0
          ],
          "confidence": 0.9866174459457397
        },
        {
          "text": "i1",
          "bbox": [
            1638.0,
            312.0,
            1668.0,
            355.0
          ],
          "confidence": 0.6335347294807434
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4437.0,
            1287.0,
            4479.0
          ],
          "confidence": 0.9964374303817749
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Rofr/Rofo/Rofn_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "If Pfizer and Exact are unable to reach agreement on the terms of such Product rights within forty-five (45) days of the commencement of negotiations, then Exact shall be free to enter into negotiations and consummate an agreement with any Third Party regarding such OB/Gyn Commercial Rights; provided that the economic terms of such agreement shall be no more favorable to such Third Party than those last offered to Pfizer.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Rofr/Rofo/Rofn_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "During the Term, if Exact (i) enters a formal process authorized or directed by its board of directors or CEO to seek and enter into an arrangement or (ii) intends to agree to a term sheet or seeks to sign a letter of intent or similar arrangement to grant an exclusive commercial license to a Third Party solely to promote or sell the Product outside the Territory (\"Ex-US Commercial Rights\"), Exact shall first notify Pfizer of such intent (a \"Ex-US Commercial Rights Transfer Notice\") and Pfizer shall have thirty (30) days thereafter to notify Exact of its desire to obtain the Ex-US Commercial Rights that are the subject of the Ex-US Commercial Rights Transfer Notice.",
      "page_number": 3,
      "words": [
        {
          "text": "Exhibit 8.8(b)",
          "bbox": [
            277.0,
            254.0,
            519.0,
            302.0
          ],
          "confidence": 0.9773956537246704
        },
        {
          "text": "Tail Period Advertising Services",
          "bbox": [
            808.0,
            258.0,
            1403.0,
            298.0
          ],
          "confidence": 0.9866174459457397
        },
        {
          "text": "i1",
          "bbox": [
            1638.0,
            312.0,
            1668.0,
            355.0
          ],
          "confidence": 0.6335347294807434
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4437.0,
            1287.0,
            4479.0
          ],
          "confidence": 0.9964374303817749
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Rofr/Rofo/Rofn_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "During the Term, if Exact (i) enters a formal process authorized or directed by its board of directors or CEO to seek and enter into an arrangement or (ii) intends to agree to a term sheet or seeks to sign a letter of intent or similar arrangement to grant an exclusive commercial license to a Third Party solely to promote or sell the Product outside the Territory (\"Ex-US Commercial Rights\"), Exact shall first notify Pfizer of such intent (a \"Ex-US Commercial Rights Transfer Notice\") and Pfizer shall have thirty (30) days thereafter to notify Exact of its desire to obtain the Ex-US Commercial Rights that are the subject of the Ex-US Commercial Rights Transfer Notice.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Rofr/Rofo/Rofn_4",
      "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
      "answer_text": "Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the Ex-US Commercial Rights.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Change Of Control_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "This Agreement may be terminated by either Party upon six (6) months written notice following a Change of Control of Exact; provided that such notice is given within thirty (30) days of the consummation of such Change of Control.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Change Of Control_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "This Agreement may be terminated by either Party upon six (6) months written notice following a Change of Control of Exact; provided that such notice is given within thirty (30) days of the consummation of such Change of Control.",
      "page_number": 5,
      "words": [
        {
          "text": "1.5\"Alliance Manager\" shall have the meaning set forth in Section 2.5.",
          "bbox": [
            475.0,
            254.0,
            1796.0,
            298.0
          ],
          "confidence": 0.9890038371086121
        },
        {
          "text": "1.6\"Annual Marketing Plan\"' shall mean the plan for the Marketing and Promotion of the Product in the Territory for each full or partial",
          "bbox": [
            477.0,
            316.0,
            2992.0,
            353.0
          ],
          "confidence": 0.9888446927070618
        },
        {
          "text": "Calendar Year as described in Section 3.3, as prepared and updated from time to time pursuant to Section 3.3..",
          "bbox": [
            642.0,
            369.0,
            2659.0,
            413.0
          ],
          "confidence": 0.9882045984268188
        },
        {
          "text": "1.7\"Annual Supplemental Promotion Fee\"' shall have the meaning set forth in Section 4.2(c)(i)..",
          "bbox": [
            477.0,
            426.0,
            2238.0,
            468.0
          ],
          "confidence": 0.9870630502700806
        },
        {
          "text": "1.8\"Applicable Compliance/Review Policies\"' shall mean, with respect to Pfizer, its written Code of Ethics and Professional Conduct and,.",
          "bbox": [
            477.0,
            482.0,
            3014.0,
            524.0
          ],
          "confidence": 0.9912572503089905
        },
        {
          "text": "with respect to Exact, its written Code of Business Conduct and Ethics, and such policies and standard operating procedures",
          "bbox": [
            642.0,
            539.0,
            2969.0,
            581.0
          ],
          "confidence": 0.9917171001434326
        },
        {
          "text": "that are adhered to by such Party in connection with the Product and any payments or services contemplated by this",
          "bbox": [
            640.0,
            592.0,
            2820.0,
            638.0
          ],
          "confidence": 0.9860061407089233
        },
        {
          "text": "Agreement, as the same may be amended from time to time.",
          "bbox": [
            643.0,
            651.0,
            1736.0,
            691.0
          ],
          "confidence": 0.9950719475746155
        },
        {
          "text": "1.9\"Applicable Law\"' shall mean any law, statute, rule, regulation, order, judgment, ordinance, administrative code, decree, directive,",
          "bbox": [
            475.0,
            704.0,
            2916.0,
            751.0
          ],
          "confidence": 0.9942479729652405
        },
        {
          "text": "injunction or permit (including Regulatory Approvals) of any court, arbitral body, agency, department, authority or other.",
          "bbox": [
            643.0,
            764.0,
            2882.0,
            806.0
          ],
          "confidence": 0.9893744587898254
        },
        {
          "text": "instrumentality of any national, state, county, city or other political subdivision applicable to a Party's activities to be performed",
          "bbox": [
            642.0,
            820.0,
            3021.0,
            863.0
          ],
          "confidence": 0.9948800206184387
        },
        {
          "text": "under this Agreement. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall",
          "bbox": [
            643.0,
            875.0,
            2989.0,
            917.0
          ],
          "confidence": 0.9867214560508728
        },
        {
          "text": "be deemed to include all amendments, replacements or successors thereto.",
          "bbox": [
            642.0,
            932.0,
            2028.0,
            974.0
          ],
          "confidence": 0.9949407577514648
        },
        {
          "text": "1.10\"Audited Party\" shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            985.0,
            1831.0,
            1029.0
          ],
          "confidence": 0.9958505630493164
        },
        {
          "text": "1.11\"Auditing Party\"' shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            1043.0,
            1849.0,
            1085.0
          ],
          "confidence": 0.9746250510215759
        },
        {
          "text": "1.12\"Baseline Laboratory Service Revenue\" shall mean, with respect to a particular Calendar Year during the Term, the amounts set.",
          "bbox": [
            473.0,
            1096.0,
            2934.0,
            1140.0
          ],
          "confidence": 0.9947289228439331
        },
        {
          "text": "forth in Section 4.2(b).",
          "bbox": [
            642.0,
            1155.0,
            1051.0,
            1195.0
          ],
          "confidence": 0.9629735946655273
        },
        {
          "text": "1.13\"Baseline M&P Expense\" shall have the meaning set forth in Section 3.6..",
          "bbox": [
            475.0,
            1212.0,
            1923.0,
            1254.0
          ],
          "confidence": 0.9764768481254578
        },
        {
          "text": "1.14\"Business Day\"' shall mean any day other than a Saturday, Sunday, or a bank or other public holiday in New York, New York, United.",
          "bbox": [
            475.0,
            1266.0,
            3016.0,
            1310.0
          ],
          "confidence": 0.9815430045127869
        },
        {
          "text": "States.",
          "bbox": [
            639.0,
            1323.0,
            769.0,
            1365.0
          ],
          "confidence": 0.9991849660873413
        },
        {
          "text": "1.15\"Calendar Quarter' shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30,",
          "bbox": [
            473.0,
            1376.0,
            2905.0,
            1422.0
          ],
          "confidence": 0.988274335861206
        },
        {
          "text": "September 30 or December 31.",
          "bbox": [
            643.0,
            1436.0,
            1202.0,
            1478.0
          ],
          "confidence": 0.9999055862426758
        },
        {
          "text": "1.16\"Calendar Year' shall mean the respective periods of twelve (12) calendar months, each such period ending on December 31 of the.",
          "bbox": [
            473.0,
            1491.0,
            2996.0,
            1535.0
          ],
          "confidence": 0.9880089163780212
        },
        {
          "text": "applicable year for as long as this Agreement is in effect.",
          "bbox": [
            642.0,
            1544.0,
            1697.0,
            1594.0
          ],
          "confidence": 0.9885498285293579
        },
        {
          "text": "1.17\"Calendar Year Baseline Laboratory Service Revenue\" shall have the meaning set forth in Section 4.2(b).",
          "bbox": [
            475.0,
            1604.0,
            2525.0,
            1646.0
          ],
          "confidence": 0.9913415908813477
        },
        {
          "text": "1.18\"Change of Control' shall mean, with respect to a Party: (a) the sale of all or substantially all of such Party's assets or business.",
          "bbox": [
            475.0,
            1661.0,
            2929.0,
            1703.0
          ],
          "confidence": 0.9942373037338257
        },
        {
          "text": "relating to the subject matter of this Agreement; (b) a merger, reorganization, or consolidation involving such Party in which the.",
          "bbox": [
            638.0,
            1712.0,
            3018.0,
            1763.0
          ],
          "confidence": 0.9887958765029907
        },
        {
          "text": "holders of voting securities of such Party outstanding immediately",
          "bbox": [
            640.0,
            1771.0,
            1883.0,
            1816.0
          ],
          "confidence": 0.9987452030181885
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1831.0,
            1669.0,
            1866.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9922685027122498
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Change Of Control_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Notwithstanding the foregoing, either Party may, without consent of the other Party, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate of such Party, or in whole to its successor in interest in connection with the sale of all or substantially all of its stock or its assets to which this Agreement relates, or in connection with a merger, acquisition or similar transaction.",
      "page_number": 3,
      "words": [
        {
          "text": "Exhibit 8.8(b)",
          "bbox": [
            277.0,
            254.0,
            519.0,
            302.0
          ],
          "confidence": 0.9773956537246704
        },
        {
          "text": "Tail Period Advertising Services",
          "bbox": [
            808.0,
            258.0,
            1403.0,
            298.0
          ],
          "confidence": 0.9866174459457397
        },
        {
          "text": "i1",
          "bbox": [
            1638.0,
            312.0,
            1668.0,
            355.0
          ],
          "confidence": 0.6335347294807434
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4437.0,
            1287.0,
            4479.0
          ],
          "confidence": 0.9964374303817749
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Change Of Control_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Notwithstanding the foregoing, either Party may, without consent of the other Party, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate of such Party, or in whole to its successor in interest in connection with the sale of all or substantially all of its stock or its assets to which this Agreement relates, or in connection with a merger, acquisition or similar transaction.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Anti-Assignment_4",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "This Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the prior written consent of the other Party.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Revenue/Profit Sharing_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "After the expiration of the Term or termination pursuant to Section 8.4 by either Party or Section 8.6 by Exact, based on cumulative Incremental Laboratory Services Revenue achieved during the Term or up to the termination date, Exact agrees to pay Pfizer the applicable royalty payment set forth below for twelve (12) consecutive Calendar Quarters following the expiration of the Term (the \"Tail Period\"); provided, however, the Tail Period shall be reduced to the number of full Calendar Quarters completed during the Term if less than twelve (12) Calendar Quarters if either Party terminates the Agreement without cause pursuant to Section 8.4 or Exact terminates as a result of a Change of Control pursuant to Section 8.6.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Revenue/Profit Sharing_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "After the expiration of the Term or termination pursuant to Section 8.4 by either Party or Section 8.6 by Exact, based on cumulative Incremental Laboratory Services Revenue achieved during the Term or up to the termination date, Exact agrees to pay Pfizer the applicable royalty payment set forth below for twelve (12) consecutive Calendar Quarters following the expiration of the Term (the \"Tail Period\"); provided, however, the Tail Period shall be reduced to the number of full Calendar Quarters completed during the Term if less than twelve (12) Calendar Quarters if either Party terminates the Agreement without cause pursuant to Section 8.4 or Exact terminates as a result of a Change of Control pursuant to Section 8.6.",
      "page_number": 5,
      "words": [
        {
          "text": "1.5\"Alliance Manager\" shall have the meaning set forth in Section 2.5.",
          "bbox": [
            475.0,
            254.0,
            1796.0,
            298.0
          ],
          "confidence": 0.9890038371086121
        },
        {
          "text": "1.6\"Annual Marketing Plan\"' shall mean the plan for the Marketing and Promotion of the Product in the Territory for each full or partial",
          "bbox": [
            477.0,
            316.0,
            2992.0,
            353.0
          ],
          "confidence": 0.9888446927070618
        },
        {
          "text": "Calendar Year as described in Section 3.3, as prepared and updated from time to time pursuant to Section 3.3..",
          "bbox": [
            642.0,
            369.0,
            2659.0,
            413.0
          ],
          "confidence": 0.9882045984268188
        },
        {
          "text": "1.7\"Annual Supplemental Promotion Fee\"' shall have the meaning set forth in Section 4.2(c)(i)..",
          "bbox": [
            477.0,
            426.0,
            2238.0,
            468.0
          ],
          "confidence": 0.9870630502700806
        },
        {
          "text": "1.8\"Applicable Compliance/Review Policies\"' shall mean, with respect to Pfizer, its written Code of Ethics and Professional Conduct and,.",
          "bbox": [
            477.0,
            482.0,
            3014.0,
            524.0
          ],
          "confidence": 0.9912572503089905
        },
        {
          "text": "with respect to Exact, its written Code of Business Conduct and Ethics, and such policies and standard operating procedures",
          "bbox": [
            642.0,
            539.0,
            2969.0,
            581.0
          ],
          "confidence": 0.9917171001434326
        },
        {
          "text": "that are adhered to by such Party in connection with the Product and any payments or services contemplated by this",
          "bbox": [
            640.0,
            592.0,
            2820.0,
            638.0
          ],
          "confidence": 0.9860061407089233
        },
        {
          "text": "Agreement, as the same may be amended from time to time.",
          "bbox": [
            643.0,
            651.0,
            1736.0,
            691.0
          ],
          "confidence": 0.9950719475746155
        },
        {
          "text": "1.9\"Applicable Law\"' shall mean any law, statute, rule, regulation, order, judgment, ordinance, administrative code, decree, directive,",
          "bbox": [
            475.0,
            704.0,
            2916.0,
            751.0
          ],
          "confidence": 0.9942479729652405
        },
        {
          "text": "injunction or permit (including Regulatory Approvals) of any court, arbitral body, agency, department, authority or other.",
          "bbox": [
            643.0,
            764.0,
            2882.0,
            806.0
          ],
          "confidence": 0.9893744587898254
        },
        {
          "text": "instrumentality of any national, state, county, city or other political subdivision applicable to a Party's activities to be performed",
          "bbox": [
            642.0,
            820.0,
            3021.0,
            863.0
          ],
          "confidence": 0.9948800206184387
        },
        {
          "text": "under this Agreement. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall",
          "bbox": [
            643.0,
            875.0,
            2989.0,
            917.0
          ],
          "confidence": 0.9867214560508728
        },
        {
          "text": "be deemed to include all amendments, replacements or successors thereto.",
          "bbox": [
            642.0,
            932.0,
            2028.0,
            974.0
          ],
          "confidence": 0.9949407577514648
        },
        {
          "text": "1.10\"Audited Party\" shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            985.0,
            1831.0,
            1029.0
          ],
          "confidence": 0.9958505630493164
        },
        {
          "text": "1.11\"Auditing Party\"' shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            1043.0,
            1849.0,
            1085.0
          ],
          "confidence": 0.9746250510215759
        },
        {
          "text": "1.12\"Baseline Laboratory Service Revenue\" shall mean, with respect to a particular Calendar Year during the Term, the amounts set.",
          "bbox": [
            473.0,
            1096.0,
            2934.0,
            1140.0
          ],
          "confidence": 0.9947289228439331
        },
        {
          "text": "forth in Section 4.2(b).",
          "bbox": [
            642.0,
            1155.0,
            1051.0,
            1195.0
          ],
          "confidence": 0.9629735946655273
        },
        {
          "text": "1.13\"Baseline M&P Expense\" shall have the meaning set forth in Section 3.6..",
          "bbox": [
            475.0,
            1212.0,
            1923.0,
            1254.0
          ],
          "confidence": 0.9764768481254578
        },
        {
          "text": "1.14\"Business Day\"' shall mean any day other than a Saturday, Sunday, or a bank or other public holiday in New York, New York, United.",
          "bbox": [
            475.0,
            1266.0,
            3016.0,
            1310.0
          ],
          "confidence": 0.9815430045127869
        },
        {
          "text": "States.",
          "bbox": [
            639.0,
            1323.0,
            769.0,
            1365.0
          ],
          "confidence": 0.9991849660873413
        },
        {
          "text": "1.15\"Calendar Quarter' shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30,",
          "bbox": [
            473.0,
            1376.0,
            2905.0,
            1422.0
          ],
          "confidence": 0.988274335861206
        },
        {
          "text": "September 30 or December 31.",
          "bbox": [
            643.0,
            1436.0,
            1202.0,
            1478.0
          ],
          "confidence": 0.9999055862426758
        },
        {
          "text": "1.16\"Calendar Year' shall mean the respective periods of twelve (12) calendar months, each such period ending on December 31 of the.",
          "bbox": [
            473.0,
            1491.0,
            2996.0,
            1535.0
          ],
          "confidence": 0.9880089163780212
        },
        {
          "text": "applicable year for as long as this Agreement is in effect.",
          "bbox": [
            642.0,
            1544.0,
            1697.0,
            1594.0
          ],
          "confidence": 0.9885498285293579
        },
        {
          "text": "1.17\"Calendar Year Baseline Laboratory Service Revenue\" shall have the meaning set forth in Section 4.2(b).",
          "bbox": [
            475.0,
            1604.0,
            2525.0,
            1646.0
          ],
          "confidence": 0.9913415908813477
        },
        {
          "text": "1.18\"Change of Control' shall mean, with respect to a Party: (a) the sale of all or substantially all of such Party's assets or business.",
          "bbox": [
            475.0,
            1661.0,
            2929.0,
            1703.0
          ],
          "confidence": 0.9942373037338257
        },
        {
          "text": "relating to the subject matter of this Agreement; (b) a merger, reorganization, or consolidation involving such Party in which the.",
          "bbox": [
            638.0,
            1712.0,
            3018.0,
            1763.0
          ],
          "confidence": 0.9887958765029907
        },
        {
          "text": "holders of voting securities of such Party outstanding immediately",
          "bbox": [
            640.0,
            1771.0,
            1883.0,
            1816.0
          ],
          "confidence": 0.9987452030181885
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1831.0,
            1669.0,
            1866.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9922685027122498
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Revenue/Profit Sharing_5",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "Such royalty payment shall be payable to Pfizer within thirty (30) days of the end of each Calendar Quarter.",
      "page_number": 5,
      "words": [
        {
          "text": "1.5\"Alliance Manager\" shall have the meaning set forth in Section 2.5.",
          "bbox": [
            475.0,
            254.0,
            1796.0,
            298.0
          ],
          "confidence": 0.9890038371086121
        },
        {
          "text": "1.6\"Annual Marketing Plan\"' shall mean the plan for the Marketing and Promotion of the Product in the Territory for each full or partial",
          "bbox": [
            477.0,
            316.0,
            2992.0,
            353.0
          ],
          "confidence": 0.9888446927070618
        },
        {
          "text": "Calendar Year as described in Section 3.3, as prepared and updated from time to time pursuant to Section 3.3..",
          "bbox": [
            642.0,
            369.0,
            2659.0,
            413.0
          ],
          "confidence": 0.9882045984268188
        },
        {
          "text": "1.7\"Annual Supplemental Promotion Fee\"' shall have the meaning set forth in Section 4.2(c)(i)..",
          "bbox": [
            477.0,
            426.0,
            2238.0,
            468.0
          ],
          "confidence": 0.9870630502700806
        },
        {
          "text": "1.8\"Applicable Compliance/Review Policies\"' shall mean, with respect to Pfizer, its written Code of Ethics and Professional Conduct and,.",
          "bbox": [
            477.0,
            482.0,
            3014.0,
            524.0
          ],
          "confidence": 0.9912572503089905
        },
        {
          "text": "with respect to Exact, its written Code of Business Conduct and Ethics, and such policies and standard operating procedures",
          "bbox": [
            642.0,
            539.0,
            2969.0,
            581.0
          ],
          "confidence": 0.9917171001434326
        },
        {
          "text": "that are adhered to by such Party in connection with the Product and any payments or services contemplated by this",
          "bbox": [
            640.0,
            592.0,
            2820.0,
            638.0
          ],
          "confidence": 0.9860061407089233
        },
        {
          "text": "Agreement, as the same may be amended from time to time.",
          "bbox": [
            643.0,
            651.0,
            1736.0,
            691.0
          ],
          "confidence": 0.9950719475746155
        },
        {
          "text": "1.9\"Applicable Law\"' shall mean any law, statute, rule, regulation, order, judgment, ordinance, administrative code, decree, directive,",
          "bbox": [
            475.0,
            704.0,
            2916.0,
            751.0
          ],
          "confidence": 0.9942479729652405
        },
        {
          "text": "injunction or permit (including Regulatory Approvals) of any court, arbitral body, agency, department, authority or other.",
          "bbox": [
            643.0,
            764.0,
            2882.0,
            806.0
          ],
          "confidence": 0.9893744587898254
        },
        {
          "text": "instrumentality of any national, state, county, city or other political subdivision applicable to a Party's activities to be performed",
          "bbox": [
            642.0,
            820.0,
            3021.0,
            863.0
          ],
          "confidence": 0.9948800206184387
        },
        {
          "text": "under this Agreement. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall",
          "bbox": [
            643.0,
            875.0,
            2989.0,
            917.0
          ],
          "confidence": 0.9867214560508728
        },
        {
          "text": "be deemed to include all amendments, replacements or successors thereto.",
          "bbox": [
            642.0,
            932.0,
            2028.0,
            974.0
          ],
          "confidence": 0.9949407577514648
        },
        {
          "text": "1.10\"Audited Party\" shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            985.0,
            1831.0,
            1029.0
          ],
          "confidence": 0.9958505630493164
        },
        {
          "text": "1.11\"Auditing Party\"' shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            1043.0,
            1849.0,
            1085.0
          ],
          "confidence": 0.9746250510215759
        },
        {
          "text": "1.12\"Baseline Laboratory Service Revenue\" shall mean, with respect to a particular Calendar Year during the Term, the amounts set.",
          "bbox": [
            473.0,
            1096.0,
            2934.0,
            1140.0
          ],
          "confidence": 0.9947289228439331
        },
        {
          "text": "forth in Section 4.2(b).",
          "bbox": [
            642.0,
            1155.0,
            1051.0,
            1195.0
          ],
          "confidence": 0.9629735946655273
        },
        {
          "text": "1.13\"Baseline M&P Expense\" shall have the meaning set forth in Section 3.6..",
          "bbox": [
            475.0,
            1212.0,
            1923.0,
            1254.0
          ],
          "confidence": 0.9764768481254578
        },
        {
          "text": "1.14\"Business Day\"' shall mean any day other than a Saturday, Sunday, or a bank or other public holiday in New York, New York, United.",
          "bbox": [
            475.0,
            1266.0,
            3016.0,
            1310.0
          ],
          "confidence": 0.9815430045127869
        },
        {
          "text": "States.",
          "bbox": [
            639.0,
            1323.0,
            769.0,
            1365.0
          ],
          "confidence": 0.9991849660873413
        },
        {
          "text": "1.15\"Calendar Quarter' shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30,",
          "bbox": [
            473.0,
            1376.0,
            2905.0,
            1422.0
          ],
          "confidence": 0.988274335861206
        },
        {
          "text": "September 30 or December 31.",
          "bbox": [
            643.0,
            1436.0,
            1202.0,
            1478.0
          ],
          "confidence": 0.9999055862426758
        },
        {
          "text": "1.16\"Calendar Year' shall mean the respective periods of twelve (12) calendar months, each such period ending on December 31 of the.",
          "bbox": [
            473.0,
            1491.0,
            2996.0,
            1535.0
          ],
          "confidence": 0.9880089163780212
        },
        {
          "text": "applicable year for as long as this Agreement is in effect.",
          "bbox": [
            642.0,
            1544.0,
            1697.0,
            1594.0
          ],
          "confidence": 0.9885498285293579
        },
        {
          "text": "1.17\"Calendar Year Baseline Laboratory Service Revenue\" shall have the meaning set forth in Section 4.2(b).",
          "bbox": [
            475.0,
            1604.0,
            2525.0,
            1646.0
          ],
          "confidence": 0.9913415908813477
        },
        {
          "text": "1.18\"Change of Control' shall mean, with respect to a Party: (a) the sale of all or substantially all of such Party's assets or business.",
          "bbox": [
            475.0,
            1661.0,
            2929.0,
            1703.0
          ],
          "confidence": 0.9942373037338257
        },
        {
          "text": "relating to the subject matter of this Agreement; (b) a merger, reorganization, or consolidation involving such Party in which the.",
          "bbox": [
            638.0,
            1712.0,
            3018.0,
            1763.0
          ],
          "confidence": 0.9887958765029907
        },
        {
          "text": "holders of voting securities of such Party outstanding immediately",
          "bbox": [
            640.0,
            1771.0,
            1883.0,
            1816.0
          ],
          "confidence": 0.9987452030181885
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1831.0,
            1669.0,
            1866.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9922685027122498
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Revenue/Profit Sharing_33_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "Royalty payments shall be determined by multiplying the Laboratory Services Revenue and the applicable royalty rate from the chart below. Cumulative Incremental Laboratory Services Revenue during the Term Applicable Royalty Rate If < $200 million 0% If > $200 million and < $400 million 1% If > $400 million and < $600 million 2% If > $600 million 3%",
      "page_number": 33,
      "words": [
        {
          "text": "For any investment period less than a full Calendar Year (other than 2018), Exact's Baseline M&P Expense and Shared M&P",
          "bbox": [
            633.0,
            254.0,
            2925.0,
            300.0
          ],
          "confidence": 0.9963009357452393
        },
        {
          "text": "Expense investment shall be adjusted pro rata based on the number of months remaining until the end of the Calendar Year. For",
          "bbox": [
            634.0,
            314.0,
            2994.0,
            356.0
          ],
          "confidence": 0.997031033039093
        },
        {
          "text": "Calendar Year 2018, Exact's Baseline M&P Expense and Shared M&P Expense shall be adjusted to equal the number of months",
          "bbox": [
            636.0,
            369.0,
            2983.0,
            411.0
          ],
          "confidence": 0.9870148301124573
        },
        {
          "text": "remaining from the Launch Date to December 31, 2018 divided by twelve (12) multiplied by eighty million dollars ($80,000,000) or",
          "bbox": [
            633.0,
            424.0,
            3011.0,
            470.0
          ],
          "confidence": 0.9917376041412354
        },
        {
          "text": "twenty-four million dollars ($24,000,o00), as applicable; provided that the requirements of this Section 3.6 are satisfied. Exact",
          "bbox": [
            634.0,
            482.0,
            2940.0,
            524.0
          ],
          "confidence": 0.9841041564941406
        },
        {
          "text": "shall have no obligation to incur Shared M&P Expenses in excess of the amount in the above chart for the given Calendar Year,",
          "bbox": [
            634.0,
            537.0,
            2992.0,
            581.0
          ],
          "confidence": 0.9940897822380066
        },
        {
          "text": "unless the Parties each agree to increase their portion of the Shared M&P Expense..",
          "bbox": [
            638.0,
            598.0,
            2171.0,
            634.0
          ],
          "confidence": 0.9905911087989807
        },
        {
          "text": "3.7Changes in Shared M&P Expenses. In the event the Parties agree to not implement or to discontinue implementation of a strategy or",
          "bbox": [
            446.0,
            649.0,
            2980.0,
            694.0
          ],
          "confidence": 0.9968793392181396
        },
        {
          "text": "tactic included in any Annual Marketing Plan, the applicable Shared M&P Expense investment set forth above shall be either (a)",
          "bbox": [
            614.0,
            707.0,
            2994.0,
            749.0
          ],
          "confidence": 0.9985091090202332
        },
        {
          "text": "place of the strategy or tactic that was not implemented or was discontinued, which adjustment will reflect any difference in cost",
          "bbox": [
            616.0,
            820.0,
            3003.0,
            863.0
          ],
          "confidence": 0.9794955253601074
        },
        {
          "text": "of such substitute strategy or tactic or (b) reduced by the amount(s) allocated in the applicable budget for such strategy or tactic",
          "bbox": [
            614.0,
            873.0,
            3012.0,
            919.0
          ],
          "confidence": 0.9957975745201111
        },
        {
          "text": "under the applicable Annual Marketing Plan, if the Parties, during good faith discussions at the JSC, agree not to implement a",
          "bbox": [
            614.0,
            932.0,
            2949.0,
            974.0
          ],
          "confidence": 0.987469494342804
        },
        {
          "text": "substitute strategy or tactic in place of the strategy or tactic that was not implemented or which was discontinued. Any amount",
          "bbox": [
            614.0,
            989.0,
            2987.0,
            1031.0
          ],
          "confidence": 0.992645263671875
        },
        {
          "text": "saved as result of this Section 3.7 shall be re-deployed to other expenses associated with the Marketing of the Product, unless",
          "bbox": [
            613.0,
            1042.0,
            2965.0,
            1085.0
          ],
          "confidence": 0.9887098670005798
        },
        {
          "text": "otherwise determined by the JSC.",
          "bbox": [
            618.0,
            1102.0,
            1232.0,
            1138.0
          ],
          "confidence": 0.9765181541442871
        },
        {
          "text": "4.ACCOUNTING.",
          "bbox": [
            281.0,
            1157.0,
            622.0,
            1193.0
          ],
          "confidence": 0.9740423560142517
        },
        {
          "text": "4.1 Responsibility for Shared M&P Expenses.",
          "bbox": [
            444.0,
            1210.0,
            1307.0,
            1254.0
          ],
          "confidence": 0.9884071946144104
        },
        {
          "text": "(a)General. Shared M&P Expenses contributed by Exact and Pfizer pursuant to Sections 3.5 and 3.6 shall be used solely to fund",
          "bbox": [
            616.0,
            1268.0,
            2989.0,
            1310.0
          ],
          "confidence": 0.9960057139396667
        },
        {
          "text": "activities pursuant to the Annual Marketing Plan. The Parties shall agree to Calendar Quarter phasing of Baseline M&P",
          "bbox": [
            779.0,
            1321.0,
            3002.0,
            1367.0
          ],
          "confidence": 0.9942648410797119
        },
        {
          "text": "Expenses and Shared M&P Expenses for budgeting purposes. The Parties will spend amounts contributed to Baseline.",
          "bbox": [
            783.0,
            1380.0,
            2976.0,
            1424.0
          ],
          "confidence": 0.9920803904533386
        },
        {
          "text": "M&P Expenses and Shared M&P Expenses simultaneously throughout each Calendar Year, in a manner consistent with",
          "bbox": [
            781.0,
            1436.0,
            2994.0,
            1478.0
          ],
          "confidence": 0.9958170652389526
        },
        {
          "text": "budgeted but not spent in Calendar Quarter may be rolled over into the next Calendar Quarter. For the avoidance of.",
          "bbox": [
            781.0,
            1546.0,
            2929.0,
            1592.0
          ],
          "confidence": 0.9895590543746948
        },
        {
          "text": "doubt, Pfizer will match dollar for dollar Exact's Shared M&P Expense for a Calendar Year to up to the amounts set forth",
          "bbox": [
            783.0,
            1604.0,
            2992.0,
            1646.0
          ],
          "confidence": 0.9969136714935303
        },
        {
          "text": "in Section 3.5.",
          "bbox": [
            781.0,
            1661.0,
            1040.0,
            1699.0
          ],
          "confidence": 0.9752325415611267
        },
        {
          "text": "(b)Remainder of 2018. Promptly after the Effective Date, Exact shall discuss with Pfizer its planned Marketing and Promotional",
          "bbox": [
            618.0,
            1720.0,
            2974.0,
            1756.0
          ],
          "confidence": 0.9946068525314331
        },
        {
          "text": "that Pfizer may understand and recommend",
          "bbox": [
            785.0,
            1831.0,
            1586.0,
            1868.0
          ],
          "confidence": 0.9909166097640991
        },
        {
          "text": "30",
          "bbox": [
            1629.0,
            1882.0,
            1677.0,
            1924.0
          ],
          "confidence": 0.9910356998443604
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9909111857414246
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "4.ACCOUNTING.",
          "page": 33,
          "bbox": [
            281.0,
            1157.0,
            622.0,
            1193.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Revenue/Profit Sharing_34_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "Royalty payments shall be determined by multiplying the Laboratory Services Revenue and the applicable royalty rate from the chart below. Cumulative Incremental Laboratory Services Revenue during the Term Applicable Royalty Rate If < $200 million 0% If > $200 million and < $400 million 1% If > $400 million and < $600 million 2% If > $600 million 3%",
      "page_number": 34,
      "words": [
        {
          "text": "reallocation of all or any portion of such planned Marketing and Promotional spend associated with the Product. Budget",
          "bbox": [
            781.0,
            258.0,
            3023.0,
            300.0
          ],
          "confidence": 0.9923194050788879
        },
        {
          "text": "phasing of 2018 pro-rated Baseline M&P Expenses and pro-rated Shared M&P Expenses shall be done on the Calendar",
          "bbox": [
            783.0,
            311.0,
            2987.0,
            358.0
          ],
          "confidence": 0.9959399104118347
        },
        {
          "text": "Quarter basis. Exact agrees it shall spend at least eighty million dollars ($80,o0o,ooo) toward Marketing and Promotion.",
          "bbox": [
            785.0,
            371.0,
            2963.0,
            413.0
          ],
          "confidence": 0.9826511740684509
        },
        {
          "text": "(including any amounts spent between January 1, 2018 and the Effective Date) and the pro-rated Shared M&P Expense",
          "bbox": [
            783.0,
            428.0,
            2989.0,
            470.0
          ],
          "confidence": 0.9929174184799194
        },
        {
          "text": "for 2018.",
          "bbox": [
            783.0,
            482.0,
            939.0,
            521.0
          ],
          "confidence": 0.9945371150970459
        },
        {
          "text": "(c)Reporting. Within fifteen (15) Business Days after the end of each month during the Term beginning with October, 2018, Exact",
          "bbox": [
            616.0,
            537.0,
            3012.0,
            581.0
          ],
          "confidence": 0.9935125708580017
        },
        {
          "text": "shall provide to Pfizer a written report setting forth the amount of Baseline M&P Expenses and Shared M&P Expenses",
          "bbox": [
            783.0,
            598.0,
            2971.0,
            634.0
          ],
          "confidence": 0.9828574657440186
        },
        {
          "text": "incurred and paid for by Exact during such month, which report shall also provide sufficient itemization and detail related",
          "bbox": [
            783.0,
            649.0,
            3029.0,
            691.0
          ],
          "confidence": 0.9873493909835815
        },
        {
          "text": "to such expenses in order for Pfizer to confirm that such Baseline M&P Expenses and Shared M&P Expenses were",
          "bbox": [
            785.0,
            709.0,
            2898.0,
            746.0
          ],
          "confidence": 0.9992592930793762
        },
        {
          "text": "incurred pursuant to the Annual Marketing Plan. Pfizer, within fifteen (15) Business Days after the end of each month",
          "bbox": [
            783.0,
            766.0,
            2958.0,
            802.0
          ],
          "confidence": 0.9905714392662048
        },
        {
          "text": "during the Term, beginning with October, 2018, shall prepare and provide to Exact a written report setting forth the",
          "bbox": [
            785.0,
            822.0,
            2898.0,
            859.0
          ],
          "confidence": 0.9898773431777954
        },
        {
          "text": "aggregate amount of Shared M&P Expenses incurred and paid for by Pfizer during such month, along with sufficient",
          "bbox": [
            778.0,
            870.0,
            2947.0,
            923.0
          ],
          "confidence": 0.9857324957847595
        },
        {
          "text": "itemization and detail related to such expenses in order for Exact to confirm that such Shared M&P Expenses were",
          "bbox": [
            779.0,
            928.0,
            2893.0,
            974.0
          ],
          "confidence": 0.9964749217033386
        },
        {
          "text": "incurred pursuant to the Annual Marketing Plan..",
          "bbox": [
            783.0,
            990.0,
            1687.0,
            1027.0
          ],
          "confidence": 0.990655243396759
        },
        {
          "text": "4.2 Promotion Fee",
          "bbox": [
            448.0,
            1042.0,
            790.0,
            1082.0
          ],
          "confidence": 0.9922495484352112
        },
        {
          "text": "(a)Calculation of Promotion Fee. From the Launch Date and ending on the last day of the next Calendar Quarter and each",
          "bbox": [
            614.0,
            1096.0,
            2878.0,
            1142.0
          ],
          "confidence": 0.9964135885238647
        },
        {
          "text": "subsequent Calendar Quarter during the Term, Exact shall owe Pfizer a service fee equal to fifty percent (50%) of the",
          "bbox": [
            781.0,
            1155.0,
            2934.0,
            1199.0
          ],
          "confidence": 0.9916784763336182
        },
        {
          "text": "product of: Laboratory Service Revenue minus Baseline Laboratory Service Revenue (\"Incremental Laboratory Service",
          "bbox": [
            781.0,
            1210.0,
            3012.0,
            1255.0
          ],
          "confidence": 0.9976793527603149
        },
        {
          "text": "Revenue\") for the Calendar Quarter multiplied by Gross Margin Percent for the Calendar Quarter (such product, the",
          "bbox": [
            783.0,
            1266.0,
            2925.0,
            1308.0
          ],
          "confidence": 0.9885416626930237
        },
        {
          "text": "\"Promotion Fee'). In no event shall the Gross Margin Percent used in the calculation of the Promotion Fee be less than",
          "bbox": [
            781.0,
            1321.0,
            3002.0,
            1365.0
          ],
          "confidence": 0.9889373183250427
        },
        {
          "text": "sixty-eight percent (68%) or more than seventy-four percent (74%). The calculation of the Promotion Fee pursuant to",
          "bbox": [
            781.0,
            1378.0,
            2954.0,
            1424.0
          ],
          "confidence": 0.9887783527374268
        },
        {
          "text": "this Section 4.2(a) is subject to Section 4.2(c) below. Promotion Fee(s) and all compensation paid by Exact to Pfizer under",
          "bbox": [
            783.0,
            1436.0,
            3025.0,
            1478.0
          ],
          "confidence": 0.9969960451126099
        },
        {
          "text": "this Agreement, even where calculated as a percentage of sales, is intended to compensate Pfizer a fair market value for",
          "bbox": [
            783.0,
            1493.0,
            2998.0,
            1535.0
          ],
          "confidence": 0.993235170841217
        },
        {
          "text": "the entirety of services that Pfizer is providing to Exact hereunder..",
          "bbox": [
            785.0,
            1551.0,
            2003.0,
            1588.0
          ],
          "confidence": 0.9940460324287415
        },
        {
          "text": "The formula for the calculation of the Promotion Fee is as follows..",
          "bbox": [
            783.0,
            1606.0,
            2001.0,
            1643.0
          ],
          "confidence": 0.9825472235679626
        },
        {
          "text": "A = Laboratory Service Revenue",
          "bbox": [
            950.0,
            1661.0,
            1559.0,
            1701.0
          ],
          "confidence": 0.9977778196334839
        },
        {
          "text": "B = Baseline Laboratory Service Revenue.",
          "bbox": [
            950.0,
            1720.0,
            1722.0,
            1756.0
          ],
          "confidence": 0.9871435165405273
        },
        {
          "text": "C = Gross Margin Percent.",
          "bbox": [
            952.0,
            1776.0,
            1436.0,
            1813.0
          ],
          "confidence": 0.9637587666511536
        },
        {
          "text": "Promotion Fee = 0.5 * (A-B) * C",
          "bbox": [
            952.0,
            1831.0,
            1542.0,
            1868.0
          ],
          "confidence": 0.9781373143196106
        },
        {
          "text": "31",
          "bbox": [
            1628.0,
            1882.0,
            1673.0,
            1924.0
          ],
          "confidence": 0.998062252998352
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9910149574279785
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Revenue/Profit Sharing_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "Subject to Pfizer's compliance with Sections 3.4(a)(i) and 3.4(a)(ii), (A) Exact shall pay Pfizer the amount, if any, by which the aggregate amount of the Promotion Fee incurred by Exact to Pfizer during the remainder of 2018 Calendar Year and 2019 Calendar Year (the \"First Promotion Fee Period\") is less than $37.5 million (the \"First Supplemental Promotion Fee\"), and (B) Exact shall pay Pfizer the amount, if any, by which the aggregate Promotion Fee incurred by Exact to Pfizer during each of Calendar Year 2020 and 2021 is less than $30 million (\"Annual Supplemental Promotion Fee\"), in each case to compensate Pfizer for the sales, Marketing and other performance provided by Pfizer under this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "TABLE OF CONTENTS",
          "bbox": [
            1425.0,
            256.0,
            1880.0,
            292.0
          ],
          "confidence": 0.972561240196228
        },
        {
          "text": "Page",
          "bbox": [
            2886.0,
            309.0,
            2985.0,
            359.0
          ],
          "confidence": 0.9998502731323242
        },
        {
          "text": "1.",
          "bbox": [
            270.0,
            358.0,
            321.0,
            407.0
          ],
          "confidence": 0.8988077640533447
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            468.0,
            364.0,
            745.0,
            400.0
          ],
          "confidence": 0.9987927079200745
        },
        {
          "text": "1",
          "bbox": [
            2998.0,
            362.0,
            3030.0,
            402.0
          ],
          "confidence": 0.9999563694000244
        },
        {
          "text": "2.",
          "bbox": [
            263.0,
            408.0,
            326.0,
            469.0
          ],
          "confidence": 0.9996874332427979
        },
        {
          "text": "GOVERNANCE",
          "bbox": [
            468.0,
            420.0,
            774.0,
            457.0
          ],
          "confidence": 0.9996355772018433
        },
        {
          "text": "10",
          "bbox": [
            2974.0,
            417.0,
            3034.0,
            460.0
          ],
          "confidence": 0.9995191097259521
        },
        {
          "text": "2.1",
          "bbox": [
            462.0,
            471.0,
            522.0,
            517.0
          ],
          "confidence": 0.9998382925987244
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            651.0,
            475.0,
            1115.0,
            517.0
          ],
          "confidence": 0.9998593926429749
        },
        {
          "text": "10",
          "bbox": [
            2982.0,
            471.0,
            3034.0,
            517.0
          ],
          "confidence": 0.9996199607849121
        },
        {
          "text": "2.2",
          "bbox": [
            462.0,
            528.0,
            524.0,
            572.0
          ],
          "confidence": 0.999803364276886
        },
        {
          "text": "Joint Operations Committee",
          "bbox": [
            652.0,
            534.0,
            1167.0,
            570.0
          ],
          "confidence": 0.9999331831932068
        },
        {
          "text": "13",
          "bbox": [
            2983.0,
            530.0,
            3030.0,
            572.0
          ],
          "confidence": 0.9999063611030579
        },
        {
          "text": "2.3",
          "bbox": [
            462.0,
            583.0,
            522.0,
            629.0
          ],
          "confidence": 0.9998774528503418
        },
        {
          "text": "Joint Review Committee",
          "bbox": [
            651.0,
            587.0,
            1097.0,
            627.0
          ],
          "confidence": 0.976010262966156
        },
        {
          "text": "14",
          "bbox": [
            2977.0,
            580.0,
            3036.0,
            632.0
          ],
          "confidence": 0.9999385476112366
        },
        {
          "text": "2.4",
          "bbox": [
            462.0,
            640.0,
            524.0,
            683.0
          ],
          "confidence": 0.9998382925987244
        },
        {
          "text": "Finance Representative",
          "bbox": [
            652.0,
            643.0,
            1089.0,
            683.0
          ],
          "confidence": 0.9999425411224365
        },
        {
          "text": "15",
          "bbox": [
            2982.0,
            638.0,
            3032.0,
            685.0
          ],
          "confidence": 0.9998509287834167
        },
        {
          "text": "2.5",
          "bbox": [
            462.0,
            696.0,
            524.0,
            740.0
          ],
          "confidence": 0.9998595118522644
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            652.0,
            696.0,
            1010.0,
            744.0
          ],
          "confidence": 0.9999042749404907
        },
        {
          "text": "15",
          "bbox": [
            2982.0,
            694.0,
            3032.0,
            742.0
          ],
          "confidence": 0.9997546076774597
        },
        {
          "text": "2.6",
          "bbox": [
            462.0,
            751.0,
            526.0,
            797.0
          ],
          "confidence": 0.9999013543128967
        },
        {
          "text": "Compliance Managers",
          "bbox": [
            651.0,
            753.0,
            1073.0,
            801.0
          ],
          "confidence": 0.9998858571052551
        },
        {
          "text": "16",
          "bbox": [
            2979.0,
            748.0,
            3035.0,
            800.0
          ],
          "confidence": 0.9997362494468689
        },
        {
          "text": "3.",
          "bbox": [
            272.0,
            810.0,
            319.0,
            852.0
          ],
          "confidence": 0.9999758005142212
        },
        {
          "text": "APPOINTMENT; PRODUCT OWNERSHIP; MARKETING AND SALES",
          "bbox": [
            468.0,
            813.0,
            1843.0,
            850.0
          ],
          "confidence": 0.9891181588172913
        },
        {
          "text": "17",
          "bbox": [
            2972.0,
            810.0,
            3032.0,
            853.0
          ],
          "confidence": 0.9998164176940918
        },
        {
          "text": "3.1",
          "bbox": [
            462.0,
            864.0,
            522.0,
            908.0
          ],
          "confidence": 0.9998445510864258
        },
        {
          "text": "Appointment",
          "bbox": [
            650.0,
            866.0,
            906.0,
            912.0
          ],
          "confidence": 0.9999716281890869
        },
        {
          "text": "17",
          "bbox": [
            2980.0,
            864.0,
            3032.0,
            910.0
          ],
          "confidence": 0.9999139308929443
        },
        {
          "text": "3.2",
          "bbox": [
            462.0,
            921.0,
            524.0,
            965.0
          ],
          "confidence": 0.9997804760932922
        },
        {
          "text": "Responsibility for Product",
          "bbox": [
            652.0,
            925.0,
            1146.0,
            967.0
          ],
          "confidence": 0.9999520182609558
        },
        {
          "text": "19",
          "bbox": [
            2983.0,
            923.0,
            3030.0,
            965.0
          ],
          "confidence": 0.9998000860214233
        },
        {
          "text": "3.3",
          "bbox": [
            462.0,
            978.0,
            524.0,
            1021.0
          ],
          "confidence": 0.9999095797538757
        },
        {
          "text": "Annual Marketing Plan",
          "bbox": [
            654.0,
            981.0,
            1086.0,
            1018.0
          ],
          "confidence": 0.9967995882034302
        },
        {
          "text": "26",
          "bbox": [
            2980.0,
            976.0,
            3032.0,
            1021.0
          ],
          "confidence": 0.9998294115066528
        },
        {
          "text": "3.4",
          "bbox": [
            462.0,
            1032.0,
            524.0,
            1076.0
          ],
          "confidence": 0.999795138835907
        },
        {
          "text": "Sales Promotion, Detailing Efforts and IDN Promotion",
          "bbox": [
            654.0,
            1038.0,
            1651.0,
            1074.0
          ],
          "confidence": 0.9988903403282166
        },
        {
          "text": "27",
          "bbox": [
            2980.0,
            1032.0,
            3032.0,
            1080.0
          ],
          "confidence": 0.999879777431488
        },
        {
          "text": "3.5",
          "bbox": [
            462.0,
            1089.0,
            524.0,
            1133.0
          ],
          "confidence": 0.999901533126831
        },
        {
          "text": "Pfizer Investment and Support.",
          "bbox": [
            652.0,
            1091.0,
            1218.0,
            1133.0
          ],
          "confidence": 0.9910087585449219
        },
        {
          "text": "28",
          "bbox": [
            2980.0,
            1089.0,
            3032.0,
            1137.0
          ],
          "confidence": 0.9999079704284668
        },
        {
          "text": "3.6",
          "bbox": [
            462.0,
            1146.0,
            526.0,
            1190.0
          ],
          "confidence": 0.999901533126831
        },
        {
          "text": "Exact Investment and Support.",
          "bbox": [
            651.0,
            1146.0,
            1218.0,
            1191.0
          ],
          "confidence": 0.9756210446357727
        },
        {
          "text": "29",
          "bbox": [
            2980.0,
            1144.0,
            3032.0,
            1191.0
          ],
          "confidence": 0.9997735023498535
        },
        {
          "text": "3.7",
          "bbox": [
            462.0,
            1201.0,
            524.0,
            1246.0
          ],
          "confidence": 0.9998155236244202
        },
        {
          "text": "Changes in Shared M&P Expenses.",
          "bbox": [
            651.0,
            1202.0,
            1300.0,
            1248.0
          ],
          "confidence": 0.9710713624954224
        },
        {
          "text": "30",
          "bbox": [
            2980.0,
            1199.0,
            3032.0,
            1246.0
          ],
          "confidence": 0.9996087551116943
        },
        {
          "text": "4.",
          "bbox": [
            274.0,
            1259.0,
            317.0,
            1301.0
          ],
          "confidence": 0.9998270273208618
        },
        {
          "text": "ACCOUNTING",
          "bbox": [
            466.0,
            1261.0,
            761.0,
            1299.0
          ],
          "confidence": 0.9994717836380005
        },
        {
          "text": "30",
          "bbox": [
            2972.0,
            1257.0,
            3032.0,
            1301.0
          ],
          "confidence": 0.9997038841247559
        },
        {
          "text": "4.1",
          "bbox": [
            462.0,
            1312.0,
            522.0,
            1358.0
          ],
          "confidence": 0.9998102784156799
        },
        {
          "text": "Responsibility for Shared M&P Expenses.",
          "bbox": [
            652.0,
            1318.0,
            1423.0,
            1360.0
          ],
          "confidence": 0.9861323237419128
        },
        {
          "text": "30",
          "bbox": [
            2976.0,
            1309.0,
            3034.0,
            1361.0
          ],
          "confidence": 0.9994354844093323
        },
        {
          "text": "4.2",
          "bbox": [
            462.0,
            1369.0,
            524.0,
            1414.0
          ],
          "confidence": 0.99981290102005
        },
        {
          "text": "Promotion Fee",
          "bbox": [
            654.0,
            1374.0,
            924.0,
            1411.0
          ],
          "confidence": 0.9999128580093384
        },
        {
          "text": "31",
          "bbox": [
            2980.0,
            1367.0,
            3030.0,
            1414.0
          ],
          "confidence": 0.9999569058418274
        },
        {
          "text": "4.3",
          "bbox": [
            462.0,
            1425.0,
            524.0,
            1469.0
          ],
          "confidence": 0.9997981190681458
        },
        {
          "text": "Fee Statements and Payments",
          "bbox": [
            651.0,
            1427.0,
            1211.0,
            1469.0
          ],
          "confidence": 0.9828200936317444
        },
        {
          "text": "33",
          "bbox": [
            2982.0,
            1427.0,
            3029.0,
            1469.0
          ],
          "confidence": 0.9999467730522156
        },
        {
          "text": "4.4",
          "bbox": [
            462.0,
            1482.0,
            524.0,
            1526.0
          ],
          "confidence": 0.9997560381889343
        },
        {
          "text": "Taxes and Withholding.",
          "bbox": [
            649.0,
            1478.0,
            1086.0,
            1530.0
          ],
          "confidence": 0.977773904800415
        },
        {
          "text": "34",
          "bbox": [
            2980.0,
            1482.0,
            3032.0,
            1528.0
          ],
          "confidence": 0.9999403357505798
        },
        {
          "text": "4.5",
          "bbox": [
            462.0,
            1537.0,
            524.0,
            1582.0
          ],
          "confidence": 0.9998634457588196
        },
        {
          "text": "No Partnership Provision",
          "bbox": [
            651.0,
            1540.0,
            1122.0,
            1583.0
          ],
          "confidence": 0.9925678372383118
        },
        {
          "text": "35",
          "bbox": [
            2980.0,
            1537.0,
            3032.0,
            1582.0
          ],
          "confidence": 0.9999524354934692
        },
        {
          "text": "4.6",
          "bbox": [
            462.0,
            1595.0,
            526.0,
            1639.0
          ],
          "confidence": 0.9998771548271179
        },
        {
          "text": "Payments; Currency.",
          "bbox": [
            650.0,
            1593.0,
            1033.0,
            1643.0
          ],
          "confidence": 0.9698137044906616
        },
        {
          "text": "35",
          "bbox": [
            2980.0,
            1593.0,
            3032.0,
            1639.0
          ],
          "confidence": 0.9999392032623291
        },
        {
          "text": "4.7",
          "bbox": [
            462.0,
            1650.0,
            524.0,
            1694.0
          ],
          "confidence": 0.999767005443573
        },
        {
          "text": "Maintenance of Records; Audits.",
          "bbox": [
            652.0,
            1656.0,
            1265.0,
            1692.0
          ],
          "confidence": 0.9820064306259155
        },
        {
          "text": "35",
          "bbox": [
            2980.0,
            1650.0,
            3032.0,
            1696.0
          ],
          "confidence": 0.9999517202377319
        },
        {
          "text": "5.",
          "bbox": [
            274.0,
            1705.0,
            317.0,
            1751.0
          ],
          "confidence": 0.9999572038650513
        },
        {
          "text": "REPRESENTATIONS, WARRANTIES AND COVENANTS",
          "bbox": [
            468.0,
            1710.0,
            1580.0,
            1747.0
          ],
          "confidence": 0.9886522889137268
        },
        {
          "text": "37",
          "bbox": [
            2972.0,
            1707.0,
            3032.0,
            1751.0
          ],
          "confidence": 0.9999163746833801
        },
        {
          "text": "5.1",
          "bbox": [
            464.0,
            1762.0,
            522.0,
            1807.0
          ],
          "confidence": 0.9998762607574463
        },
        {
          "text": "Mutual Representations and Warranties.",
          "bbox": [
            652.0,
            1765.0,
            1401.0,
            1807.0
          ],
          "confidence": 0.9904761910438538
        },
        {
          "text": "37",
          "bbox": [
            2980.0,
            1763.0,
            3032.0,
            1809.0
          ],
          "confidence": 0.9999504089355469
        },
        {
          "text": "5.2",
          "bbox": [
            464.0,
            1818.0,
            524.0,
            1864.0
          ],
          "confidence": 0.9026532173156738
        },
        {
          "text": "Representations and Warranties of Exact",
          "bbox": [
            652.0,
            1822.0,
            1410.0,
            1862.0
          ],
          "confidence": 0.9908421039581299
        },
        {
          "text": "38",
          "bbox": [
            2980.0,
            1818.0,
            3032.0,
            1866.0
          ],
          "confidence": 0.9998841285705566
        },
        {
          "text": "5.3",
          "bbox": [
            464.0,
            1873.0,
            524.0,
            1919.0
          ],
          "confidence": 0.8968498110771179
        },
        {
          "text": "Covenants",
          "bbox": [
            652.0,
            1876.0,
            859.0,
            1919.0
          ],
          "confidence": 0.9998775124549866
        },
        {
          "text": "39",
          "bbox": [
            2980.0,
            1873.0,
            3032.0,
            1919.0
          ],
          "confidence": 0.9998854994773865
        },
        {
          "text": "5.4",
          "bbox": [
            461.0,
            1927.0,
            527.0,
            1978.0
          ],
          "confidence": 0.9997851848602295
        },
        {
          "text": "Compliance with Law and Ethical Business Practices",
          "bbox": [
            656.0,
            1935.0,
            1626.0,
            1972.0
          ],
          "confidence": 0.9921623468399048
        },
        {
          "text": "40",
          "bbox": [
            2980.0,
            1930.0,
            3032.0,
            1975.0
          ],
          "confidence": 0.9993378520011902
        },
        {
          "text": "5.5",
          "bbox": [
            464.0,
            1986.0,
            524.0,
            2032.0
          ],
          "confidence": 0.8501482009887695
        },
        {
          "text": "Notice of Investigations",
          "bbox": [
            651.0,
            1988.0,
            1106.0,
            2030.0
          ],
          "confidence": 0.9999415278434753
        },
        {
          "text": "43",
          "bbox": [
            2982.0,
            1988.0,
            3029.0,
            2030.0
          ],
          "confidence": 0.9999153017997742
        },
        {
          "text": "5.6",
          "bbox": [
            464.0,
            2041.0,
            524.0,
            2087.0
          ],
          "confidence": 0.9998176693916321
        },
        {
          "text": "Representation by Legal Counsel",
          "bbox": [
            654.0,
            2047.0,
            1276.0,
            2089.0
          ],
          "confidence": 0.9850961565971375
        },
        {
          "text": "43",
          "bbox": [
            2976.0,
            2038.0,
            3032.0,
            2088.0
          ],
          "confidence": 0.9999315142631531
        },
        {
          "text": "5.7",
          "bbox": [
            462.0,
            2098.0,
            524.0,
            2143.0
          ],
          "confidence": 0.9998096823692322
        },
        {
          "text": "No Inconsistent Agreements.",
          "bbox": [
            652.0,
            2100.0,
            1193.0,
            2145.0
          ],
          "confidence": 0.9836775660514832
        },
        {
          "text": "43",
          "bbox": [
            2977.0,
            2093.0,
            3034.0,
            2147.0
          ],
          "confidence": 0.9998714327812195
        },
        {
          "text": "5.8",
          "bbox": [
            464.0,
            2154.0,
            524.0,
            2200.0
          ],
          "confidence": 0.999863862991333
        },
        {
          "text": "Disclaimer",
          "bbox": [
            652.0,
            2158.0,
            848.0,
            2196.0
          ],
          "confidence": 0.9999488592147827
        },
        {
          "text": "44",
          "bbox": [
            2980.0,
            2154.0,
            3032.0,
            2200.0
          ],
          "confidence": 0.999557614326477
        },
        {
          "text": "6.",
          "bbox": [
            274.0,
            2213.0,
            319.0,
            2255.0
          ],
          "confidence": 0.7983464002609253
        },
        {
          "text": "INDEMNIFICATION; LIMITATION OF LIABILITY AND INSURANCE",
          "bbox": [
            466.0,
            2217.0,
            1798.0,
            2253.0
          ],
          "confidence": 0.9960425496101379
        },
        {
          "text": "44",
          "bbox": [
            2976.0,
            2215.0,
            3032.0,
            2253.0
          ],
          "confidence": 0.9999170899391174
        },
        {
          "text": "6.1",
          "bbox": [
            462.0,
            2268.0,
            522.0,
            2312.0
          ],
          "confidence": 0.9997587203979492
        },
        {
          "text": "Indemnification",
          "bbox": [
            652.0,
            2269.0,
            944.0,
            2310.0
          ],
          "confidence": 0.9998759031295776
        },
        {
          "text": "44",
          "bbox": [
            2980.0,
            2268.0,
            3032.0,
            2313.0
          ],
          "confidence": 0.99964839220047
        },
        {
          "text": "6.2",
          "bbox": [
            464.0,
            2323.0,
            524.0,
            2368.0
          ],
          "confidence": 0.9997497200965881
        },
        {
          "text": "Insurance Requirements",
          "bbox": [
            651.0,
            2324.0,
            1108.0,
            2370.0
          ],
          "confidence": 0.9962896704673767
        },
        {
          "text": "45",
          "bbox": [
            2983.0,
            2324.0,
            3030.0,
            2366.0
          ],
          "confidence": 0.9999210834503174
        },
        {
          "text": "6.3",
          "bbox": [
            464.0,
            2379.0,
            524.0,
            2423.0
          ],
          "confidence": 0.9997426867485046
        },
        {
          "text": "Limitation of Liability.",
          "bbox": [
            649.0,
            2377.0,
            1048.0,
            2427.0
          ],
          "confidence": 0.9703847765922546
        },
        {
          "text": "46",
          "bbox": [
            2983.0,
            2381.0,
            3030.0,
            2423.0
          ],
          "confidence": 0.9999144077301025
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4437.0,
            1287.0,
            4479.0
          ],
          "confidence": 0.9897373914718628
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "TABLE OF CONTENTS",
          "page": 1,
          "bbox": [
            1425.0,
            256.0,
            1880.0,
            292.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 1,
          "bbox": [
            468.0,
            364.0,
            745.0,
            400.0
          ]
        },
        {
          "text": "GOVERNANCE",
          "page": 1,
          "bbox": [
            468.0,
            420.0,
            774.0,
            457.0
          ]
        },
        {
          "text": "APPOINTMENT; PRODUCT OWNERSHIP; MARKETING AND SALES",
          "page": 1,
          "bbox": [
            468.0,
            813.0,
            1843.0,
            850.0
          ]
        },
        {
          "text": "ACCOUNTING",
          "page": 1,
          "bbox": [
            466.0,
            1261.0,
            761.0,
            1299.0
          ]
        },
        {
          "text": "REPRESENTATIONS, WARRANTIES AND COVENANTS",
          "page": 1,
          "bbox": [
            468.0,
            1710.0,
            1580.0,
            1747.0
          ]
        },
        {
          "text": "INDEMNIFICATION; LIMITATION OF LIABILITY AND INSURANCE",
          "page": 1,
          "bbox": [
            466.0,
            2217.0,
            1798.0,
            2253.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Revenue/Profit Sharing_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "Subject to Pfizer's compliance with Sections 3.4(a)(i) and 3.4(a)(ii), (A) Exact shall pay Pfizer the amount, if any, by which the aggregate amount of the Promotion Fee incurred by Exact to Pfizer during the remainder of 2018 Calendar Year and 2019 Calendar Year (the \"First Promotion Fee Period\") is less than $37.5 million (the \"First Supplemental Promotion Fee\"), and (B) Exact shall pay Pfizer the amount, if any, by which the aggregate Promotion Fee incurred by Exact to Pfizer during each of Calendar Year 2020 and 2021 is less than $30 million (\"Annual Supplemental Promotion Fee\"), in each case to compensate Pfizer for the sales, Marketing and other performance provided by Pfizer under this Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "7.",
          "bbox": [
            274.0,
            254.0,
            317.0,
            300.0
          ],
          "confidence": 0.9998791813850403
        },
        {
          "text": "CONFIDENTIALITY; PUBLICITY",
          "bbox": [
            469.0,
            258.0,
            1115.0,
            294.0
          ],
          "confidence": 0.9989007711410522
        },
        {
          "text": "46",
          "bbox": [
            2974.0,
            254.0,
            3032.0,
            300.0
          ],
          "confidence": 0.9997206926345825
        },
        {
          "text": "7.1",
          "bbox": [
            462.0,
            311.0,
            522.0,
            355.0
          ],
          "confidence": 0.9999106526374817
        },
        {
          "text": "Confidentiality",
          "bbox": [
            650.0,
            309.0,
            930.0,
            358.0
          ],
          "confidence": 0.9999611973762512
        },
        {
          "text": "46",
          "bbox": [
            2980.0,
            311.0,
            3032.0,
            356.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "7.2",
          "bbox": [
            462.0,
            367.0,
            524.0,
            411.0
          ],
          "confidence": 0.9996507167816162
        },
        {
          "text": "Authorized Disclosure and Use",
          "bbox": [
            654.0,
            371.0,
            1236.0,
            407.0
          ],
          "confidence": 0.993081271648407
        },
        {
          "text": "47",
          "bbox": [
            2976.0,
            362.0,
            3034.0,
            414.0
          ],
          "confidence": 0.9998974204063416
        },
        {
          "text": "7.3",
          "bbox": [
            462.0,
            422.0,
            522.0,
            468.0
          ],
          "confidence": 0.9999073147773743
        },
        {
          "text": "Certain Regulatory Filings",
          "bbox": [
            651.0,
            422.0,
            1140.0,
            472.0
          ],
          "confidence": 0.9997837543487549
        },
        {
          "text": "47",
          "bbox": [
            2980.0,
            422.0,
            3032.0,
            468.0
          ],
          "confidence": 0.9999006986618042
        },
        {
          "text": "7.4",
          "bbox": [
            462.0,
            479.0,
            524.0,
            523.0
          ],
          "confidence": 0.9998576641082764
        },
        {
          "text": "Public Announcements",
          "bbox": [
            652.0,
            480.0,
            1093.0,
            523.0
          ],
          "confidence": 0.9984183311462402
        },
        {
          "text": "47",
          "bbox": [
            2980.0,
            479.0,
            3032.0,
            524.0
          ],
          "confidence": 0.999897301197052
        },
        {
          "text": "7.5",
          "bbox": [
            462.0,
            534.0,
            524.0,
            579.0
          ],
          "confidence": 0.9998933672904968
        },
        {
          "text": "Use of Names",
          "bbox": [
            650.0,
            535.0,
            914.0,
            578.0
          ],
          "confidence": 0.97193843126297
        },
        {
          "text": "48",
          "bbox": [
            2983.0,
            537.0,
            3030.0,
            579.0
          ],
          "confidence": 0.9995381236076355
        },
        {
          "text": "8.",
          "bbox": [
            272.0,
            592.0,
            317.0,
            636.0
          ],
          "confidence": 0.9999796152114868
        },
        {
          "text": "TERM AND TERMINATION",
          "bbox": [
            468.0,
            598.0,
            1008.0,
            629.0
          ],
          "confidence": 0.9702898263931274
        },
        {
          "text": "48",
          "bbox": [
            2974.0,
            590.0,
            3032.0,
            636.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "8.1",
          "bbox": [
            462.0,
            647.0,
            522.0,
            693.0
          ],
          "confidence": 0.9998836517333984
        },
        {
          "text": "Term",
          "bbox": [
            647.0,
            647.0,
            749.0,
            693.0
          ],
          "confidence": 0.9997935891151428
        },
        {
          "text": "48",
          "bbox": [
            2980.0,
            647.0,
            3032.0,
            694.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "8.2",
          "bbox": [
            464.0,
            704.0,
            524.0,
            747.0
          ],
          "confidence": 0.9999227523803711
        },
        {
          "text": "Renewal",
          "bbox": [
            652.0,
            705.0,
            814.0,
            744.0
          ],
          "confidence": 0.9998234510421753
        },
        {
          "text": "48",
          "bbox": [
            2982.0,
            702.0,
            3032.0,
            749.0
          ],
          "confidence": 0.9999050498008728
        },
        {
          "text": "8.3",
          "bbox": [
            461.0,
            756.0,
            525.0,
            806.0
          ],
          "confidence": 0.9998739361763
        },
        {
          "text": "Termination for Cause",
          "bbox": [
            652.0,
            764.0,
            1062.0,
            800.0
          ],
          "confidence": 0.9999273419380188
        },
        {
          "text": "48",
          "bbox": [
            2983.0,
            760.0,
            3030.0,
            802.0
          ],
          "confidence": 0.9998279809951782
        },
        {
          "text": "8.4",
          "bbox": [
            466.0,
            819.0,
            526.0,
            859.0
          ],
          "confidence": 0.9999211430549622
        },
        {
          "text": "Termination Without Cause",
          "bbox": [
            651.0,
            817.0,
            1164.0,
            857.0
          ],
          "confidence": 0.9992270469665527
        },
        {
          "text": "49",
          "bbox": [
            2980.0,
            813.0,
            3032.0,
            861.0
          ],
          "confidence": 0.9997913241386414
        },
        {
          "text": "8.5",
          "bbox": [
            462.0,
            870.0,
            524.0,
            915.0
          ],
          "confidence": 0.9999166131019592
        },
        {
          "text": "Mutual Termination",
          "bbox": [
            652.0,
            873.0,
            1021.0,
            914.0
          ],
          "confidence": 0.9999244213104248
        },
        {
          "text": "49",
          "bbox": [
            2982.0,
            870.0,
            3032.0,
            917.0
          ],
          "confidence": 0.9998093843460083
        },
        {
          "text": "8.6",
          "bbox": [
            462.0,
            928.0,
            526.0,
            972.0
          ],
          "confidence": 0.9998876452445984
        },
        {
          "text": "Termination for Change of Control",
          "bbox": [
            651.0,
            930.0,
            1291.0,
            970.0
          ],
          "confidence": 0.9878026843070984
        },
        {
          "text": "49",
          "bbox": [
            2982.0,
            926.0,
            3032.0,
            974.0
          ],
          "confidence": 0.9998805522918701
        },
        {
          "text": "8.7",
          "bbox": [
            462.0,
            985.0,
            524.0,
            1029.0
          ],
          "confidence": 0.9998836517333984
        },
        {
          "text": "Royalty Upon Expiration",
          "bbox": [
            651.0,
            985.0,
            1113.0,
            1031.0
          ],
          "confidence": 0.9998092651367188
        },
        {
          "text": "49",
          "bbox": [
            2980.0,
            983.0,
            3032.0,
            1029.0
          ],
          "confidence": 0.9997520446777344
        },
        {
          "text": "8.8",
          "bbox": [
            462.0,
            1040.0,
            524.0,
            1085.0
          ],
          "confidence": 0.9999175071716309
        },
        {
          "text": "Consequences of Termination",
          "bbox": [
            654.0,
            1043.0,
            1209.0,
            1084.0
          ],
          "confidence": 0.9935645461082458
        },
        {
          "text": "50",
          "bbox": [
            2983.0,
            1042.0,
            3030.0,
            1084.0
          ],
          "confidence": 0.9998683929443359
        },
        {
          "text": "8.9",
          "bbox": [
            464.0,
            1095.0,
            524.0,
            1140.0
          ],
          "confidence": 0.9999069571495056
        },
        {
          "text": "Survival of Certain Obligations",
          "bbox": [
            651.0,
            1096.0,
            1229.0,
            1142.0
          ],
          "confidence": 0.9996927380561829
        },
        {
          "text": "50",
          "bbox": [
            2980.0,
            1095.0,
            3032.0,
            1140.0
          ],
          "confidence": 0.999791145324707
        },
        {
          "text": "9.",
          "bbox": [
            274.0,
            1151.0,
            317.0,
            1197.0
          ],
          "confidence": 0.9999210834503174
        },
        {
          "text": "MISCELLANEOUS",
          "bbox": [
            464.0,
            1153.0,
            837.0,
            1191.0
          ],
          "confidence": 0.9989362955093384
        },
        {
          "text": "51",
          "bbox": [
            2974.0,
            1151.0,
            3030.0,
            1197.0
          ],
          "confidence": 0.9999614357948303
        },
        {
          "text": "9.1",
          "bbox": [
            462.0,
            1208.0,
            522.0,
            1254.0
          ],
          "confidence": 0.9999165534973145
        },
        {
          "text": "Interpretation",
          "bbox": [
            654.0,
            1213.0,
            910.0,
            1252.0
          ],
          "confidence": 0.9999763369560242
        },
        {
          "text": "51",
          "bbox": [
            2982.0,
            1210.0,
            3029.0,
            1252.0
          ],
          "confidence": 0.9998899698257446
        },
        {
          "text": "9.2",
          "bbox": [
            462.0,
            1265.0,
            524.0,
            1308.0
          ],
          "confidence": 0.9998903274536133
        },
        {
          "text": "Assignment",
          "bbox": [
            652.0,
            1268.0,
            884.0,
            1312.0
          ],
          "confidence": 0.999955952167511
        },
        {
          "text": "51",
          "bbox": [
            2980.0,
            1263.0,
            3030.0,
            1310.0
          ],
          "confidence": 0.9998958706855774
        },
        {
          "text": "9.3",
          "bbox": [
            462.0,
            1319.0,
            524.0,
            1365.0
          ],
          "confidence": 0.9999290108680725
        },
        {
          "text": "Further Actions",
          "bbox": [
            652.0,
            1325.0,
            952.0,
            1363.0
          ],
          "confidence": 0.9999575018882751
        },
        {
          "text": "51",
          "bbox": [
            2980.0,
            1319.0,
            3030.0,
            1367.0
          ],
          "confidence": 0.9998900890350342
        },
        {
          "text": "9.4",
          "bbox": [
            462.0,
            1376.0,
            526.0,
            1420.0
          ],
          "confidence": 0.9998784065246582
        },
        {
          "text": "Force Majeure.",
          "bbox": [
            652.0,
            1381.0,
            923.0,
            1420.0
          ],
          "confidence": 0.9674030542373657
        },
        {
          "text": "51",
          "bbox": [
            2980.0,
            1374.0,
            3030.0,
            1422.0
          ],
          "confidence": 0.9997887015342712
        },
        {
          "text": "9.5",
          "bbox": [
            462.0,
            1433.0,
            524.0,
            1476.0
          ],
          "confidence": 0.9998992085456848
        },
        {
          "text": "Notices",
          "bbox": [
            649.0,
            1432.0,
            800.0,
            1477.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "52",
          "bbox": [
            2980.0,
            1433.0,
            3032.0,
            1478.0
          ],
          "confidence": 0.9999459385871887
        },
        {
          "text": "9.6",
          "bbox": [
            462.0,
            1487.0,
            526.0,
            1533.0
          ],
          "confidence": 0.999930202960968
        },
        {
          "text": "Amendment",
          "bbox": [
            650.0,
            1487.0,
            885.0,
            1535.0
          ],
          "confidence": 0.9999175667762756
        },
        {
          "text": "53",
          "bbox": [
            2982.0,
            1486.0,
            3030.0,
            1535.0
          ],
          "confidence": 0.9999337792396545
        },
        {
          "text": "9.7",
          "bbox": [
            462.0,
            1544.0,
            524.0,
            1590.0
          ],
          "confidence": 0.9998974800109863
        },
        {
          "text": "Waiver",
          "bbox": [
            650.0,
            1546.0,
            791.0,
            1590.0
          ],
          "confidence": 0.9999167919158936
        },
        {
          "text": "53",
          "bbox": [
            2982.0,
            1542.0,
            3030.0,
            1592.0
          ],
          "confidence": 0.9999328851699829
        },
        {
          "text": "9.8",
          "bbox": [
            462.0,
            1601.0,
            524.0,
            1645.0
          ],
          "confidence": 0.9999217987060547
        },
        {
          "text": "Severability",
          "bbox": [
            649.0,
            1600.0,
            872.0,
            1649.0
          ],
          "confidence": 0.9999056458473206
        },
        {
          "text": "53",
          "bbox": [
            2983.0,
            1603.0,
            3029.0,
            1645.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "9.9",
          "bbox": [
            462.0,
            1657.0,
            524.0,
            1701.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Descriptive Headings",
          "bbox": [
            649.0,
            1659.0,
            1055.0,
            1705.0
          ],
          "confidence": 0.999782383441925
        },
        {
          "text": "53",
          "bbox": [
            2983.0,
            1659.0,
            3029.0,
            1701.0
          ],
          "confidence": 0.9999603629112244
        },
        {
          "text": "9.10",
          "bbox": [
            462.0,
            1714.0,
            544.0,
            1756.0
          ],
          "confidence": 0.9999563694000244
        },
        {
          "text": "Governing Law",
          "bbox": [
            650.0,
            1714.0,
            941.0,
            1764.0
          ],
          "confidence": 0.999907374382019
        },
        {
          "text": "53",
          "bbox": [
            2983.0,
            1714.0,
            3029.0,
            1756.0
          ],
          "confidence": 0.9999500513076782
        },
        {
          "text": "9.11",
          "bbox": [
            464.0,
            1771.0,
            540.0,
            1813.0
          ],
          "confidence": 0.9998437166213989
        },
        {
          "text": "Dispute Resolution",
          "bbox": [
            654.0,
            1774.0,
            1013.0,
            1813.0
          ],
          "confidence": 0.9999619722366333
        },
        {
          "text": "53",
          "bbox": [
            2983.0,
            1771.0,
            3029.0,
            1813.0
          ],
          "confidence": 0.9999603629112244
        },
        {
          "text": "9.12",
          "bbox": [
            462.0,
            1824.0,
            546.0,
            1871.0
          ],
          "confidence": 0.9999512434005737
        },
        {
          "text": "Entire Agreement of the Parties",
          "bbox": [
            652.0,
            1829.0,
            1236.0,
            1871.0
          ],
          "confidence": 0.987617015838623
        },
        {
          "text": "54",
          "bbox": [
            2983.0,
            1826.0,
            3030.0,
            1868.0
          ],
          "confidence": 0.9999532103538513
        },
        {
          "text": "9.13",
          "bbox": [
            460.0,
            1880.0,
            546.0,
            1928.0
          ],
          "confidence": 0.9999438524246216
        },
        {
          "text": "Independent Contractors",
          "bbox": [
            654.0,
            1888.0,
            1122.0,
            1924.0
          ],
          "confidence": 0.9999504089355469
        },
        {
          "text": "54",
          "bbox": [
            2983.0,
            1882.0,
            3030.0,
            1924.0
          ],
          "confidence": 0.9999532103538513
        },
        {
          "text": "9.14",
          "bbox": [
            464.0,
            1939.0,
            546.0,
            1981.0
          ],
          "confidence": 0.9999440908432007
        },
        {
          "text": "No Legal Advice",
          "bbox": [
            651.0,
            1941.0,
            970.0,
            1984.0
          ],
          "confidence": 0.9905310869216919
        },
        {
          "text": "54",
          "bbox": [
            2980.0,
            1937.0,
            3032.0,
            1983.0
          ],
          "confidence": 0.9999135732650757
        },
        {
          "text": "9.15",
          "bbox": [
            460.0,
            1992.0,
            546.0,
            2039.0
          ],
          "confidence": 0.9999337196350098
        },
        {
          "text": "Counterparts",
          "bbox": [
            650.0,
            1995.0,
            899.0,
            2043.0
          ],
          "confidence": 0.9999749064445496
        },
        {
          "text": "54",
          "bbox": [
            2983.0,
            1995.0,
            3030.0,
            2037.0
          ],
          "confidence": 0.9999554753303528
        },
        {
          "text": "EXHIBITS",
          "bbox": [
            277.0,
            2054.0,
            482.0,
            2092.0
          ],
          "confidence": 0.9985084533691406
        },
        {
          "text": "Exhibit 1.24",
          "bbox": [
            275.0,
            2105.0,
            490.0,
            2147.0
          ],
          "confidence": 0.9998055100440979
        },
        {
          "text": "Cost of Sales",
          "bbox": [
            808.0,
            2109.0,
            1053.0,
            2147.0
          ],
          "confidence": 0.9995453953742981
        },
        {
          "text": "Exhibit 1.39",
          "bbox": [
            277.0,
            2165.0,
            488.0,
            2202.0
          ],
          "confidence": 0.9993863105773926
        },
        {
          "text": "Exact Trademarks",
          "bbox": [
            810.0,
            2167.0,
            1129.0,
            2204.0
          ],
          "confidence": 0.9999196529388428
        },
        {
          "text": "Exhibit 2.2(c)(iv)",
          "bbox": [
            273.0,
            2214.0,
            580.0,
            2264.0
          ],
          "confidence": 0.9976734519004822
        },
        {
          "text": "Calendar Quarter Performance Metrics.",
          "bbox": [
            808.0,
            2220.0,
            1517.0,
            2260.0
          ],
          "confidence": 0.9893094897270203
        },
        {
          "text": "Exhibit 3.2(c)(i)",
          "bbox": [
            277.0,
            2273.0,
            555.0,
            2321.0
          ],
          "confidence": 0.9983024597167969
        },
        {
          "text": "Sales Deployment Plan",
          "bbox": [
            806.0,
            2275.0,
            1236.0,
            2321.0
          ],
          "confidence": 0.9996693134307861
        },
        {
          "text": "Exhibit 3.3(b)",
          "bbox": [
            273.0,
            2328.0,
            521.0,
            2378.0
          ],
          "confidence": 0.9708530306816101
        },
        {
          "text": "Annua1 Marketing Plan Outline",
          "bbox": [
            810.0,
            2337.0,
            1387.0,
            2374.0
          ],
          "confidence": 0.9817324876785278
        },
        {
          "text": "Exhibit 3.4(a)",
          "bbox": [
            273.0,
            2384.0,
            517.0,
            2434.0
          ],
          "confidence": 0.9990342855453491
        },
        {
          "text": "Promotion Fee Reduction",
          "bbox": [
            807.0,
            2392.0,
            1280.0,
            2429.0
          ],
          "confidence": 0.9958807826042175
        },
        {
          "text": "Exhibit 7.4",
          "bbox": [
            277.0,
            2447.0,
            469.0,
            2485.0
          ],
          "confidence": 0.9636997580528259
        },
        {
          "text": "Press Release",
          "bbox": [
            807.0,
            2447.0,
            1064.0,
            2483.0
          ],
          "confidence": 0.9969821572303772
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "CONFIDENTIALITY; PUBLICITY",
          "page": 2,
          "bbox": [
            469.0,
            258.0,
            1115.0,
            294.0
          ]
        },
        {
          "text": "TERM AND TERMINATION",
          "page": 2,
          "bbox": [
            468.0,
            598.0,
            1008.0,
            629.0
          ]
        },
        {
          "text": "MISCELLANEOUS",
          "page": 2,
          "bbox": [
            464.0,
            1153.0,
            837.0,
            1191.0
          ]
        },
        {
          "text": "EXHIBITS",
          "page": 2,
          "bbox": [
            277.0,
            2054.0,
            482.0,
            2092.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Revenue/Profit Sharing_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "From the Launch Date and ending on the last day of the next Calendar Quarter and each subsequent Calendar Quarter during the Term, Exact shall owe Pfizer a service fee equal to fifty percent (50%) of the product of: Laboratory Service Revenue minus Baseline Laboratory Service Revenue (\"Incremental Laboratory Service Revenue\") for the Calendar Quarter multiplied by Gross Margin Percent for the Calendar Quarter (such product, the \"Promotion Fee\").",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Revenue/Profit Sharing_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, orÂ services?",
      "answer_text": "From the Launch Date and ending on the last day of the next Calendar Quarter and each subsequent Calendar Quarter during the Term, Exact shall owe Pfizer a service fee equal to fifty percent (50%) of the product of: Laboratory Service Revenue minus Baseline Laboratory Service Revenue (\"Incremental Laboratory Service Revenue\") for the Calendar Quarter multiplied by Gross Margin Percent for the Calendar Quarter (such product, the \"Promotion Fee\").",
      "page_number": 5,
      "words": [
        {
          "text": "1.5\"Alliance Manager\" shall have the meaning set forth in Section 2.5.",
          "bbox": [
            475.0,
            254.0,
            1796.0,
            298.0
          ],
          "confidence": 0.9890038371086121
        },
        {
          "text": "1.6\"Annual Marketing Plan\"' shall mean the plan for the Marketing and Promotion of the Product in the Territory for each full or partial",
          "bbox": [
            477.0,
            316.0,
            2992.0,
            353.0
          ],
          "confidence": 0.9888446927070618
        },
        {
          "text": "Calendar Year as described in Section 3.3, as prepared and updated from time to time pursuant to Section 3.3..",
          "bbox": [
            642.0,
            369.0,
            2659.0,
            413.0
          ],
          "confidence": 0.9882045984268188
        },
        {
          "text": "1.7\"Annual Supplemental Promotion Fee\"' shall have the meaning set forth in Section 4.2(c)(i)..",
          "bbox": [
            477.0,
            426.0,
            2238.0,
            468.0
          ],
          "confidence": 0.9870630502700806
        },
        {
          "text": "1.8\"Applicable Compliance/Review Policies\"' shall mean, with respect to Pfizer, its written Code of Ethics and Professional Conduct and,.",
          "bbox": [
            477.0,
            482.0,
            3014.0,
            524.0
          ],
          "confidence": 0.9912572503089905
        },
        {
          "text": "with respect to Exact, its written Code of Business Conduct and Ethics, and such policies and standard operating procedures",
          "bbox": [
            642.0,
            539.0,
            2969.0,
            581.0
          ],
          "confidence": 0.9917171001434326
        },
        {
          "text": "that are adhered to by such Party in connection with the Product and any payments or services contemplated by this",
          "bbox": [
            640.0,
            592.0,
            2820.0,
            638.0
          ],
          "confidence": 0.9860061407089233
        },
        {
          "text": "Agreement, as the same may be amended from time to time.",
          "bbox": [
            643.0,
            651.0,
            1736.0,
            691.0
          ],
          "confidence": 0.9950719475746155
        },
        {
          "text": "1.9\"Applicable Law\"' shall mean any law, statute, rule, regulation, order, judgment, ordinance, administrative code, decree, directive,",
          "bbox": [
            475.0,
            704.0,
            2916.0,
            751.0
          ],
          "confidence": 0.9942479729652405
        },
        {
          "text": "injunction or permit (including Regulatory Approvals) of any court, arbitral body, agency, department, authority or other.",
          "bbox": [
            643.0,
            764.0,
            2882.0,
            806.0
          ],
          "confidence": 0.9893744587898254
        },
        {
          "text": "instrumentality of any national, state, county, city or other political subdivision applicable to a Party's activities to be performed",
          "bbox": [
            642.0,
            820.0,
            3021.0,
            863.0
          ],
          "confidence": 0.9948800206184387
        },
        {
          "text": "under this Agreement. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall",
          "bbox": [
            643.0,
            875.0,
            2989.0,
            917.0
          ],
          "confidence": 0.9867214560508728
        },
        {
          "text": "be deemed to include all amendments, replacements or successors thereto.",
          "bbox": [
            642.0,
            932.0,
            2028.0,
            974.0
          ],
          "confidence": 0.9949407577514648
        },
        {
          "text": "1.10\"Audited Party\" shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            985.0,
            1831.0,
            1029.0
          ],
          "confidence": 0.9958505630493164
        },
        {
          "text": "1.11\"Auditing Party\"' shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            1043.0,
            1849.0,
            1085.0
          ],
          "confidence": 0.9746250510215759
        },
        {
          "text": "1.12\"Baseline Laboratory Service Revenue\" shall mean, with respect to a particular Calendar Year during the Term, the amounts set.",
          "bbox": [
            473.0,
            1096.0,
            2934.0,
            1140.0
          ],
          "confidence": 0.9947289228439331
        },
        {
          "text": "forth in Section 4.2(b).",
          "bbox": [
            642.0,
            1155.0,
            1051.0,
            1195.0
          ],
          "confidence": 0.9629735946655273
        },
        {
          "text": "1.13\"Baseline M&P Expense\" shall have the meaning set forth in Section 3.6..",
          "bbox": [
            475.0,
            1212.0,
            1923.0,
            1254.0
          ],
          "confidence": 0.9764768481254578
        },
        {
          "text": "1.14\"Business Day\"' shall mean any day other than a Saturday, Sunday, or a bank or other public holiday in New York, New York, United.",
          "bbox": [
            475.0,
            1266.0,
            3016.0,
            1310.0
          ],
          "confidence": 0.9815430045127869
        },
        {
          "text": "States.",
          "bbox": [
            639.0,
            1323.0,
            769.0,
            1365.0
          ],
          "confidence": 0.9991849660873413
        },
        {
          "text": "1.15\"Calendar Quarter' shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30,",
          "bbox": [
            473.0,
            1376.0,
            2905.0,
            1422.0
          ],
          "confidence": 0.988274335861206
        },
        {
          "text": "September 30 or December 31.",
          "bbox": [
            643.0,
            1436.0,
            1202.0,
            1478.0
          ],
          "confidence": 0.9999055862426758
        },
        {
          "text": "1.16\"Calendar Year' shall mean the respective periods of twelve (12) calendar months, each such period ending on December 31 of the.",
          "bbox": [
            473.0,
            1491.0,
            2996.0,
            1535.0
          ],
          "confidence": 0.9880089163780212
        },
        {
          "text": "applicable year for as long as this Agreement is in effect.",
          "bbox": [
            642.0,
            1544.0,
            1697.0,
            1594.0
          ],
          "confidence": 0.9885498285293579
        },
        {
          "text": "1.17\"Calendar Year Baseline Laboratory Service Revenue\" shall have the meaning set forth in Section 4.2(b).",
          "bbox": [
            475.0,
            1604.0,
            2525.0,
            1646.0
          ],
          "confidence": 0.9913415908813477
        },
        {
          "text": "1.18\"Change of Control' shall mean, with respect to a Party: (a) the sale of all or substantially all of such Party's assets or business.",
          "bbox": [
            475.0,
            1661.0,
            2929.0,
            1703.0
          ],
          "confidence": 0.9942373037338257
        },
        {
          "text": "relating to the subject matter of this Agreement; (b) a merger, reorganization, or consolidation involving such Party in which the.",
          "bbox": [
            638.0,
            1712.0,
            3018.0,
            1763.0
          ],
          "confidence": 0.9887958765029907
        },
        {
          "text": "holders of voting securities of such Party outstanding immediately",
          "bbox": [
            640.0,
            1771.0,
            1883.0,
            1816.0
          ],
          "confidence": 0.9987452030181885
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1831.0,
            1669.0,
            1866.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9922685027122498
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Minimum Commitment_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "Notwithstanding the above, Pfizer agrees to invest its portion of Shared M&P Expense each Calendar Year subject to, (a) Exact spending at least twelve million dollars ($12,000,000) in Baseline M&P Expense each Calendar Quarter (provided, that notwithstanding Exact's quarterly spend for Baseline M&P Expense, Exact shall spend a total of eighty million dollars ($80,000,000) in Baseline M&P Expense each Calendar Year measured as of the end of each Calendar Year), (b) an amount equal to the total Shared M&P Expense contributed by both Parties is used for Marketing and Promotion and (c) a total sum of not less than eighty million dollars ($80,000,000) of Baseline M&P Expense is used for Marketing and Promotional activities, including the costs of Exact Sponsorships and Related Activities; provided, however, the Parties may agree to reallocate Shared M&P Expenses by 28\n\nSource: EXACT SCIENCES CORP, 8-K, 8/22/2018\n\n\n\n\n\nmutual written consent.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Minimum Commitment_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "Notwithstanding the above, Pfizer agrees to invest its portion of Shared M&P Expense each Calendar Year subject to, (a) Exact spending at least twelve million dollars ($12,000,000) in Baseline M&P Expense each Calendar Quarter (provided, that notwithstanding Exact's quarterly spend for Baseline M&P Expense, Exact shall spend a total of eighty million dollars ($80,000,000) in Baseline M&P Expense each Calendar Year measured as of the end of each Calendar Year), (b) an amount equal to the total Shared M&P Expense contributed by both Parties is used for Marketing and Promotion and (c) a total sum of not less than eighty million dollars ($80,000,000) of Baseline M&P Expense is used for Marketing and Promotional activities, including the costs of Exact Sponsorships and Related Activities; provided, however, the Parties may agree to reallocate Shared M&P Expenses by 28\n\nSource: EXACT SCIENCES CORP, 8-K, 8/22/2018\n\n\n\n\n\nmutual written consent.",
      "page_number": 5,
      "words": [
        {
          "text": "1.5\"Alliance Manager\" shall have the meaning set forth in Section 2.5.",
          "bbox": [
            475.0,
            254.0,
            1796.0,
            298.0
          ],
          "confidence": 0.9890038371086121
        },
        {
          "text": "1.6\"Annual Marketing Plan\"' shall mean the plan for the Marketing and Promotion of the Product in the Territory for each full or partial",
          "bbox": [
            477.0,
            316.0,
            2992.0,
            353.0
          ],
          "confidence": 0.9888446927070618
        },
        {
          "text": "Calendar Year as described in Section 3.3, as prepared and updated from time to time pursuant to Section 3.3..",
          "bbox": [
            642.0,
            369.0,
            2659.0,
            413.0
          ],
          "confidence": 0.9882045984268188
        },
        {
          "text": "1.7\"Annual Supplemental Promotion Fee\"' shall have the meaning set forth in Section 4.2(c)(i)..",
          "bbox": [
            477.0,
            426.0,
            2238.0,
            468.0
          ],
          "confidence": 0.9870630502700806
        },
        {
          "text": "1.8\"Applicable Compliance/Review Policies\"' shall mean, with respect to Pfizer, its written Code of Ethics and Professional Conduct and,.",
          "bbox": [
            477.0,
            482.0,
            3014.0,
            524.0
          ],
          "confidence": 0.9912572503089905
        },
        {
          "text": "with respect to Exact, its written Code of Business Conduct and Ethics, and such policies and standard operating procedures",
          "bbox": [
            642.0,
            539.0,
            2969.0,
            581.0
          ],
          "confidence": 0.9917171001434326
        },
        {
          "text": "that are adhered to by such Party in connection with the Product and any payments or services contemplated by this",
          "bbox": [
            640.0,
            592.0,
            2820.0,
            638.0
          ],
          "confidence": 0.9860061407089233
        },
        {
          "text": "Agreement, as the same may be amended from time to time.",
          "bbox": [
            643.0,
            651.0,
            1736.0,
            691.0
          ],
          "confidence": 0.9950719475746155
        },
        {
          "text": "1.9\"Applicable Law\"' shall mean any law, statute, rule, regulation, order, judgment, ordinance, administrative code, decree, directive,",
          "bbox": [
            475.0,
            704.0,
            2916.0,
            751.0
          ],
          "confidence": 0.9942479729652405
        },
        {
          "text": "injunction or permit (including Regulatory Approvals) of any court, arbitral body, agency, department, authority or other.",
          "bbox": [
            643.0,
            764.0,
            2882.0,
            806.0
          ],
          "confidence": 0.9893744587898254
        },
        {
          "text": "instrumentality of any national, state, county, city or other political subdivision applicable to a Party's activities to be performed",
          "bbox": [
            642.0,
            820.0,
            3021.0,
            863.0
          ],
          "confidence": 0.9948800206184387
        },
        {
          "text": "under this Agreement. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall",
          "bbox": [
            643.0,
            875.0,
            2989.0,
            917.0
          ],
          "confidence": 0.9867214560508728
        },
        {
          "text": "be deemed to include all amendments, replacements or successors thereto.",
          "bbox": [
            642.0,
            932.0,
            2028.0,
            974.0
          ],
          "confidence": 0.9949407577514648
        },
        {
          "text": "1.10\"Audited Party\" shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            985.0,
            1831.0,
            1029.0
          ],
          "confidence": 0.9958505630493164
        },
        {
          "text": "1.11\"Auditing Party\"' shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            1043.0,
            1849.0,
            1085.0
          ],
          "confidence": 0.9746250510215759
        },
        {
          "text": "1.12\"Baseline Laboratory Service Revenue\" shall mean, with respect to a particular Calendar Year during the Term, the amounts set.",
          "bbox": [
            473.0,
            1096.0,
            2934.0,
            1140.0
          ],
          "confidence": 0.9947289228439331
        },
        {
          "text": "forth in Section 4.2(b).",
          "bbox": [
            642.0,
            1155.0,
            1051.0,
            1195.0
          ],
          "confidence": 0.9629735946655273
        },
        {
          "text": "1.13\"Baseline M&P Expense\" shall have the meaning set forth in Section 3.6..",
          "bbox": [
            475.0,
            1212.0,
            1923.0,
            1254.0
          ],
          "confidence": 0.9764768481254578
        },
        {
          "text": "1.14\"Business Day\"' shall mean any day other than a Saturday, Sunday, or a bank or other public holiday in New York, New York, United.",
          "bbox": [
            475.0,
            1266.0,
            3016.0,
            1310.0
          ],
          "confidence": 0.9815430045127869
        },
        {
          "text": "States.",
          "bbox": [
            639.0,
            1323.0,
            769.0,
            1365.0
          ],
          "confidence": 0.9991849660873413
        },
        {
          "text": "1.15\"Calendar Quarter' shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30,",
          "bbox": [
            473.0,
            1376.0,
            2905.0,
            1422.0
          ],
          "confidence": 0.988274335861206
        },
        {
          "text": "September 30 or December 31.",
          "bbox": [
            643.0,
            1436.0,
            1202.0,
            1478.0
          ],
          "confidence": 0.9999055862426758
        },
        {
          "text": "1.16\"Calendar Year' shall mean the respective periods of twelve (12) calendar months, each such period ending on December 31 of the.",
          "bbox": [
            473.0,
            1491.0,
            2996.0,
            1535.0
          ],
          "confidence": 0.9880089163780212
        },
        {
          "text": "applicable year for as long as this Agreement is in effect.",
          "bbox": [
            642.0,
            1544.0,
            1697.0,
            1594.0
          ],
          "confidence": 0.9885498285293579
        },
        {
          "text": "1.17\"Calendar Year Baseline Laboratory Service Revenue\" shall have the meaning set forth in Section 4.2(b).",
          "bbox": [
            475.0,
            1604.0,
            2525.0,
            1646.0
          ],
          "confidence": 0.9913415908813477
        },
        {
          "text": "1.18\"Change of Control' shall mean, with respect to a Party: (a) the sale of all or substantially all of such Party's assets or business.",
          "bbox": [
            475.0,
            1661.0,
            2929.0,
            1703.0
          ],
          "confidence": 0.9942373037338257
        },
        {
          "text": "relating to the subject matter of this Agreement; (b) a merger, reorganization, or consolidation involving such Party in which the.",
          "bbox": [
            638.0,
            1712.0,
            3018.0,
            1763.0
          ],
          "confidence": 0.9887958765029907
        },
        {
          "text": "holders of voting securities of such Party outstanding immediately",
          "bbox": [
            640.0,
            1771.0,
            1883.0,
            1816.0
          ],
          "confidence": 0.9987452030181885
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1831.0,
            1669.0,
            1866.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9922685027122498
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Minimum Commitment_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "Exact agrees it shall spend at least eighty million dollars ($80,000,000) toward Marketing and Promotion (including any amounts spent between January 1, 2018 and the Effective Date) and the pro-rated Shared M&P Expense for 2018.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Minimum Commitment_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
      "answer_text": "Exact agrees it shall spend at least eighty million dollars ($80,000,000) toward Marketing and Promotion (including any amounts spent between January 1, 2018 and the Effective Date) and the pro-rated Shared M&P Expense for 2018.",
      "page_number": 5,
      "words": [
        {
          "text": "1.5\"Alliance Manager\" shall have the meaning set forth in Section 2.5.",
          "bbox": [
            475.0,
            254.0,
            1796.0,
            298.0
          ],
          "confidence": 0.9890038371086121
        },
        {
          "text": "1.6\"Annual Marketing Plan\"' shall mean the plan for the Marketing and Promotion of the Product in the Territory for each full or partial",
          "bbox": [
            477.0,
            316.0,
            2992.0,
            353.0
          ],
          "confidence": 0.9888446927070618
        },
        {
          "text": "Calendar Year as described in Section 3.3, as prepared and updated from time to time pursuant to Section 3.3..",
          "bbox": [
            642.0,
            369.0,
            2659.0,
            413.0
          ],
          "confidence": 0.9882045984268188
        },
        {
          "text": "1.7\"Annual Supplemental Promotion Fee\"' shall have the meaning set forth in Section 4.2(c)(i)..",
          "bbox": [
            477.0,
            426.0,
            2238.0,
            468.0
          ],
          "confidence": 0.9870630502700806
        },
        {
          "text": "1.8\"Applicable Compliance/Review Policies\"' shall mean, with respect to Pfizer, its written Code of Ethics and Professional Conduct and,.",
          "bbox": [
            477.0,
            482.0,
            3014.0,
            524.0
          ],
          "confidence": 0.9912572503089905
        },
        {
          "text": "with respect to Exact, its written Code of Business Conduct and Ethics, and such policies and standard operating procedures",
          "bbox": [
            642.0,
            539.0,
            2969.0,
            581.0
          ],
          "confidence": 0.9917171001434326
        },
        {
          "text": "that are adhered to by such Party in connection with the Product and any payments or services contemplated by this",
          "bbox": [
            640.0,
            592.0,
            2820.0,
            638.0
          ],
          "confidence": 0.9860061407089233
        },
        {
          "text": "Agreement, as the same may be amended from time to time.",
          "bbox": [
            643.0,
            651.0,
            1736.0,
            691.0
          ],
          "confidence": 0.9950719475746155
        },
        {
          "text": "1.9\"Applicable Law\"' shall mean any law, statute, rule, regulation, order, judgment, ordinance, administrative code, decree, directive,",
          "bbox": [
            475.0,
            704.0,
            2916.0,
            751.0
          ],
          "confidence": 0.9942479729652405
        },
        {
          "text": "injunction or permit (including Regulatory Approvals) of any court, arbitral body, agency, department, authority or other.",
          "bbox": [
            643.0,
            764.0,
            2882.0,
            806.0
          ],
          "confidence": 0.9893744587898254
        },
        {
          "text": "instrumentality of any national, state, county, city or other political subdivision applicable to a Party's activities to be performed",
          "bbox": [
            642.0,
            820.0,
            3021.0,
            863.0
          ],
          "confidence": 0.9948800206184387
        },
        {
          "text": "under this Agreement. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall",
          "bbox": [
            643.0,
            875.0,
            2989.0,
            917.0
          ],
          "confidence": 0.9867214560508728
        },
        {
          "text": "be deemed to include all amendments, replacements or successors thereto.",
          "bbox": [
            642.0,
            932.0,
            2028.0,
            974.0
          ],
          "confidence": 0.9949407577514648
        },
        {
          "text": "1.10\"Audited Party\" shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            985.0,
            1831.0,
            1029.0
          ],
          "confidence": 0.9958505630493164
        },
        {
          "text": "1.11\"Auditing Party\"' shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            1043.0,
            1849.0,
            1085.0
          ],
          "confidence": 0.9746250510215759
        },
        {
          "text": "1.12\"Baseline Laboratory Service Revenue\" shall mean, with respect to a particular Calendar Year during the Term, the amounts set.",
          "bbox": [
            473.0,
            1096.0,
            2934.0,
            1140.0
          ],
          "confidence": 0.9947289228439331
        },
        {
          "text": "forth in Section 4.2(b).",
          "bbox": [
            642.0,
            1155.0,
            1051.0,
            1195.0
          ],
          "confidence": 0.9629735946655273
        },
        {
          "text": "1.13\"Baseline M&P Expense\" shall have the meaning set forth in Section 3.6..",
          "bbox": [
            475.0,
            1212.0,
            1923.0,
            1254.0
          ],
          "confidence": 0.9764768481254578
        },
        {
          "text": "1.14\"Business Day\"' shall mean any day other than a Saturday, Sunday, or a bank or other public holiday in New York, New York, United.",
          "bbox": [
            475.0,
            1266.0,
            3016.0,
            1310.0
          ],
          "confidence": 0.9815430045127869
        },
        {
          "text": "States.",
          "bbox": [
            639.0,
            1323.0,
            769.0,
            1365.0
          ],
          "confidence": 0.9991849660873413
        },
        {
          "text": "1.15\"Calendar Quarter' shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30,",
          "bbox": [
            473.0,
            1376.0,
            2905.0,
            1422.0
          ],
          "confidence": 0.988274335861206
        },
        {
          "text": "September 30 or December 31.",
          "bbox": [
            643.0,
            1436.0,
            1202.0,
            1478.0
          ],
          "confidence": 0.9999055862426758
        },
        {
          "text": "1.16\"Calendar Year' shall mean the respective periods of twelve (12) calendar months, each such period ending on December 31 of the.",
          "bbox": [
            473.0,
            1491.0,
            2996.0,
            1535.0
          ],
          "confidence": 0.9880089163780212
        },
        {
          "text": "applicable year for as long as this Agreement is in effect.",
          "bbox": [
            642.0,
            1544.0,
            1697.0,
            1594.0
          ],
          "confidence": 0.9885498285293579
        },
        {
          "text": "1.17\"Calendar Year Baseline Laboratory Service Revenue\" shall have the meaning set forth in Section 4.2(b).",
          "bbox": [
            475.0,
            1604.0,
            2525.0,
            1646.0
          ],
          "confidence": 0.9913415908813477
        },
        {
          "text": "1.18\"Change of Control' shall mean, with respect to a Party: (a) the sale of all or substantially all of such Party's assets or business.",
          "bbox": [
            475.0,
            1661.0,
            2929.0,
            1703.0
          ],
          "confidence": 0.9942373037338257
        },
        {
          "text": "relating to the subject matter of this Agreement; (b) a merger, reorganization, or consolidation involving such Party in which the.",
          "bbox": [
            638.0,
            1712.0,
            3018.0,
            1763.0
          ],
          "confidence": 0.9887958765029907
        },
        {
          "text": "holders of voting securities of such Party outstanding immediately",
          "bbox": [
            640.0,
            1771.0,
            1883.0,
            1816.0
          ],
          "confidence": 0.9987452030181885
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1831.0,
            1669.0,
            1866.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9922685027122498
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__License Grant_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Subject to the terms of this Agreement, Exact on behalf of itself and its Affiliates, hereby grants to Pfizer a non-exclusive, royalty free license, with the right to sublicense to one or more of its Affiliates, under the Exact House Marks, the Exact Trademarks and the Exact Copyrights, during the Term, to the extent necessary or appropriate to allow Pfizer and its Affiliates to carry out activities under this Agreement including to Promote and Detail the Product in the Co-Promote Field in the Territory.",
      "page_number": 3,
      "words": [
        {
          "text": "Exhibit 8.8(b)",
          "bbox": [
            277.0,
            254.0,
            519.0,
            302.0
          ],
          "confidence": 0.9773956537246704
        },
        {
          "text": "Tail Period Advertising Services",
          "bbox": [
            808.0,
            258.0,
            1403.0,
            298.0
          ],
          "confidence": 0.9866174459457397
        },
        {
          "text": "i1",
          "bbox": [
            1638.0,
            312.0,
            1668.0,
            355.0
          ],
          "confidence": 0.6335347294807434
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4437.0,
            1287.0,
            4479.0
          ],
          "confidence": 0.9964374303817749
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__License Grant_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Subject to the terms of this Agreement, Exact on behalf of itself and its Affiliates, hereby grants to Pfizer a non-exclusive, royalty free license, with the right to sublicense to one or more of its Affiliates, under the Exact House Marks, the Exact Trademarks and the Exact Copyrights, during the Term, to the extent necessary or appropriate to allow Pfizer and its Affiliates to carry out activities under this Agreement including to Promote and Detail the Product in the Co-Promote Field in the Territory.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Non-Transferable License_4",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
      "answer_text": "Except as set forth in this Agreement, such right shall be non-transferable and non-sublicensable.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Non-Transferable License_4",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
      "answer_text": "(except as provided in this Agreement) and shall automatically terminate upon the expiration or earlier termination of this Agreement.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Non-Transferable License_6",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
      "answer_text": "Such license shall be non-transferable and non-sublicensable",
      "page_number": 6,
      "words": [
        {
          "text": "prior thereto cease to hold at least fifty percent (50%) of the combined voting power of the surviving entity or acquiring entity",
          "bbox": [
            642.0,
            256.0,
            2985.0,
            302.0
          ],
          "confidence": 0.9912095069885254
        },
        {
          "text": "(or its parent) immediately after such merger, reorganization, or consolidation; or (c) the acquisition of more than fifty percent",
          "bbox": [
            645.0,
            318.0,
            2965.0,
            355.0
          ],
          "confidence": 0.9936476349830627
        },
        {
          "text": "(50%) of the voting equity securities of such Party as a result of a single transaction or a series of related transactions.",
          "bbox": [
            643.0,
            371.0,
            2842.0,
            413.0
          ],
          "confidence": 0.9942152500152588
        },
        {
          "text": "1.19\"CIA\" shall have the meaning set forth in Section 5.4(j).",
          "bbox": [
            473.0,
            422.0,
            1595.0,
            470.0
          ],
          "confidence": 0.9803626537322998
        },
        {
          "text": "1.20\"Claims\" shall have the meaning set forth in Section 6.1(a)",
          "bbox": [
            475.0,
            482.0,
            1660.0,
            524.0
          ],
          "confidence": 0.9939401149749756
        },
        {
          "text": "1.21\"Compliance Manager\" shall have the meaning set forth in Section 2.6.",
          "bbox": [
            473.0,
            535.0,
            1887.0,
            579.0
          ],
          "confidence": 0.9967371225357056
        },
        {
          "text": "1.22\"Confidential Information' shall have the meaning set forth in Section 7.1.",
          "bbox": [
            475.0,
            594.0,
            1950.0,
            636.0
          ],
          "confidence": 0.9855698943138123
        },
        {
          "text": "1.23\"Co-Promote Field\"' shall mean those physicians and practices customarily considered primary care or gastroenterology providers.",
          "bbox": [
            475.0,
            651.0,
            2985.0,
            694.0
          ],
          "confidence": 0.9849609732627869
        },
        {
          "text": "and practices and, subject to Sections 3.1(c)(ii) and 4.2(d), the OB/Gyn Field, in the Territory. For clarity, if Exact, either through",
          "bbox": [
            643.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.990959882736206
        },
        {
          "text": "its own Sales Representative or by agreement with a Third Party, launches the Product in the OB/Gyn Field, the Co-Promote",
          "bbox": [
            645.0,
            766.0,
            2938.0,
            802.0
          ],
          "confidence": 0.9923662543296814
        },
        {
          "text": "Field shall not include the OB/Gyn Field.",
          "bbox": [
            640.0,
            817.0,
            1392.0,
            857.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "1.24\"Cost of Sales\" shall mean the direct and indirect costs attributable to sales of the Product Laboratory Services, as calculated in",
          "bbox": [
            475.0,
            873.0,
            2938.0,
            914.0
          ],
          "confidence": 0.9904496073722839
        },
        {
          "text": "accordance with Exhibit 1.24, and as consistently determined in accordance with GAAP.",
          "bbox": [
            642.0,
            930.0,
            2269.0,
            970.0
          ],
          "confidence": 0.9978407621383667
        },
        {
          "text": "1.25\"Debarred/Excluded\"' shall have the meaning set forth in Section 5.1(g).",
          "bbox": [
            475.0,
            985.0,
            1890.0,
            1031.0
          ],
          "confidence": 0.9756522178649902
        },
        {
          "text": "1.26\"Detail'' shall mean a customary face-to-face or non-face-to-face contact of a Sales Representative of a Party with an Eligible",
          "bbox": [
            478.0,
            1045.0,
            2878.0,
            1082.0
          ],
          "confidence": 0.989501953125
        },
        {
          "text": "Prescriber during which such Sales Representative makes a presentation of certain of the Product's attributes, such as",
          "bbox": [
            642.0,
            1100.0,
            2840.0,
            1142.0
          ],
          "confidence": 0.9924894571304321
        },
        {
          "text": "describing the FDA-approved indicated uses, safety, effectiveness, or other relevant characteristics of the Product, in a fair and.",
          "bbox": [
            642.0,
            1153.0,
            3014.0,
            1199.0
          ],
          "confidence": 0.9917008280754089
        },
        {
          "text": "balanced manner and in accordance with the requirements of this Agreement and Applicable Law and in a manner that is",
          "bbox": [
            642.0,
            1212.0,
            2886.0,
            1254.0
          ],
          "confidence": 0.9945916533470154
        },
        {
          "text": "customary for the purpose of Promoting a prescription medical device subject to pre-market approval, but excluding: (a) any",
          "bbox": [
            642.0,
            1266.0,
            2942.0,
            1312.0
          ],
          "confidence": 0.9923741817474365
        },
        {
          "text": "activities performed by any Representative other than a Sales Representative who is not conducting a face-to-face or non-face-",
          "bbox": [
            643.0,
            1325.0,
            3007.0,
            1367.0
          ],
          "confidence": 0.9974873065948486
        },
        {
          "text": "to-face sales call, (b) presentations made at conventions or (c) mere delivery of savings cards, coupons or similar items without",
          "bbox": [
            643.0,
            1380.0,
            3007.0,
            1422.0
          ],
          "confidence": 0.994062066078186
        },
        {
          "text": "discussions with an Eligible Prescriber about the Product; provided that, such measurement shall be on the same basis as the",
          "bbox": [
            642.0,
            1433.0,
            2971.0,
            1478.0
          ],
          "confidence": 0.9994331002235413
        },
        {
          "text": "recording Party's measurement for its Sales Representatives' detailing of its other medical devices subject to pre-market",
          "bbox": [
            642.0,
            1493.0,
            2866.0,
            1535.0
          ],
          "confidence": 0.9990984797477722
        },
        {
          "text": "approval or prescription pharmaceutical products (as applicable), consistently applied throughout the Term. For clarity, non-",
          "bbox": [
            642.0,
            1546.0,
            2954.0,
            1593.0
          ],
          "confidence": 0.9885960817337036
        },
        {
          "text": "face-to-face contact shall mean e-detailing, video detailing or other presentation of Promotional Material by a Sales",
          "bbox": [
            642.0,
            1604.0,
            2780.0,
            1646.0
          ],
          "confidence": 0.9996817708015442
        },
        {
          "text": "Representative to an Eligible Prescriber via audio, video, internet, using webex or other similar live conference applications, and",
          "bbox": [
            642.0,
            1661.0,
            3011.0,
            1703.0
          ],
          "confidence": 0.9919133186340332
        },
        {
          "text": "in all instances that allows for real time, detailed and substantive communication between the Sales Representative and the",
          "bbox": [
            643.0,
            1720.0,
            2924.0,
            1756.0
          ],
          "confidence": 0.9878406524658203
        },
        {
          "text": "Eligible Prescriber regarding the Product and would be considered a Detail by Pfizer for its own products under its own",
          "bbox": [
            642.0,
            1771.0,
            2855.0,
            1816.0
          ],
          "confidence": 0.9985542893409729
        },
        {
          "text": "guidelines, but shall exclude any such communications, such as telephone calls, during which such detailed and visual",
          "bbox": [
            642.0,
            1827.0,
            2855.0,
            1873.0
          ],
          "confidence": 0.9895199537277222
        },
        {
          "text": "3",
          "bbox": [
            1638.0,
            1886.0,
            1669.0,
            1922.0
          ],
          "confidence": 0.9973418116569519
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.991153359413147
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Affiliate License-Licensor_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor?Â ",
      "answer_text": "Subject to the terms of this Agreement, Exact on behalf of itself and its Affiliates, hereby grants to Pfizer a non-exclusive, royalty free license, with the right to sublicense to one or more of its Affiliates, under the Exact House Marks, the Exact Trademarks and the Exact Copyrights, during the Term, to the extent necessary or appropriate to allow Pfizer and its Affiliates to carry out activities under this Agreement including to Promote and Detail the Product in the Co-Promote Field in the Territory.",
      "page_number": 3,
      "words": [
        {
          "text": "Exhibit 8.8(b)",
          "bbox": [
            277.0,
            254.0,
            519.0,
            302.0
          ],
          "confidence": 0.9773956537246704
        },
        {
          "text": "Tail Period Advertising Services",
          "bbox": [
            808.0,
            258.0,
            1403.0,
            298.0
          ],
          "confidence": 0.9866174459457397
        },
        {
          "text": "i1",
          "bbox": [
            1638.0,
            312.0,
            1668.0,
            355.0
          ],
          "confidence": 0.6335347294807434
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4437.0,
            1287.0,
            4479.0
          ],
          "confidence": 0.9964374303817749
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Affiliate License-Licensor_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor?Â ",
      "answer_text": "Subject to the terms of this Agreement, Exact on behalf of itself and its Affiliates, hereby grants to Pfizer a non-exclusive, royalty free license, with the right to sublicense to one or more of its Affiliates, under the Exact House Marks, the Exact Trademarks and the Exact Copyrights, during the Term, to the extent necessary or appropriate to allow Pfizer and its Affiliates to carry out activities under this Agreement including to Promote and Detail the Product in the Co-Promote Field in the Territory.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Affiliate License-Licensee_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "Subject to the terms of this Agreement, Exact on behalf of itself and its Affiliates, hereby grants to Pfizer a non-exclusive, royalty free license, with the right to sublicense to one or more of its Affiliates, under the Exact House Marks, the Exact Trademarks and the Exact Copyrights, during the Term, to the extent necessary or appropriate to allow Pfizer and its Affiliates to carry out activities under this Agreement including to Promote and Detail the Product in the Co-Promote Field in the Territory.",
      "page_number": 3,
      "words": [
        {
          "text": "Exhibit 8.8(b)",
          "bbox": [
            277.0,
            254.0,
            519.0,
            302.0
          ],
          "confidence": 0.9773956537246704
        },
        {
          "text": "Tail Period Advertising Services",
          "bbox": [
            808.0,
            258.0,
            1403.0,
            298.0
          ],
          "confidence": 0.9866174459457397
        },
        {
          "text": "i1",
          "bbox": [
            1638.0,
            312.0,
            1668.0,
            355.0
          ],
          "confidence": 0.6335347294807434
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4437.0,
            1287.0,
            4479.0
          ],
          "confidence": 0.9964374303817749
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Affiliate License-Licensee_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "Subject to the terms of this Agreement, Exact on behalf of itself and its Affiliates, hereby grants to Pfizer a non-exclusive, royalty free license, with the right to sublicense to one or more of its Affiliates, under the Exact House Marks, the Exact Trademarks and the Exact Copyrights, during the Term, to the extent necessary or appropriate to allow Pfizer and its Affiliates to carry out activities under this Agreement including to Promote and Detail the Product in the Co-Promote Field in the Territory.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Post-Termination Services_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "After the expiration of the Term or termination pursuant to Section 8.4 by either Party or Section 8.6 by Exact, based on cumulative Incremental Laboratory Services Revenue achieved during the Term or up to the termination date, Exact agrees to pay Pfizer the applicable royalty payment set forth below for twelve (12) consecutive Calendar Quarters following the expiration of the Term (the \"Tail Period\"); provided, however, the Tail Period shall be reduced to the number of full Calendar Quarters completed during the Term if less than twelve (12) Calendar Quarters if either Party terminates the Agreement without cause pursuant to Section 8.4 or Exact terminates as a result of a Change of Control pursuant to Section 8.6.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Post-Termination Services_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "After the expiration of the Term or termination pursuant to Section 8.4 by either Party or Section 8.6 by Exact, based on cumulative Incremental Laboratory Services Revenue achieved during the Term or up to the termination date, Exact agrees to pay Pfizer the applicable royalty payment set forth below for twelve (12) consecutive Calendar Quarters following the expiration of the Term (the \"Tail Period\"); provided, however, the Tail Period shall be reduced to the number of full Calendar Quarters completed during the Term if less than twelve (12) Calendar Quarters if either Party terminates the Agreement without cause pursuant to Section 8.4 or Exact terminates as a result of a Change of Control pursuant to Section 8.6.",
      "page_number": 5,
      "words": [
        {
          "text": "1.5\"Alliance Manager\" shall have the meaning set forth in Section 2.5.",
          "bbox": [
            475.0,
            254.0,
            1796.0,
            298.0
          ],
          "confidence": 0.9890038371086121
        },
        {
          "text": "1.6\"Annual Marketing Plan\"' shall mean the plan for the Marketing and Promotion of the Product in the Territory for each full or partial",
          "bbox": [
            477.0,
            316.0,
            2992.0,
            353.0
          ],
          "confidence": 0.9888446927070618
        },
        {
          "text": "Calendar Year as described in Section 3.3, as prepared and updated from time to time pursuant to Section 3.3..",
          "bbox": [
            642.0,
            369.0,
            2659.0,
            413.0
          ],
          "confidence": 0.9882045984268188
        },
        {
          "text": "1.7\"Annual Supplemental Promotion Fee\"' shall have the meaning set forth in Section 4.2(c)(i)..",
          "bbox": [
            477.0,
            426.0,
            2238.0,
            468.0
          ],
          "confidence": 0.9870630502700806
        },
        {
          "text": "1.8\"Applicable Compliance/Review Policies\"' shall mean, with respect to Pfizer, its written Code of Ethics and Professional Conduct and,.",
          "bbox": [
            477.0,
            482.0,
            3014.0,
            524.0
          ],
          "confidence": 0.9912572503089905
        },
        {
          "text": "with respect to Exact, its written Code of Business Conduct and Ethics, and such policies and standard operating procedures",
          "bbox": [
            642.0,
            539.0,
            2969.0,
            581.0
          ],
          "confidence": 0.9917171001434326
        },
        {
          "text": "that are adhered to by such Party in connection with the Product and any payments or services contemplated by this",
          "bbox": [
            640.0,
            592.0,
            2820.0,
            638.0
          ],
          "confidence": 0.9860061407089233
        },
        {
          "text": "Agreement, as the same may be amended from time to time.",
          "bbox": [
            643.0,
            651.0,
            1736.0,
            691.0
          ],
          "confidence": 0.9950719475746155
        },
        {
          "text": "1.9\"Applicable Law\"' shall mean any law, statute, rule, regulation, order, judgment, ordinance, administrative code, decree, directive,",
          "bbox": [
            475.0,
            704.0,
            2916.0,
            751.0
          ],
          "confidence": 0.9942479729652405
        },
        {
          "text": "injunction or permit (including Regulatory Approvals) of any court, arbitral body, agency, department, authority or other.",
          "bbox": [
            643.0,
            764.0,
            2882.0,
            806.0
          ],
          "confidence": 0.9893744587898254
        },
        {
          "text": "instrumentality of any national, state, county, city or other political subdivision applicable to a Party's activities to be performed",
          "bbox": [
            642.0,
            820.0,
            3021.0,
            863.0
          ],
          "confidence": 0.9948800206184387
        },
        {
          "text": "under this Agreement. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall",
          "bbox": [
            643.0,
            875.0,
            2989.0,
            917.0
          ],
          "confidence": 0.9867214560508728
        },
        {
          "text": "be deemed to include all amendments, replacements or successors thereto.",
          "bbox": [
            642.0,
            932.0,
            2028.0,
            974.0
          ],
          "confidence": 0.9949407577514648
        },
        {
          "text": "1.10\"Audited Party\" shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            985.0,
            1831.0,
            1029.0
          ],
          "confidence": 0.9958505630493164
        },
        {
          "text": "1.11\"Auditing Party\"' shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            1043.0,
            1849.0,
            1085.0
          ],
          "confidence": 0.9746250510215759
        },
        {
          "text": "1.12\"Baseline Laboratory Service Revenue\" shall mean, with respect to a particular Calendar Year during the Term, the amounts set.",
          "bbox": [
            473.0,
            1096.0,
            2934.0,
            1140.0
          ],
          "confidence": 0.9947289228439331
        },
        {
          "text": "forth in Section 4.2(b).",
          "bbox": [
            642.0,
            1155.0,
            1051.0,
            1195.0
          ],
          "confidence": 0.9629735946655273
        },
        {
          "text": "1.13\"Baseline M&P Expense\" shall have the meaning set forth in Section 3.6..",
          "bbox": [
            475.0,
            1212.0,
            1923.0,
            1254.0
          ],
          "confidence": 0.9764768481254578
        },
        {
          "text": "1.14\"Business Day\"' shall mean any day other than a Saturday, Sunday, or a bank or other public holiday in New York, New York, United.",
          "bbox": [
            475.0,
            1266.0,
            3016.0,
            1310.0
          ],
          "confidence": 0.9815430045127869
        },
        {
          "text": "States.",
          "bbox": [
            639.0,
            1323.0,
            769.0,
            1365.0
          ],
          "confidence": 0.9991849660873413
        },
        {
          "text": "1.15\"Calendar Quarter' shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30,",
          "bbox": [
            473.0,
            1376.0,
            2905.0,
            1422.0
          ],
          "confidence": 0.988274335861206
        },
        {
          "text": "September 30 or December 31.",
          "bbox": [
            643.0,
            1436.0,
            1202.0,
            1478.0
          ],
          "confidence": 0.9999055862426758
        },
        {
          "text": "1.16\"Calendar Year' shall mean the respective periods of twelve (12) calendar months, each such period ending on December 31 of the.",
          "bbox": [
            473.0,
            1491.0,
            2996.0,
            1535.0
          ],
          "confidence": 0.9880089163780212
        },
        {
          "text": "applicable year for as long as this Agreement is in effect.",
          "bbox": [
            642.0,
            1544.0,
            1697.0,
            1594.0
          ],
          "confidence": 0.9885498285293579
        },
        {
          "text": "1.17\"Calendar Year Baseline Laboratory Service Revenue\" shall have the meaning set forth in Section 4.2(b).",
          "bbox": [
            475.0,
            1604.0,
            2525.0,
            1646.0
          ],
          "confidence": 0.9913415908813477
        },
        {
          "text": "1.18\"Change of Control' shall mean, with respect to a Party: (a) the sale of all or substantially all of such Party's assets or business.",
          "bbox": [
            475.0,
            1661.0,
            2929.0,
            1703.0
          ],
          "confidence": 0.9942373037338257
        },
        {
          "text": "relating to the subject matter of this Agreement; (b) a merger, reorganization, or consolidation involving such Party in which the.",
          "bbox": [
            638.0,
            1712.0,
            3018.0,
            1763.0
          ],
          "confidence": 0.9887958765029907
        },
        {
          "text": "holders of voting securities of such Party outstanding immediately",
          "bbox": [
            640.0,
            1771.0,
            1883.0,
            1816.0
          ],
          "confidence": 0.9987452030181885
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1831.0,
            1669.0,
            1866.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9922685027122498
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Post-Termination Services_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Exact shall use commercially reasonable efforts to provide six (6) month notice prior to the expiry of the Term, or in the case of termination by Pfizer under Section 8.4, within the applicable notice period in advance of the effective date of such termination, that Exact intends for Pfizer to continue providing Advertising services for the Product pursuant to Section 3.2(d).",
      "page_number": 3,
      "words": [
        {
          "text": "Exhibit 8.8(b)",
          "bbox": [
            277.0,
            254.0,
            519.0,
            302.0
          ],
          "confidence": 0.9773956537246704
        },
        {
          "text": "Tail Period Advertising Services",
          "bbox": [
            808.0,
            258.0,
            1403.0,
            298.0
          ],
          "confidence": 0.9866174459457397
        },
        {
          "text": "i1",
          "bbox": [
            1638.0,
            312.0,
            1668.0,
            355.0
          ],
          "confidence": 0.6335347294807434
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4437.0,
            1287.0,
            4479.0
          ],
          "confidence": 0.9964374303817749
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Post-Termination Services_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Exact shall use commercially reasonable efforts to provide six (6) month notice prior to the expiry of the Term, or in the case of termination by Pfizer under Section 8.4, within the applicable notice period in advance of the effective date of such termination, that Exact intends for Pfizer to continue providing Advertising services for the Product pursuant to Section 3.2(d).",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Audit Rights_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Upon thirty (30) days prior written notice from a Party (the \"Auditing Party\"), the other Party (the \"Audited Party\") shall permit an independent certified public accounting firm of nationally recognized standing selected by the Auditing Party and reasonably acceptable to the Audited Party, to examine, at the Auditing Party's sole expense, the relevant books and records of the Audited Party and its Affiliates as may be reasonably necessary to verify the accuracy of the reports submitted by the Audited Party in accordance with Sections 3.4(d), 4.1(c) and 4.3(a) and the payment of Promotion Fees hereunder.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Audit Rights_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Upon thirty (30) days prior written notice from a Party (the \"Auditing Party\"), the other Party (the \"Audited Party\") shall permit an independent certified public accounting firm of nationally recognized standing selected by the Auditing Party and reasonably acceptable to the Audited Party, to examine, at the Auditing Party's sole expense, the relevant books and records of the Audited Party and its Affiliates as may be reasonably necessary to verify the accuracy of the reports submitted by the Audited Party in accordance with Sections 3.4(d), 4.1(c) and 4.3(a) and the payment of Promotion Fees hereunder.",
      "page_number": 5,
      "words": [
        {
          "text": "1.5\"Alliance Manager\" shall have the meaning set forth in Section 2.5.",
          "bbox": [
            475.0,
            254.0,
            1796.0,
            298.0
          ],
          "confidence": 0.9890038371086121
        },
        {
          "text": "1.6\"Annual Marketing Plan\"' shall mean the plan for the Marketing and Promotion of the Product in the Territory for each full or partial",
          "bbox": [
            477.0,
            316.0,
            2992.0,
            353.0
          ],
          "confidence": 0.9888446927070618
        },
        {
          "text": "Calendar Year as described in Section 3.3, as prepared and updated from time to time pursuant to Section 3.3..",
          "bbox": [
            642.0,
            369.0,
            2659.0,
            413.0
          ],
          "confidence": 0.9882045984268188
        },
        {
          "text": "1.7\"Annual Supplemental Promotion Fee\"' shall have the meaning set forth in Section 4.2(c)(i)..",
          "bbox": [
            477.0,
            426.0,
            2238.0,
            468.0
          ],
          "confidence": 0.9870630502700806
        },
        {
          "text": "1.8\"Applicable Compliance/Review Policies\"' shall mean, with respect to Pfizer, its written Code of Ethics and Professional Conduct and,.",
          "bbox": [
            477.0,
            482.0,
            3014.0,
            524.0
          ],
          "confidence": 0.9912572503089905
        },
        {
          "text": "with respect to Exact, its written Code of Business Conduct and Ethics, and such policies and standard operating procedures",
          "bbox": [
            642.0,
            539.0,
            2969.0,
            581.0
          ],
          "confidence": 0.9917171001434326
        },
        {
          "text": "that are adhered to by such Party in connection with the Product and any payments or services contemplated by this",
          "bbox": [
            640.0,
            592.0,
            2820.0,
            638.0
          ],
          "confidence": 0.9860061407089233
        },
        {
          "text": "Agreement, as the same may be amended from time to time.",
          "bbox": [
            643.0,
            651.0,
            1736.0,
            691.0
          ],
          "confidence": 0.9950719475746155
        },
        {
          "text": "1.9\"Applicable Law\"' shall mean any law, statute, rule, regulation, order, judgment, ordinance, administrative code, decree, directive,",
          "bbox": [
            475.0,
            704.0,
            2916.0,
            751.0
          ],
          "confidence": 0.9942479729652405
        },
        {
          "text": "injunction or permit (including Regulatory Approvals) of any court, arbitral body, agency, department, authority or other.",
          "bbox": [
            643.0,
            764.0,
            2882.0,
            806.0
          ],
          "confidence": 0.9893744587898254
        },
        {
          "text": "instrumentality of any national, state, county, city or other political subdivision applicable to a Party's activities to be performed",
          "bbox": [
            642.0,
            820.0,
            3021.0,
            863.0
          ],
          "confidence": 0.9948800206184387
        },
        {
          "text": "under this Agreement. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall",
          "bbox": [
            643.0,
            875.0,
            2989.0,
            917.0
          ],
          "confidence": 0.9867214560508728
        },
        {
          "text": "be deemed to include all amendments, replacements or successors thereto.",
          "bbox": [
            642.0,
            932.0,
            2028.0,
            974.0
          ],
          "confidence": 0.9949407577514648
        },
        {
          "text": "1.10\"Audited Party\" shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            985.0,
            1831.0,
            1029.0
          ],
          "confidence": 0.9958505630493164
        },
        {
          "text": "1.11\"Auditing Party\"' shall have the meaning set forth in Section 4.7(b)(i).",
          "bbox": [
            477.0,
            1043.0,
            1849.0,
            1085.0
          ],
          "confidence": 0.9746250510215759
        },
        {
          "text": "1.12\"Baseline Laboratory Service Revenue\" shall mean, with respect to a particular Calendar Year during the Term, the amounts set.",
          "bbox": [
            473.0,
            1096.0,
            2934.0,
            1140.0
          ],
          "confidence": 0.9947289228439331
        },
        {
          "text": "forth in Section 4.2(b).",
          "bbox": [
            642.0,
            1155.0,
            1051.0,
            1195.0
          ],
          "confidence": 0.9629735946655273
        },
        {
          "text": "1.13\"Baseline M&P Expense\" shall have the meaning set forth in Section 3.6..",
          "bbox": [
            475.0,
            1212.0,
            1923.0,
            1254.0
          ],
          "confidence": 0.9764768481254578
        },
        {
          "text": "1.14\"Business Day\"' shall mean any day other than a Saturday, Sunday, or a bank or other public holiday in New York, New York, United.",
          "bbox": [
            475.0,
            1266.0,
            3016.0,
            1310.0
          ],
          "confidence": 0.9815430045127869
        },
        {
          "text": "States.",
          "bbox": [
            639.0,
            1323.0,
            769.0,
            1365.0
          ],
          "confidence": 0.9991849660873413
        },
        {
          "text": "1.15\"Calendar Quarter' shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30,",
          "bbox": [
            473.0,
            1376.0,
            2905.0,
            1422.0
          ],
          "confidence": 0.988274335861206
        },
        {
          "text": "September 30 or December 31.",
          "bbox": [
            643.0,
            1436.0,
            1202.0,
            1478.0
          ],
          "confidence": 0.9999055862426758
        },
        {
          "text": "1.16\"Calendar Year' shall mean the respective periods of twelve (12) calendar months, each such period ending on December 31 of the.",
          "bbox": [
            473.0,
            1491.0,
            2996.0,
            1535.0
          ],
          "confidence": 0.9880089163780212
        },
        {
          "text": "applicable year for as long as this Agreement is in effect.",
          "bbox": [
            642.0,
            1544.0,
            1697.0,
            1594.0
          ],
          "confidence": 0.9885498285293579
        },
        {
          "text": "1.17\"Calendar Year Baseline Laboratory Service Revenue\" shall have the meaning set forth in Section 4.2(b).",
          "bbox": [
            475.0,
            1604.0,
            2525.0,
            1646.0
          ],
          "confidence": 0.9913415908813477
        },
        {
          "text": "1.18\"Change of Control' shall mean, with respect to a Party: (a) the sale of all or substantially all of such Party's assets or business.",
          "bbox": [
            475.0,
            1661.0,
            2929.0,
            1703.0
          ],
          "confidence": 0.9942373037338257
        },
        {
          "text": "relating to the subject matter of this Agreement; (b) a merger, reorganization, or consolidation involving such Party in which the.",
          "bbox": [
            638.0,
            1712.0,
            3018.0,
            1763.0
          ],
          "confidence": 0.9887958765029907
        },
        {
          "text": "holders of voting securities of such Party outstanding immediately",
          "bbox": [
            640.0,
            1771.0,
            1883.0,
            1816.0
          ],
          "confidence": 0.9987452030181885
        },
        {
          "text": "2",
          "bbox": [
            1638.0,
            1831.0,
            1669.0,
            1866.0
          ],
          "confidence": 0.988454282283783
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9922685027122498
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Audit Rights_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Upon thirty (30) days prior written notice from an Auditing Party, the Audited Party shall permit the Auditing Party's external auditors access to any relevant books documents, papers, and records of the Party involving any report delivered pursuant to Sections 3.2(d), 3.4(d) and 4.3(a) of this Agreement and the activities performed under this Agreement, if the other Party has credible evidence that the other Party violated terms of this Agreement, including with respect to Product Training under Section 3(e).",
      "page_number": 3,
      "words": [
        {
          "text": "Exhibit 8.8(b)",
          "bbox": [
            277.0,
            254.0,
            519.0,
            302.0
          ],
          "confidence": 0.9773956537246704
        },
        {
          "text": "Tail Period Advertising Services",
          "bbox": [
            808.0,
            258.0,
            1403.0,
            298.0
          ],
          "confidence": 0.9866174459457397
        },
        {
          "text": "i1",
          "bbox": [
            1638.0,
            312.0,
            1668.0,
            355.0
          ],
          "confidence": 0.6335347294807434
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4437.0,
            1287.0,
            4479.0
          ],
          "confidence": 0.9964374303817749
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Audit Rights_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right toÂ  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Upon thirty (30) days prior written notice from an Auditing Party, the Audited Party shall permit the Auditing Party's external auditors access to any relevant books documents, papers, and records of the Party involving any report delivered pursuant to Sections 3.2(d), 3.4(d) and 4.3(a) of this Agreement and the activities performed under this Agreement, if the other Party has credible evidence that the other Party violated terms of this Agreement, including with respect to Product Training under Section 3(e).",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Uncapped Liability_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a partyâs liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
      "answer_text": "NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, EXCEPT FOR (A) INDEMNIFICATION OBLIGATIONS OF A PARTY UNDER SECTION 6.1, (B) A BREACH OF SECTION 7 BY A PARTY OR (C) THE WILLFUL MISCONDUCT OR GROSS NEGLIGENCE OF A PARTY, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING LOST PROFITS, LOST REVENUES OR PENALTIES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.",
      "page_number": 3,
      "words": [
        {
          "text": "Exhibit 8.8(b)",
          "bbox": [
            277.0,
            254.0,
            519.0,
            302.0
          ],
          "confidence": 0.9773956537246704
        },
        {
          "text": "Tail Period Advertising Services",
          "bbox": [
            808.0,
            258.0,
            1403.0,
            298.0
          ],
          "confidence": 0.9866174459457397
        },
        {
          "text": "i1",
          "bbox": [
            1638.0,
            312.0,
            1668.0,
            355.0
          ],
          "confidence": 0.6335347294807434
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4437.0,
            1287.0,
            4479.0
          ],
          "confidence": 0.9964374303817749
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Uncapped Liability_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a partyâs liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
      "answer_text": "NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, EXCEPT FOR (A) INDEMNIFICATION OBLIGATIONS OF A PARTY UNDER SECTION 6.1, (B) A BREACH OF SECTION 7 BY A PARTY OR (C) THE WILLFUL MISCONDUCT OR GROSS NEGLIGENCE OF A PARTY, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING LOST PROFITS, LOST REVENUES OR PENALTIES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Cap On Liability_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a partyâs obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, EXCEPT FOR (A) INDEMNIFICATION OBLIGATIONS OF A PARTY UNDER SECTION 6.1, (B) A BREACH OF SECTION 7 BY A PARTY OR (C) THE WILLFUL MISCONDUCT OR GROSS NEGLIGENCE OF A PARTY, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING LOST PROFITS, LOST REVENUES OR PENALTIES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.",
      "page_number": 3,
      "words": [
        {
          "text": "Exhibit 8.8(b)",
          "bbox": [
            277.0,
            254.0,
            519.0,
            302.0
          ],
          "confidence": 0.9773956537246704
        },
        {
          "text": "Tail Period Advertising Services",
          "bbox": [
            808.0,
            258.0,
            1403.0,
            298.0
          ],
          "confidence": 0.9866174459457397
        },
        {
          "text": "i1",
          "bbox": [
            1638.0,
            312.0,
            1668.0,
            355.0
          ],
          "confidence": 0.6335347294807434
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4437.0,
            1287.0,
            4479.0
          ],
          "confidence": 0.9964374303817749
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Cap On Liability_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a partyâs obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, EXCEPT FOR (A) INDEMNIFICATION OBLIGATIONS OF A PARTY UNDER SECTION 6.1, (B) A BREACH OF SECTION 7 BY A PARTY OR (C) THE WILLFUL MISCONDUCT OR GROSS NEGLIGENCE OF A PARTY, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING LOST PROFITS, LOST REVENUES OR PENALTIES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Insurance_4",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Pfizer and its Affiliates will be an additional insured on Exact's commercial general liability and products liability policies, and be provided with a waiver of subrogation.",
      "page_number": 4,
      "words": [
        {
          "text": "AGREEMENT",
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ],
          "confidence": 0.9994295835494995
        },
        {
          "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
          "bbox": [
            473.0,
            311.0,
            2936.0,
            356.0
          ],
          "confidence": 0.9840105772018433
        },
        {
          "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
          "bbox": [
            308.0,
            367.0,
            2904.0,
            413.0
          ],
          "confidence": 0.9912877678871155
        },
        {
          "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
          "bbox": [
            306.0,
            424.0,
            2958.0,
            468.0
          ],
          "confidence": 0.9896254539489746
        },
        {
          "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
          "bbox": [
            306.0,
            482.0,
            2079.0,
            524.0
          ],
          "confidence": 0.9861899614334106
        },
        {
          "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
          "bbox": [
            475.0,
            535.0,
            2519.0,
            581.0
          ],
          "confidence": 0.9942227602005005
        },
        {
          "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
          "bbox": [
            473.0,
            588.0,
            2851.0,
            640.0
          ],
          "confidence": 0.9969527721405029
        },
        {
          "text": "prescription products; and",
          "bbox": [
            304.0,
            649.0,
            807.0,
            694.0
          ],
          "confidence": 0.9998782873153687
        },
        {
          "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
          "bbox": [
            475.0,
            707.0,
            2992.0,
            749.0
          ],
          "confidence": 0.9872405529022217
        },
        {
          "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
          "bbox": [
            304.0,
            762.0,
            3023.0,
            806.0
          ],
          "confidence": 0.9898486733436584
        },
        {
          "text": "invest in Exact's Promotion of the Product in the United States.",
          "bbox": [
            306.0,
            820.0,
            1472.0,
            857.0
          ],
          "confidence": 0.9991772174835205
        },
        {
          "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
          "bbox": [
            469.0,
            872.0,
            2998.0,
            916.0
          ],
          "confidence": 0.9942070245742798
        },
        {
          "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
          "bbox": [
            306.0,
            932.0,
            2115.0,
            974.0
          ],
          "confidence": 0.9851760268211365
        },
        {
          "text": "1.DEFINITIONS.",
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ],
          "confidence": 0.9991698265075684
        },
        {
          "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            475.0,
            1043.0,
            1827.0,
            1085.0
          ],
          "confidence": 0.9904266595840454
        },
        {
          "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
          "bbox": [
            471.0,
            1095.0,
            2976.0,
            1146.0
          ],
          "confidence": 0.9886809587478638
        },
        {
          "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
          "bbox": [
            643.0,
            1157.0,
            2924.0,
            1199.0
          ],
          "confidence": 0.9968469142913818
        },
        {
          "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
          "bbox": [
            642.0,
            1212.0,
            2982.0,
            1254.0
          ],
          "confidence": 0.999542772769928
        },
        {
          "text": "healthcare institutions and healthcare providers..",
          "bbox": [
            640.0,
            1264.0,
            1546.0,
            1310.0
          ],
          "confidence": 0.9882785677909851
        },
        {
          "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
          "bbox": [
            475.0,
            1321.0,
            2944.0,
            1365.0
          ],
          "confidence": 0.9841283559799194
        },
        {
          "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
          "bbox": [
            642.0,
            1380.0,
            2992.0,
            1422.0
          ],
          "confidence": 0.9886681437492371
        },
        {
          "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
          "bbox": [
            643.0,
            1436.0,
            2953.0,
            1478.0
          ],
          "confidence": 0.9956369400024414
        },
        {
          "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
          "bbox": [
            642.0,
            1493.0,
            2963.0,
            1535.0
          ],
          "confidence": 0.9946187734603882
        },
        {
          "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
          "bbox": [
            642.0,
            1550.0,
            3014.0,
            1592.0
          ],
          "confidence": 0.9957184791564941
        },
        {
          "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
          "bbox": [
            642.0,
            1603.0,
            2973.0,
            1648.0
          ],
          "confidence": 0.9958446621894836
        },
        {
          "text": "otherwise, until such time as such restrictions are no longer in effect.",
          "bbox": [
            642.0,
            1661.0,
            1921.0,
            1701.0
          ],
          "confidence": 0.9943870902061462
        },
        {
          "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            1716.0,
            1702.0,
            1760.0
          ],
          "confidence": 0.9774678349494934
        },
        {
          "text": "1",
          "bbox": [
            1640.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.9970255494117737
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9957988858222961
        }
      ],
      "nearby_headers": [
        {
          "text": "AGREEMENT",
          "page": 4,
          "bbox": [
            1521.0,
            254.0,
            1787.0,
            296.0
          ]
        },
        {
          "text": "1.DEFINITIONS.",
          "page": 4,
          "bbox": [
            281.0,
            987.0,
            602.0,
            1025.0
          ]
        }
      ]
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Insurance_9_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Each Party agrees to obtain and maintain, during the Term and for five (5) years after the Term, commercial general liability insurance, including products liability insurance, with minimum \"A-\" AM Best rated insurance carriers, in each case with limits of not less than five million dollars ($5,000,000) per occurrence and in the aggregate",
      "page_number": 9,
      "words": [
        {
          "text": "authority of Pfizer or any of its Affiliates to a Sales Representative involved in the Promotion of the Product under this",
          "bbox": [
            643.0,
            258.0,
            2846.0,
            300.0
          ],
          "confidence": 0.9979860186576843
        },
        {
          "text": "Agreement based directly or indirectly on the sales of the products (including the Product) being Promoted by such Sales",
          "bbox": [
            643.0,
            314.0,
            2909.0,
            356.0
          ],
          "confidence": 0.987593412399292
        },
        {
          "text": "Representative in the Territory, including any target bonus, award or other incentive, but excluding (i) base salary and (ii) single",
          "bbox": [
            643.0,
            371.0,
            3009.0,
            413.0
          ],
          "confidence": 0.9902706742286682
        },
        {
          "text": "product ad hoc awards or other similar individual product incentives, such as \"special incentive plans\" that, in the aggregate,",
          "bbox": [
            640.0,
            426.0,
            2976.0,
            470.0
          ],
          "confidence": 0.992321789264679
        },
        {
          "text": "do not exceed $2,o00 per Calendar Year.",
          "bbox": [
            643.0,
            482.0,
            1368.0,
            523.0
          ],
          "confidence": 0.9864369630813599
        },
        {
          "text": "1.56\"Included Revenue Percentage\" shall have the meaning set forth in Section 4.2(d).",
          "bbox": [
            475.0,
            535.0,
            2088.0,
            581.0
          ],
          "confidence": 0.9926280975341797
        },
        {
          "text": "1.57\"Incremental Laboratory Service Revenue\" shall have the meaning set forth in Section 4.2(a)..",
          "bbox": [
            475.0,
            592.0,
            2306.0,
            636.0
          ],
          "confidence": 0.9860894083976746
        },
        {
          "text": "1.58\"Indemnified Party\" shall have the meaning set forth in Section 6.1(c)(i)",
          "bbox": [
            475.0,
            651.0,
            1901.0,
            693.0
          ],
          "confidence": 0.9900813698768616
        },
        {
          "text": "1.59\"Indemnifying Party\" shall have the meaning set forth in Section 6.1(c)(i)",
          "bbox": [
            473.0,
            704.0,
            1930.0,
            749.0
          ],
          "confidence": 0.9943262934684753
        },
        {
          "text": "1.60\"JOC\" shall have the meaning set forth in Section 2.2(a)",
          "bbox": [
            473.0,
            760.0,
            1611.0,
            806.0
          ],
          "confidence": 0.9901962876319885
        },
        {
          "text": "1.61\"JOC Co-Chair\"' shall have the meaning set forth in Section 2.2(a)..",
          "bbox": [
            475.0,
            819.0,
            1805.0,
            861.0
          ],
          "confidence": 0.9832525253295898
        },
        {
          "text": "1.62\"JRC\" shall have the meaning set forth in Section 2.3(a).",
          "bbox": [
            475.0,
            873.0,
            1615.0,
            914.0
          ],
          "confidence": 0.992034375667572
        },
        {
          "text": "1.63\"JSC\" shall have the meaning set forth in Section 2.1(a)..",
          "bbox": [
            475.0,
            930.0,
            1610.0,
            970.0
          ],
          "confidence": 0.9814099073410034
        },
        {
          "text": "1.64\"JSC Co-Chair\"' shall have the meaning set forth in Section 2.1(b)..",
          "bbox": [
            475.0,
            987.0,
            1803.0,
            1027.0
          ],
          "confidence": 0.9888525009155273
        },
        {
          "text": "1.65\"JSC Members\"' shall have the meaning set forth in Section 2.1(a)..",
          "bbox": [
            475.0,
            1043.0,
            1802.0,
            1085.0
          ],
          "confidence": 0.988053023815155
        },
        {
          "text": "1.66\"KAM Team' shall have the meaning set forth in Section 3.4(c)..",
          "bbox": [
            473.0,
            1096.0,
            1749.0,
            1142.0
          ],
          "confidence": 0.9822599291801453
        },
        {
          "text": "1.67\"Laboratory Service Revenue\"' shall mean, with respect to a particular Calendar Quarter, as applicable, Exact's revenue earned from",
          "bbox": [
            475.0,
            1155.0,
            2991.0,
            1197.0
          ],
          "confidence": 0.9952684044837952
        },
        {
          "text": "performing the Product Laboratory Service in the Territory with regard to patient samples collected in the Territory, subject to",
          "bbox": [
            642.0,
            1210.0,
            2965.0,
            1255.0
          ],
          "confidence": 0.995022177696228
        },
        {
          "text": "Section 4.2(d), as calculated by Exact in accordance with GAAP consistently applied, less the following deductions: (i) trade,",
          "bbox": [
            643.0,
            1268.0,
            2956.0,
            1310.0
          ],
          "confidence": 0.9911777973175049
        },
        {
          "text": "quantity or cash discounts, credits, adjustments or allowances, including without limitation those granted in connection with",
          "bbox": [
            642.0,
            1321.0,
            2967.0,
            1369.0
          ],
          "confidence": 0.9956960082054138
        },
        {
          "text": "managed care network agreements and those granted on account of price adjustments, billing errors, rejected goods, damaged",
          "bbox": [
            642.0,
            1380.0,
            2985.0,
            1422.0
          ],
          "confidence": 0.9944839477539062
        },
        {
          "text": "goods or incomplete tests or other services; (ii) rebates and chargebacks allowed, given or accrued (including, but not limited",
          "bbox": [
            642.0,
            1433.0,
            2976.0,
            1480.0
          ],
          "confidence": 0.9997325539588928
        },
        {
          "text": "to, cash, governmental and managed care rebates, hospital or other buying group chargebacks, and governmental taxes in the",
          "bbox": [
            643.0,
            1493.0,
            2983.0,
            1537.0
          ],
          "confidence": 0.9938892126083374
        },
        {
          "text": "nature of a rebate based on usage levels or sales of the Product Laboratory Service); and (iii) patient compliance incentives that",
          "bbox": [
            642.0,
            1546.0,
            3020.0,
            1592.0
          ],
          "confidence": 0.9991859793663025
        },
        {
          "text": "are treated as a reduction in revenue in accordance with GAAP, including without limitation gift cards to patients..",
          "bbox": [
            640.0,
            1603.0,
            2742.0,
            1646.0
          ],
          "confidence": 0.9961121082305908
        },
        {
          "text": "1.68\"Launch Date\"' shall mean October 1, 2018.",
          "bbox": [
            477.0,
            1659.0,
            1356.0,
            1699.0
          ],
          "confidence": 0.9834438562393188
        },
        {
          "text": "1.69\"Marketing\"' shall mean, with respect to a medical device subject to pre-market.",
          "bbox": [
            475.0,
            1714.0,
            2037.0,
            1758.0
          ],
          "confidence": 0.9799834489822388
        },
        {
          "text": "6",
          "bbox": [
            1642.0,
            1778.0,
            1666.0,
            1809.0
          ],
          "confidence": 0.979653000831604
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.991400957107544
        }
      ],
      "multi_page": true,
      "part_of": 2
    },
    {
      "id": "ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement__Insurance_10_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Each Party agrees to obtain and maintain, during the Term and for five (5) years after the Term, commercial general liability insurance, including products liability insurance, with minimum \"A-\" AM Best rated insurance carriers, in each case with limits of not less than five million dollars ($5,000,000) per occurrence and in the aggregate",
      "page_number": 10,
      "words": [
        {
          "text": "approval, Advertising, public relations, medical education activities, market research, creation, development, and distribution of",
          "bbox": [
            642.0,
            254.0,
            3020.0,
            302.0
          ],
          "confidence": 0.9892592430114746
        },
        {
          "text": "Advertising and Promotional materials, field literature, direct or indirect educational campaigns, and exhibits at seminars and",
          "bbox": [
            645.0,
            314.0,
            2949.0,
            356.0
          ],
          "confidence": 0.9962751269340515
        },
        {
          "text": "conventions. When used as a verb, \"Market' means to engage in Marketing.",
          "bbox": [
            640.0,
            365.0,
            2083.0,
            415.0
          ],
          "confidence": 0.9952799677848816
        },
        {
          "text": "1.70\"OB/Gyn Commercial Rights\"' shall have the meaning set forth in Section 3.1(c)(ii)..",
          "bbox": [
            473.0,
            424.0,
            2119.0,
            470.0
          ],
          "confidence": 0.9766764044761658
        },
        {
          "text": "1.71\"OB/Gyn Commercial Rights Transfer Notice\"' shall have the meaning set forth in Section 3.1(c)(ii)..",
          "bbox": [
            477.0,
            482.0,
            2429.0,
            524.0
          ],
          "confidence": 0.9843822717666626
        },
        {
          "text": "1.72\"OB/Gyn Field\" shall mean those healthcare professionals and practices customarily considered OB/Gyn providers and practices",
          "bbox": [
            475.0,
            539.0,
            2974.0,
            581.0
          ],
          "confidence": 0.9927505254745483
        },
        {
          "text": "1.73\"Occurrence\" shall have the meaning set forth in Section 2.6(c).",
          "bbox": [
            475.0,
            594.0,
            1758.0,
            634.0
          ],
          "confidence": 0.9901055693626404
        },
        {
          "text": "1.74\"Party\" or \"Parties\" shall have the meaning set forth in the preamble.",
          "bbox": [
            477.0,
            651.0,
            1858.0,
            693.0
          ],
          "confidence": 0.9927406311035156
        },
        {
          "text": "1.75\"Patent Rights\"' shall mean any and all (a) issued patents, (b) pending patent applications, including all provisional applications,",
          "bbox": [
            473.0,
            705.0,
            2953.0,
            749.0
          ],
          "confidence": 0.99418705701828
        },
        {
          "text": "substitutions, continuations, continuations-in-part, divisionals, and renewals, and all patents granted thereon, (c) patents of",
          "bbox": [
            643.0,
            764.0,
            2958.0,
            806.0
          ],
          "confidence": 0.9994059205055237
        },
        {
          "text": "addition, reissues, reexaminations and extensions or restorations by existing or future extension or restorations mechanisms,",
          "bbox": [
            642.0,
            817.0,
            2953.0,
            861.0
          ],
          "confidence": 0.997675359249115
        },
        {
          "text": "including patent term adjustments, patent term extensions, supplementary protection certificates or the equivalent thereof, (d)",
          "bbox": [
            640.0,
            873.0,
            2976.0,
            917.0
          ],
          "confidence": 0.9931306838989258
        },
        {
          "text": "inventor's certificates, (e) other forms of government issued rights substantially similar to the foregoing and (f) United States",
          "bbox": [
            642.0,
            932.0,
            2972.0,
            974.0
          ],
          "confidence": 0.9936177134513855
        },
        {
          "text": "and foreign counterparts of any of the foregoing.",
          "bbox": [
            642.0,
            987.0,
            1550.0,
            1029.0
          ],
          "confidence": 0.9929980039596558
        },
        {
          "text": "1.76\"Payer\" shall mean a Third Party entity that pays a portion or all of the cost of the Product Laboratory Service performed with",
          "bbox": [
            477.0,
            1043.0,
            2904.0,
            1087.0
          ],
          "confidence": 0.992758572101593
        },
        {
          "text": "respect to a given patient using the Product. For clarity, a patient who pays for the cost of his or her own Product Laboratory",
          "bbox": [
            642.0,
            1100.0,
            2967.0,
            1144.0
          ],
          "confidence": 0.9916118383407593
        },
        {
          "text": "Service, in whole or in part, shall not be included in this definition of \"Payer' and a \"Payer' may include government entities or",
          "bbox": [
            640.0,
            1153.0,
            3009.0,
            1199.0
          ],
          "confidence": 0.9957515001296997
        },
        {
          "text": "agencies, managed care organizations, and health or prescription insurance providers.",
          "bbox": [
            642.0,
            1213.0,
            2242.0,
            1255.0
          ],
          "confidence": 0.9907673597335815
        },
        {
          "text": "1.77\"Person\"' shall mean an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation,.",
          "bbox": [
            471.0,
            1263.0,
            2945.0,
            1314.0
          ],
          "confidence": 0.9846735000610352
        },
        {
          "text": "limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or",
          "bbox": [
            642.0,
            1321.0,
            2973.0,
            1369.0
          ],
          "confidence": 0.990877091884613
        },
        {
          "text": "organization, including a government or political subdivision or department or agency of a government..",
          "bbox": [
            643.0,
            1380.0,
            2566.0,
            1422.0
          ],
          "confidence": 0.9952815771102905
        },
        {
          "text": "1.78\"Pfizer\" shall have the meaning set forth in the preamble..",
          "bbox": [
            473.0,
            1433.0,
            1633.0,
            1478.0
          ],
          "confidence": 0.9814643859863281
        },
        {
          "text": "1.79\"Pfizer Indemnitee\"' shall have the meaning set forth in Section 6.1(a).",
          "bbox": [
            473.0,
            1489.0,
            1865.0,
            1535.0
          ],
          "confidence": 0.9861654043197632
        },
        {
          "text": "1.80\"Pfizer JSC Members'\" shall have the meaning set forth in Section 2.1(a)",
          "bbox": [
            475.0,
            1548.0,
            1929.0,
            1588.0
          ],
          "confidence": 0.9718734622001648
        },
        {
          "text": "1.81\"Pfizer Trainers\"' shall have the meaning set forth in Section 3.2(e)(i).",
          "bbox": [
            475.0,
            1604.0,
            1861.0,
            1645.0
          ],
          "confidence": 0.9835824370384216
        },
        {
          "text": "1.82\"PhRMA Code\" shall have the meaning set forth in Section 3.2(c)(ii).",
          "bbox": [
            471.0,
            1657.0,
            1832.0,
            1703.0
          ],
          "confidence": 0.993983805179596
        },
        {
          "text": "7",
          "bbox": [
            1638.0,
            1718.0,
            1668.0,
            1754.0
          ],
          "confidence": 0.9832367300987244
        },
        {
          "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
          "bbox": [
            332.0,
            4435.0,
            1285.0,
            4477.0
          ],
          "confidence": 0.9914414286613464
        }
      ],
      "multi_page": true,
      "part_of": 2
    }
  ]
}